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    Abstract  
 
 
 
ABSTRACT 
Abnormalities in social behavior are found in almost all psychiatric disorders, such as anxiety, 
depression, autism and schizophrenia. Thus, comprehension of the neurobiological basis of 
social interaction is important to better understand numerous pathologies and improve 
treatments. Several evidences suggest that an alteration of cannabinoid CB1 receptor function 
could be involved in the pathophysiology of such disorders. However, the role of CB1 
receptor is still unclear and its localization on different neuronal subpopulations may produce 
distinct outcomes. To dissect the role of CB1 receptor on different neuronal population, male 
mice were used – knockout mice and their respective control littermates [total deletion (CB1
-/-
); specific deletion on cortical glutamatergic neurons (GluCB1
-/-
); on GABAergic neurons of 
the forebrain (GABACB1
-/-
); or on dopaminergic D1 receptor expressing neurons (D1CB1
-/-
)], and wild-type (WT) mice treated with CB1 antagonist/inverse agonist SR141716A 
(3mg/kg). To elucidate the behavioral effects of specific CB1 receptor deficiency, D1CB1
-/- 
mice were submitted to a battery of behavioral tests which included exploration-based tests, 
depressive-like behavioral tests, and fear-related memory paradigms.  It was demonstrated 
that D1CB1
-/-
 mice exhibited significantly increased contextual and auditory-cued fear, with 
attenuated within-session extinction. Also, when all mice lines were submitted to different 
social tasks, involving male or female as the stimulus subject, GluCB1
-/- 
mice showed reduced 
interest for the social stimulus, as CB1
-/-
 or WT treated with SR141716A mice. D1CB1
-/- 
showed moderate changes in social interest, and GABACB1
-/- 
mice showed the opposite 
phenotype by spending more time investigating the social stimulus. In conclusion, specific 
reduction of endocannabinoid signaling in D1-expressing neurons is able to affect acute fear 
adaptation. Moreover, CB1 receptors specifically modulate social investigation of female 
mice in a cell-specific manner. These findings support the involvement of cannabinoid 
signaling in social alterations in psychiatry disorders. 
 
Keywords: endocannabinoid system, CB1 receptor, GABA, glutamate, dopamine, affective 
disorders, social behavior 
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1 INTRODUCTION 
Marijuana and other derivatives of the plant Cannabis sativa have been used for thousands of 
years for their therapeutic and mood-altering properties. Nowadays, Cannabis sativa belongs 
to the most popular illicit drugs used for recreational purposes in contemporary societies all 
around the world (Ehrenreich et al. 1999; Watson et al. 2000; Kano et al, 2009). Cannabis 
smoking (“marijuana”) is common particularly among adolescents and young adults.  The 
pervasiveness of this drug worldwide, along with its relatively low lethality, has led many to 
believe that it is of little harm. Indeed, the use of cannabis currently exceeds that of tobacco 
smoking among adolescents in the some countries (Chadwick et al, 2013). However, evidence 
accumulates that chronic cannabis abuse - in particular during sensitive phases of 
development - may have long-lasting psychopathological consequences. Such effects are 
mostly associated with Cannabis sativa component delta-9-tetrahydrocannabinol (THC), 
identified in 1964 (Pertwee 1997). Research focused on the relationship between mental 
health and cannabinoid components is thus important, particularly considering that psychiatric 
illnesses are complex disorders with multiple factors contributing to vulnerability and 
eventual expression of symptoms (Ashton and Moore, 2011; Schier et al, 2012), and 
cannabinoids are associated with the onset of certain diseases (Andreasson et al, 1987; 
Hambrecht and Hafner, 2000; Arseneault et al, 2002; Segev and Lev-Ran, 2012; Zamberletti 
et al, 2012; Robson et al, 2013). For example, several studies imply correlation between 
cannabis exposure during adolescence and vulnerability to drug addiction (Murray et al, 2007; 
Malone et al, 2010; Chadwick et al, 2013), schizophrenia (Andreasson et al, 1987; Hall et al. 
2004; Malone et al, 2010) and may also produce long-lasting effects on anxiety and mood 
disorders (Croxford, 2003; Mechoulam and Parker, 2013). 
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1.1 The endocannabinoid system 
 
The psychoactive effects of cannabis, principally mediated by THC, occur via its interaction 
with the endocannabinoid system, which regulates numerous biological processes involved in 
development and neuroplasticity. The endocannabinoid system consists of lipid-derived 
ligands, receptors, and enzymes that orchestrate intercellular communication and intracellular 
metabolism (Di Marzo, 2009). 
In the early-1990s a marked advance has been made in the cannabinoid research by the 
discovery of the receptors that bind THC in animal tissues. The presence of a cannabinoid 
receptor in the brain was demonstrated, followed by its cloning (Matsuda et al, 1990). The 
first cannabinoid receptor (CB1) was cloned and characterized in 1991 (Matsuda et al, 1990), 
and the second receptor (CB2) was identified in 1993 (Munro et al, 1993). They are both G 
protein-coupled seven transmembrane domain receptors and differ in their tissue distributions. 
The CB1 receptor is abundantly expressed in the central nervous system (CNS), whereas the 
CB2 receptor is also present in the CNS, but mainly in the immune system. The discovery of 
these high-affinity, stereoselective and pharmacologically distinct cannabinoid receptors in a 
rat brain tissue (Matsuda et al, 1990; Munro et al, 1993) led to a search for natural 
endogenous ligands, which bind to these cannabinoid receptors. It was assumed, as previously 
for other systems (as for opioid / morphine; Laux-Biehlmann et al, 2013), that the 
cannabinoid receptors in the brain are not present just to bind a plant constituent, but to be 
activated by specific endogenous ligands.  
Isolated from the porcine brain, the first endogenous compound presenting the similar potency 
to THC was identified as N-arachidonoylethanolamide (Devane et al, 1992). This 
endocannabinoid is better known by the name of anandamide, derived from the Sanskrit word 
for bliss, ananda. Anandamide behaves as a partial agonist of the two different cannabinoid 
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receptors, CB1 and CB2, and also binds to the transient receptor vanilloid receptor type 1 
(TRPV1). Therefore, it can activate both the endocannabinoid and endovanilloid systems. 
Another major endocannabinoid, 2-arachidonoyl glycerol (2-AG) was originally isolated from 
canine gut (Mechoulam et al, 1995) and rat brain (Sugiura et al, 1995). 2-AG is a rather 
common molecule and is present in the brain at higher concentrations than anandamide 
(Sigiura et al, 2006).  2-AG acts as a full agonist in various assay systems and is strictly 
recognized by CB1 and CB2 receptors, suggesting that 2-AG is a true natural ligand for the 
cannabinoid receptors (Sugiura et al, 2006). There is enough evidence to show that these 
endocannabinoids are synthesized from lipid membrane precursor molecules and released 
from neurons in an activity- and calcium-dependent manner, however are not stored in 
vesicles as classical neurotransmitters. They also play physiological roles as intercellular 
signaling molecules. Other putative endocannabinoids include dihomolinolenoyl 
ethanolamide (Hanus et al, 1993), docosatetraenoyl ethanolamide (Hanus et al, 1993), 2-
arachidonyl glycerol ether (noladin ether; Hanus et al, 2001), O-arachidonoylethanolamine 
(virodhamine; Porter et al, 2002), and N-arachidonoyldopamine (Huang et al, 2002). 
The year 2001 was the turning point of the cannabinoid research. In this year, 
endocannabinoids were discovered to mediate retrograde signaling at central synapses 
(Maejima et al, 2001; Wilson and Nicoll, 2001). Accordingly, endocannabinoid production 
and diffusion from the postsynaptic cell would stimulate CB1 receptors on presynaptic 
terminals, where they are frequently located, leading to decreased release of neurotransmitters 
(Wilson and Nicoll 2001). These enabled a new phase for the cannabinoid research, and also 
established a new concept of how diffusible messengers such as endocannabinoids 
(postsynaptic release of the endogenous agonist and receptor activation on presynaptic 
terminal) modulate synaptic efficacy and neural activity.  
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The degradation of endocannabinoids happens through two different pathways, hydrolysis 
and oxidation (Vandevoorde and Lambert, 2007). The enzymes that catalyze the first pathway 
include fatty acid amide hydrolase (FAAH) for anandamide and monoacylglycerol lipase 
(MGL) for 2-AG. The second pathway involves the well-known cyclooxygenase (COX) and 
lipoxygenase (LOX), which induce oxidation of the arachidonic moiety of the 
endocannabinoids. FAAH proteins are 579 amino acids in length among different species, 
such as rat, mouse, and human. FAAH is detected in many organs including brain. The 
enzyme is able to recognize a variety of fatty acid amides, but its preferred substrate is 
anandamide. It also catalyzes the hydrolysis of the ester bond of 2-AG in vitro. MGL was 
identified in 1976 (Tornqvist and Belfrage, 1976) and first cloned from a mouse adipocyte 
cDNA library (Karlsson et al, 1997), being now recognized as the main enzyme catalyzing the 
hydrolysis of 2-AG in vivo (Dinh et al, 2002; Dinh et al, 2004; Vandevoorde and Lambert, 
2007). The removal of endocannabinoids from the extracellular space occurs by a two-step 
process: the transport into cells and the subsequent enzymatic degradation (Hillard and 
Jarrahian, 2000; Fowler and Jacobsson, 2002; McFarland and Barker, 2004). Anandamide 
uptake has been observed in a number of preparations including primary neuronal cell 
cultures (Beltramo et al, 1997; Di Marzo et al, 2004; Hillard et al, 1997). Anandamide uptake 
is saturable and temperature dependent. Several structural analogs of anandamide, such as N-
arachidonoylaminophenol (AM404), have been reported to inhibit the anandamide uptake 
(Beltramo et al, 1997; Piomelli et al, 1999), and they are called anandamide transport 
inhibitors. However, their molecular identities have not been fully clarified yet. Recently, Fu 
et al (2012) identify a partly cytosolic variant of FAAH-1, termed FLAT that lacks amidase 
activity but binds anandamide with low micromolar affinity and confers anandamide transport 
on cells that are engineered to express it. Such effect is suppressed by AM404 and other 
anandamide transport inhibitors. In contrast, a new study (Leung et al, 2013) fail to detect 
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FLAT expression in DRGs and in other tissues examined, possibly suggesting that FLAT may 
exhibit a low tissue expression profile that is below the detection limit of these approaches. 
The reason for this discrepancy could be related to antibodies sensitivity, however further 
studies would be necessary to clarify this matter (Leung et al, 2013). In contrast to the 
intensive studies on the mechanisms of anandamide uptake, there is relatively little 
information concerning 2-AG uptake. Yet, there are several studies suggesting that 2-AG and 
anandamide are transported by the same system (Bisogno et al, 2001, Kano et al, 2009). 
The endocannabinoid system in involved in various functions of the CNS under physiological 
and pathological conditions, which suggests that the molecules involved in endocannabinoid 
signaling may be promising targets for clinical management of disturbed neural functions or 
pathological conditions. 
 
Figure 1. Major signalling pathways associated with cannabinoid receptor activation by 
agonists. Hydrolytic enzymes are involved in both the biosynthesis of endocannabinoids and 
in their inactivation. The enzymes for 2-arachidonoylglycerol (2-AG) biosynthesis, the 
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phospholipases C (PLC) and the sn-1-selective diacylglycerol lipases (DAGLs) seem to be 
mostly localized on the plasma membrane. The DAGLs, in particular, are located on 
postsynaptic neurons in the adult nervous system, whereas the monoacylglycerol lipase 
(MAGL) for 2-AG inactivation is localized in presynaptic neurons, which supports a possible 
role as retrograde messenger at presynaptic CB1 receptors for this compound. The 
anandamide biosynthetic enzymes and the inactivating enzyme fatty acid amide hydrolase 
(FAAH) are all located on intracellular membranes. FAAH seems to be most abundant on 
neurons postsynaptic to CB1 receptors, indicating that anandamide acts principally on these 
neurons. An as yet uncharacterised endocannabinoid membrane transporter seems to facilitate 
both endocannabinoid release and re-uptake, and might be localized on both pre- and 
postsynaptic neurons (Adapted from Di Marzo et al, 2004). 
 
 
1.2 CB1 receptors  
As mentioned above, during the 1990s CB1 receptor (Matsuda et al, 1990) was first cloned 
from rat brain cDNA. Its structure consisted of a 473-amino acid G protein-coupled receptor. 
Later, a human homolog of 472 amino acids (Gerard et al, 1990) and a mouse homolog of 473 
amino acids (Chakrabarti et al, 1995) have also been reported. These three CB1 receptors 
share 97–99% amino acid sequence similarity. Also, a number of genetic polymorphisms 
have been described in the CB1 receptor, and their correlation with various conditions has 
been examined (Norrod and Puffenbarger, 2007). Some of the polymorphisms have been 
reported to be linked to several disorders, as obesity-related phenotypes (Gazzerro et al, 
2007), schizophrenia (Chavarria-Siles et al, 2008; Ujike and Morita, 2004), childhood 
attention deficit/hyperactivity disorder (Ponce et al, 2003), and depression in Parkinson’s 
disease (Barrero et al, 2005), but results still need confirmation in independent samples. 
With the use of site-directed mutagenesis, binding properties of cannabinoids to the CB1 
receptor have been elucidated, leading to the knowledge of transmembrane helices of the 
receptor (Song and Bonner, 1996). It is proposed that the CB1 receptor likely exists as a 
homodimer in vivo (Wager-Miller et al, 2002). The magnitude of CB1 dimerization could be 
regulated by agonists’ actions (Martin and Alger, 1999). The CB1 receptor can also exist as a 
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heteromer (Mackie, 2005). One example is the heteromer between CB1 and D2 (Kearn et al, 
2005). It was demonstrated that receptor stimulation promotes the formation of CB1/D2 
complex and alters the CB1 signaling. Another example is the heteromer between CB1 and 
orexin 1 receptor (OX1R). The CB1 activation potentiated the OX1R signaling (Hilairet et al, 
2003), suggesting the interaction of these two receptors. 
In the CNS, cannabinoid receptors distribution was first demonstrated by ligand binding using 
the radiolabeled synthetic cannabinoid [
3
H]CP55,940 (Herkenham et al, 1990; 1991; Mailleux 
and Vanderhaeghen, 1992). Ligand binding sites are widely distributed in the brain at various 
levels depending on the regions and also the neuron types within a given region. High levels 
of [
3
H]CP55,940 binding are observed in layers of the olfactory bulb, hippocampus 
(particularly high in the dentate gyros and CA3 region), striatum and cerebellar molecular 
layer (Herkenham et al, 1990). Moderate levels are noted in cerebral cortex, septum, 
amygdala, hypothalamus and spinal dorsal horn. The thalamus, other nuclei in the brainstem 
and spinal ventral horn present lower ligand binding. These overall binding properties are 
preserved across mammals (Herkenham et al, 1990). These high levels of ligand binding sites 
in the telencephalic and cerebellar regions are compatible with the effects of cannabinoids on 
motor and cognitive functions. In contrast, generally low levels of ligand binding in the lower 
brain stem areas that control cardiovascular and respiratory functions may explain the lack of 
lethal effect of high doses of cannabinoids (Herkenham et al, 1991; Mailleux and 
Vanderhaeghen, 1992). Likewise, the ventromedial hypothalamic nucleus is the satiety center 
for controlling appetite and feeding behavior, moderate levels in these nuclei seem to explain 
anti-anorexic and antiemetic actions of cannabinoids. For this reason, drugs that activate the 
cannabinoid system are used in treatments for nausea and vomiting associated with cancer 
chemotherapy and for appetite suppression and cachexia in acquired immunodeficiency 
syndrome (AIDS) patients (Kano et al, 2009). 
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Considering the widely expression of CB1 in the CNS, two distinct patterns of CB1 mRNA 
expression appears.  CB1 mRNA can be present in uniform and nonuniform labelings, 
depending on brain regions (Mailleux and Vanderhaeghen, 1992, Matsuda et al, 1993). 
Uniform labeling is found in the striatum, thalamus, hypothalamus, cerebellum, and lower 
brain stem in major neuronal populations. For example, CB1 mRNA is expressed in medium 
spiny neurons and parvalbumin-positive interneurons within the striatum, and in cerebellar 
granule cells, basket cells, and stellate cells within the cerebellar cortex. In contrast, non-
uniform expression is found in the cerebral cortex, hippocampus, and amygdala, reflecting the 
presence of a few cell types expressing high CB1 mRNA. In these regions, strong expression 
is seen in cholecystokinin (CCK)-positive GABAergic interneurons, whereas no expression in 
parvalbumin-positive interneurons and generally low expression in principal (or excitatory 
glutamatergic) neurons are noted (Marsicano and Lutz, 1999; Tsou et al, 1999; Katona et al, 
2000; Katona et al, 2001; Kawamura et al., 2006; Monory et al., 2006; Azad et al., 2008; 
Morozov et al., 2009). However, sometimes the endocannabinoid system appears to be 
functionally very important in regions or cell types where the density of CB1 receptor is 
relatively low (Walker et al., 1999; Hohmann et al., 2005 Marsicano et al., 2003; Monory et 
al., 2006). 
Still on CB1 receptor location, inhibitory synapses generally have higher levels of CB1 than 
excitatory synapses among CB1-expressing synapses within given neural regions. Moreover, 
the enrichment of CB1 receptors at inhibitory synapses varies greatly depending on brain 
regions. For example, the density of CB1 on inhibitory synaptic elements is higher than 
excitatory synapses for hippocampal CA1 pyramidal cells, cerebellar Purkinje cells, and 
striatal medium spiny neurons (Kawamura et al, 2006; Uchigashima et al, 2007). The 
difference in distribution, density, and regulation of CB1 expression between excitatory and 
inhibitory synapses provides molecular and anatomical bases for biphasic psychomotor and 
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perceptual actions of marijuana that appear in time- and dose-dependent manners. It is also 
worth mentioning that while most expression CB1 receptor occurs in the limbic areas arises 
from GABAergic and glutamatergic neurons, the receptor has also been identified on 
serotonergic and noradrenergic terminals, suggesting other manners on how 
endocannabinoids influence limbic circuits (Häring et al., 2007; Oropeza et al., 2007).  
Concerning the mechanism of action of the CB1 receptor, multiple signal transduction 
pathways are activated by pharmacological stimulation of CB1 receptors primarily via the 
Gi/o family of G proteins, supported by the studies examining [35S]GTPγS binding and 
pertussis toxin (PTX) sensitivity of cannabinoid effects (Pertwee, 1997). This results in 
inhibition of adenylyl cyclase or cAMP production. Moreover, CB1 activation evokes a 
transient Ca
2+
 elevation in a phospholipase C (PLC)-dependent manner through either Gi/o 
(Sugiura et al, 1997) or Gq proteins (Lauckner et al, 2005). Activation of CB1 receptors 
modulates various types of ion channels and enzymes in a cAMP-dependent or-independent 
manner.  
The activation of CB1 receptor usually works as feedback response for several 
neurotransmitters activations, acting as a break on their release, thus protecting the brain from 
being overwhelmed by excessive excitatory or inhibitory activity. Glutamate release can be 
suppressed by cannabinoid agonists, as reported in several brain regions, including 
hippocampal, cerebellar, striatal, and cortical neurons (Shen et al, 1996; Schlicker and 
Kathmann, 2001). The cannabinoid agonist WIN55,212-2 suppress excitatory postsynaptic 
currents (EPSCs), which was shown to be sensitive to the CB1-specific antagonist 
SR141716A, confirming the involvement of CB1 receptors. The inhibitory effects of 
cannabinoids on GABA release were reported, e.g. in striatum, hippocampus, cerebellum, and 
nucleus accumbens (NAc; Chan et al, 1998; Szabo et al, 1998; Schlicker and Kathmann, 
2001). In these neurons, WIN55,212-2 suppressed GABAergic inhibitory postsynaptic 
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currents (IPSCs), but not the postsynaptic response to exogenously activation after GABA or 
the GABAA-receptor agonist administration, indicating a presynaptic site of action. Such 
response was antagonized by SR141716A, thus confirming the involvement of CB1 receptors 
(Chan and Yung, 1998; Szabo et al, 1998). WIN55,212-2 also reduced EPSCs in wildtype 
animal. However, in slices from conditional mouse mutants lacking CB1 in all principal 
forebrain neurons but not in GABAergic interneurons, WIN no longer affected glutamatergic 
synaptic transmission (Domenici et al, 2006). Modulation of voltage gated Ca
2+
 channels is 
the proposed mechanism involved in the suppression of both GABA (Hoffman and Lupica, 
2000) and glutamate release (Huang et al, 2001) in the synapses. 
Due to its broadly abundance in the CNS, association with a variety of synaptic location and 
influence on several neurotransmitters release, CB1 is implied as the primarily responsible for 
most, if not all, of the psychotropic of exogenous cannabinoids and physiological actions of 
endocannabinoids in the CNS (Elphick and Egertova, 2001). Such responses could be 
modulated based on the action of CB1 on principal projecting neurons and interneurons. The 
release and the rapid inactivation of endocannabinoids, together with the above mentioned 
differential expression of CB1, could suggest that the cannabinoid system has different, and 
occasionally opposite, modulatory functions depending on particular physiological or 
pathophysiological conditions. 
In addition, development of selective CB1 receptor antagonists, such as SR141716A (Rinaldi-
Carmona et al, 1994) and the generation of genetically engineered mice lacking CB1 
ubiquitously or in specific neuronal populations allowed researchers to better investigate the 
relative contribution of the CB1 receptor to pharmacological effects of cannabinoids and 
confirm its importance and different actions in an cell-specific fashion (Ledent et al, 1999; 
Zimmer et al, 1999; Marsicano et al, 2002; 2003; Monory et al, 2006; 2007). These studies 
have revealed that the endocannabinoid system is involved in numerous aspects of neural 
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functions. For example, blocking the endocannabinoid system suppresses the extinction of 
aversive memory (Marsicano et al, 2002), relearning of the water maze test (Varvel and 
Lichtman, 2002), cerebellum-dependent eyeblink conditioning (Kishimoto and Kano, 2006), 
drug addiction (Maldonado et al, 2006), feeding behavior (Pagotto and Pasquali, 2006), a 
certain form of stress-induced analgesia (Hohmann et al, 2005), and the recovery of 
neurobehavioral function after brain injury (Panikashvili et al, 2005). 
 
1.3 Endocannabinoids in affective disorders  
The exposure to cannabis is currently being related to the outcome of several affective 
disorders, such as major depression, anxiety and schizophrenia. Many of the adverse effects 
of cannabis result from high doses or rapid administration of THC or chronic cannabis use. 
For example, intravenous infusion of THC in normal subjects can induce transient psychotic 
symptoms, anxiety, perceptual distortion and cognitive impairment (D’souza et al, 2004; 
Morrison et al, 2009). Smoked cannabis, especially varieties with high concentrations of 
THC, can cause acute psychosis, sometimes accompanied by hypomanic features in normal 
individuals and may precipitate schizophrenia in genetically predisposed individuals (Johns, 
2001). Some longitudinal studies could even demonstrated an association between early-life 
exposure to cannabis and affective disorders, showing that frequent adolescent cannabis use 
increased depression and anxiety in early adulthood (Murray et al, 2007). 
As stated in previous section, CB1 receptors are densely located in brain areas involved in 
emotional states, including amygdala, hippocampus and other limbic sites (Herkenham et al, 
1990). As the endocannabinoid system acts as a modulator of brain excitatory (i.e. 
glutamatergic) or inhibitory (i.e. GABAergic) activity, extreme dysfunctional excitation or 
inhibition may occur leading to neuropsychological states, such as cortical malfunction 
causing mania or hyperarousal at one extreme and depression, anhedonia or apathy on the 
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other. The intrinsic tone of the endocannabinoid system may also be a major contributor to the 
spectrum of personality characteristics in normal individuals and their vulnerability to mood 
disorders. Many of these effects are biphasic and bidirectional depending on dose, mode of 
administration, environment, expectation, personality, degree of tolerance, time after dose and 
other individual factors. For instance, small to moderate doses produce euphoria, anxiolytic, 
sedative ⁄ hypnotic, myorelaxant and analgesic effects, whereas higher doses induce dysphoria 
and anxiogenic effects (Ashton and Moore, 2011). Also, patients using cannabis or synthetic 
THC compounds, like dronabinol or nabilone, for chronic pain conditions or multiple 
sclerosis reported improvement of mood and increased general well-being and mental health 
as well as improved sleep, relief of pain and spasticity and anxiolytic effects (Fabre and 
Mclendon, 1981; Ilaria et al, 1981; Martyn et al, 1995; Wade et al, 2003; Svendson et al, 
2004). However, chronic or repeated use of cannabis is also associated with tolerance, 
dependence, a withdrawal syndrome and possibly long-term cognitive impairment (Hall and 
Solowij, 1998; Ashton, 1999). 
Some of the aspects related to emotional alterations caused by cannabinoids or stressful 
situations can be modeled in laboratory (Cryan and Holmes, 2005), which facilitates the 
investigation of the neurobiology of both stress-related responses and the involvement of the 
cannabinoid system in such situations. When confronted with aversive situation, individuals 
present a behavior repertoire that serves to alert the organism of potentially dangerous or 
harmful stimuli, hence increasing the chances of survival. However, when anxiety and fear 
responses are disproportional in intensity, duration, and/or not associated with any actual risk, 
they can impair physical and psychological functions (LeDoux, 2000; Blanchard et al, 2001). 
Such overreactions may be symptomatic of anxiety-related neuropsychiatric disorders such as 
generalized anxiety, phobia and post-traumatic stress disorder (Graham et al., 2011).  
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Considering animal models of anxiety and fear, most of them take into consideration two 
main aspect of anxiety/fear behavior – one, more ethological, related to exploratory approach-
avoidance behavior that is based on the animal’s innate conflict between the natural drive to 
explore a new environment and the necessity to avoid possible dangerous situations, such as 
open, high and bright areas or contact with a predator. The other aspect is based on learned 
situation (Cryan and Holmes 2005), as learned association between a given neutral space or 
stimulus that is paired with a harmful stimulus like electrical shock. An important matter in 
animal models is the use of multifactorial analyses that reveals that a behavior measured in 
one test of anxiety may not have a similar ethological significance than the one measured in 
another test although both tests are thought to capture the anxiety dimension. Thus, anxiety-
related behaviors measured in on animal test such as the elevated plus-maze do not reflect a 
similar emotionality dimension than those measured in the social interaction test or in 
neophobia tests (Cryan and Holmes, 2005; File and Seth, 2003).  
Bearing that in mind, several animal studies point to the involvement of the endocannabinoid 
system in anxiety and fear, especially the role of the CB1 receptor in these behaviors. 
Typically, increased transmission at CB1 receptors decreases anxiety, whereas inhibition at 
CB1 receptors induces an anxiogenic-like effect (Ruehle et al, 2012; Moreira and Wotjak, 
2010). Thus, considering the action of CB1 receptors in the suppression of neurotransmitter 
release, the endocannabinoid system is seen as one of the key regulatory elements of anxiety 
and fear behavior, which, in turn, could provide new alternatives for treatment and better 
understand the mechanism behind affective disorders. 
As in humans, animal studies reported that CB1 receptor agonists induce biphasic effects, 
with a bell-shaped dose-response curve, with lower doses being anxiolytic and higher doses 
being anxiogenic (Viveros et al, 2005, Moreira et al, 2012). In addition, similar bimodal 
responses were found using CB1 receptor antagonists and other drugs interfering with the 
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molecular machinery of the endocannabinoid system (Lafenetre et al., 2007). These results 
extent to various anxiety paradigms, such as the Vogel conflict test, light/dark box and 
elevated plus-maze, where different components of the anxiety state can be measured (Cryan 
and Holmes, 2005; Rey et al, 2012; Ruehle et al, 2012). 
In different anxiety-related test, animals treated with low doses of CB1 receptor antagonist 
showed no alteration in behavior (Balerio et al, 2006), however when treated with high doses 
some studies described ineffective (Rodgers et al, 2003; Griebel et al, 2005), anxiogenic 
(Patel and Hillard, 2006; Navarro et al, 1997; Arevalo et al, 2001) or anxiolytic (Haller et al, 
2004) responses, which could be a result of different experimental conditions or animal 
species/ strains. For ubiquitous genetic ablation of CB1 receptor, some heterogeneity was also 
found, which is likely to be due to differences in the mouse lines background used, and also to 
experimental conditions. CB1 knockout (CB1-KO) mice seems to behave as control animals 
when tested in a non-aversive environment, but display higher anxiety levels than controls 
under aversive situations (Haller et al, 2004). This demonstrates the on-demand characteristic 
of the endocannabinoid system, and how only particular conditions are able to trigger the 
system. 
The endocannabinoid system is also involved in fear responses. CB1-KO mice show 
impairment extinction of the fear conditioning response when a cue was associated with 
footshock (Marsicano et al, 2002). CB1 antagonist injected in wild type mice confirmed these 
results, which are also observed in the fear potentiated startle paradigm (Chhatwal et al, 
2005). It was also described that the genetic disruption of the CB1 receptor abolished the 
contextual conditioned fear response and that the administration of CB1 receptor antagonist 
AM251 before the test session reduced it in a less efficient manner (Mikics et al, 2006), 
suggesting a differential role of the endocannabinoid system according to the blockage 
method. The use of different contextual fear conditioning protocols allowed discriminating 
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whether the endocannabinoid system modulated the acquisition/initial consolidation of fear 
memory, its reconsolidation or its extinction (Suzuki et al, 2004). Some studies suggest that 
the endocannabinoid system is involved in the acquisition of fear conditioning in particular 
conditions, with no effect in the consolidation of fear memory in either conditioning versions 
(Arenos et al, 2006; for review see Riebe et al, 2012). 
Several evidence also points to the participation of the cannabinoids system in depression-like 
behavior (Serra and Fratta, 2007). It has been shown that cannabinoid receptor agonists could 
have antidepressant activity. Also, pharmacological stimulation of CB1 receptors elicits 
antidepressant-like effects in the rat forced swimming test (Gorzalka and Hill, 2011). Such 
responses are blocked by CB1 receptor antagonists, which per se can induce a state analogous 
to depression in the rodents, including reduced food intake, heightened anxiety, increased 
wakefulness, deficits in the extinction of aversive memories and hypersensitivity to stress 
(Gorzalka and Hill, 2011). 
The bidirectional action of CB1 receptors on emotional-related responses may be related to 
the modulatory role of these targets on GABA and glutamate release across amygdala and 
other forebrain areas (Katona et al, 2000; 2001; Azad et al, 2008). As these two major 
neurotransmitters affect emotional-related in an opposite fashion, different doses of 
cannabinoids and synthetic CB1 receptor agonists may indeed produce highly divergent 
effects in relation to their ability to affect the homeostasis and the balance of GABA and 
glutamate (Bortolato and Piomelli, 2008). Furthermore, CB1 receptors have been shown to 
play critical roles in the regulation of most neurochemical substrates of stress-related 
behavior, including the neurotransmitters dopamine, serotonin, norepinephrine and 
acetylcholine, as well as stress hormones, cholecystokinin and opioid peptides (Szabo and 
Schlicker, 2005; Bortolato and Piomelli, 2008). Further, several studies using CB1 receptor 
knockout mice have reported anxiogenic / reduced fear expression responses in classical 
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paradigms (Haller et al., 2004; Martin et al., 2002). Nevertheless, contradictory data also do 
exist. Together with the susceptibility of the endocannabinoid system to environmental 
variables, the presence of CB1 receptors on glutamatergic and GABAergic neuronal 
subpopulations could provide an explanation, at least in part, for these contradictory findings. 
Depending on whether the experimental conditions predominantly modulate excitatory or 
inhibitory transmission (i.e. glutamatergic or GABAergic), the effect of the absence of CB1 
receptor signaling will lead to different behavioral outcomes. 
Nevertheless, not only GABA and glutamate are involved in the expression of emotions 
modulated by the cannabinoid system. The role of the dopaminergic neurotransmitter system 
in the processing of emotional behavior is also well established and supported by several 
preclinical and clinical data showing that dopamine, acting on dopaminergic postsynaptic D1- 
or presynaptic D2-like receptors, is of highly importance as a neuromodulator for fear and 
anxiety (LeDoux, 2000). The interaction between dopaminergic and cannabinoid system 
appears at different anatomical levels (i.e., amygdala, nucleus accumbens and striatum) and 
seems to be involved in several neurophysiological responses. More specifically, it has been 
suggested that CB1 receptor signaling modulates dopaminergic pathways by influencing 
directly or indirectly the activity of dopaminergic neurons through either post- or pre-synaptic 
mechanisms (Laviolette and Grace, 2006). However, both the mechanisms through which 
dopaminergic and endocannabinoids signaling cross-talk and the role played by the dopamine 
receptor positive neurons still remain unclear. The dopamine D1 receptors which belong to 
the “D1-like” group are expressed in brain regions involved in aversive learning and memory 
such as nucleus accumbens, hippocampus, and amygdala (Kamei et al., 1995; El-Ghundi et 
al., 2001; Nagai et al., 2007). Interestingly, the colocalization of CB1 receptors with D1 
receptors indicates that these receptors may interact by potentially modifying their respective 
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functions with important behavioral and pharmacological consequences (Hermann et al., 
2002). 
Another significant, but yet scarcely explored participation of CB1 receptor is in social 
paradigms. Social disruption is observed in many psychiatric disorders, especially those 
presenting emotion-related dysfunctions as core symptom conditions, such as social 
withdrawal, increased aggressiveness, decreased affiliative behavior and social cognition or 
loss of sexual interest, which are described in schizophrenia, autism, anxiety and major 
depression (American Psychiatric Association, 2000). Considering social aspects, rodents, 
like humans, present a large social repertoire with conspecifics, characterized by high levels 
of complexity in type and number of interactions (Crawley et al, 2007; File & Seth, 2003; 
Choleris et al, 2009). Such similarities between humans and animals underline the potential 
translational value of studies on social behavior in mice in respect to the clinical situation. 
In summary, many studies investigated the role of the cannabinoid system, in particular of the 
CB1 receptor in stress-related situation, however cellular substrates of these effects with 
regard to specific neuronal subpopulation involved (i.e., GABAergic-, glutamatergic- and D1-
expressing neurons) is still largely unexplored. Also, little is known about CB1 receptor 
participation in social behaviors in rodents. For this reason, conditional CB1 knock-out 
animals, lacking CB1 receptor specifically in GABAergic, glutamatergic and D1- positive 
neurons provide an important tool to answer these questions. 
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2 OBJECTIVE 
Considering all the above mentioned, the present work had as main objectives: 
 
- To investigate the role of CB1 receptor located in the dopamine receptor D1-
expressing neurons in emotional behavior. For this reason, conditional CB1 mutant 
mice, lacking CB1 receptors expression in neurons containing dopamine D1 receptors 
(D1CB1
−/−
), were submitted to a battery of behavioral tests, which included 
exploration-based tests, depressive-like behavioral tests, and fear-related memory 
paradigms.  
 
- Secondly, as social engagement is an important feature for species that present large 
and complex social repertoire with conspecifics, and can be disrupted in several 
psychiatry disorders where the endocannabinoid system might be involved, it was also 
evaluated the role of CB1 receptor located in different neuronal subpopulations in 
social approach tests.  
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3 MATERIALS & METHODS 
3.1 Animals 
A total of 247 adult male mice (10-20 weeks) were used. Animals were bred in our breeding 
facility (Max-Planck Institute of Biochemistry, Martinsried, Germany) and transferred to our 
experimental building. Mice were single housed and maintained in standard conditions with 
food and water ad libitum under a 12-h inverse light–dark cycle (lights off at 9 a.m.) for at 
least 14 days before starting the experiments. Total and conditional CB1 mutant mice were 
obtained and genotyped as described previously (Marsicano et al, 2002; Monory et al, 2006; 
Jacob et al, 2009). We used total CB1 receptor knockout (CB1
-/-
; from heterozygous breeding 
pairs); CB1 receptor knockout on cortical glutamatergic neurons (GluCB1
-/-
; from breeding 
pairs where only the fathers expressed the Cre-recombinase); CB1 receptor knockout on 
forebrain GABAergic neurons (GABACB1
-/-
; from breeding pairs where only the fathers 
expressed the Cre-recombinase); CB1 receptor knockout on dopamine D1-expressing neurons 
(D1CB1
-/-
; from breeding pairs where only the fathers expressed the Cre-recombinase) and 
their wildtype littermates (CB1
loxP/loxP 
= WT); alongside with wildtype mice for 
pharmacological treatment. All animals were from C57Bl/6N background, including females 
(total of 25 females were used as stimulus subject). For the social behavior-related 
experiments ovariectomized females were uses. Females underwent ovariectomization 
surgery at least 15 days before the beginning of experiments. Some females also received ß-
estradiol (micro-osmotic pump delivery) for 1 week before the beginning of experiments. 
Mice of a given experiment and line derived from at least four different litters. All behavioral 
experiments were performed during the active (dark) phase of mice between 9:30 a.m. and 5 
p.m.  
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Laboratory animal care and experimental procedures were in compliance with the European 
Union recommendations for the care and use of laboratory animals (86/609/EEC). All 
experimental procedures were approved by the Committee on Animal Health and Care of the 
State of Upper Bavaria (AZ55.2-1-54-2532-44-09), and efforts have been made to minimize 
animal suffering and reduce the number of animals used. 
 
3.1.1 Mutant mice 
CB1
−/− 
mice 
Mice with ubiquitously deletion of CB1 receptor were obtained as described previously 
(Marsicano et al, 2002). Briefly, mice bearing the floxed-neo allele were crossed with 
transgenic mice expressing Cre recombinase ubiquitously. Those carrying a germ-line 
transmissible deletion of CB1 were backcrossed for five generations into C57BL/6N (Charles 
River). Homozygous CB1-deficient mice (CB1
-/-
) and littermate controls (CB1
+/+
) from 
heterozygous breedings were used for the experiments. Experimental animals were genotyped 
by PCR, using primers G50 (5'-GCT GTC TCT GGT CCT CTT AAA-3'); G51 (5'-GGT GTC 
ACC TCT GAA AAC AGA-3') and G54-neo-null 3’ (5'-CCT ACC CGG TAG AAT TAG CTT-3'). 
 
Glu-CB1
−/−
 mice 
Mice with conditional deletion of CB1 receptor on glutamatergic neurons were obtained as 
described previously (Monory et al, 2006). Briefly, transgenic mice (NEX-Cre; where, in the 
adult brain, NEX is expressed in mature glutamatergic cortical neurons, but not in cortical 
GABAergic interneurons; Goebbels et al, 2006) were crossed with CB1
f/f
 mice to 
obtain CB1
f/f;Nex-Cre
 (GluCB1
−/−
) and 
 
littermate CB1
f/f 
controls (GluCB1
+/+
). Experimental 
animals were genotyped by PCR, using primers G50 (5'-GCT GTC TCT GGT CCT CTT AAA-
3'); G51 (5'-GGT GTC ACC TCT GAA AAC AGA-3'); G53 (5'-CTC CTG TAT GCC ATA GCT 
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CTT-3'); G100 (5'-CGG CAT GGT GCA AGT TGA ATA-3') and G101 (5'-GCG ATC GCT ATT 
TTC CAT GAG-3'). 
 
GABA-CB1
−/−
 mice 
Mice with conditional deletion of CB1 receptor on GABAergic neurons were obtained as 
described previously (Monory et al, 2006). Briefly, transgenic mice (Dlx5/6-Cre; where 
Dlx5/6 is expressed in GABAergic neurons) were produced and then crossed with CB1
f/f
 mice 
to obtain CB1
f/f;Dlx5/6-Cre
 (GABACB1
−/−
) and 
 
littermate CB1
f/f
 controls (GABACB1
+/+
). 
Experimental animals were genotyped by PCR, using primers G50 ( 5'-GCT GTC TCT GGT 
CCT CTT AAA-3' );  G51 (5'-GGT GTC ACC TCT GAA AAC AGA-3'); G53 (5'-CTC CTG TAT 
GCC ATA GCT CTT-3'); G100 (5'-CGG CAT GGT GCA AGT TGA ATA-3') and G101 (5'-GCG 
ATC GCT ATT TTC CAT GAG-3'). 
 
D1-CB1
−/−
 mice 
Mice with conditional deletion of CB1 receptor on neurons expressing dopaminergic D1 
receptors were obtained as described previously (Monory et al, 2007). The D1CB1
−/− 
line was 
generated by crossing CB1
f/f
 mice with dopamine receptor D1-Cre line, in which the Cre 
recombinase was placed under the control of the dopamine receptor D1A 
gene (Drd1a) regulatory sequences (Lemberger et al, 2007). Experimental animals were 
genotyped by PCR, using primers G50 (5'-GCT GTC TCT GGT CCT CTT AAA-3'); G51 (5'-GGT 
GTC ACC TCT GAA AAC AGA-3'); G53 (5'-CTC CTG TAT GCC ATA GCT CTT-3'); G100 (5'-
CGG CAT GGT GCA AGT TGA ATA-3') and G101 (5'-GCG ATC GCT ATT TTC CAT GAG-3'). 
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CB1
f/f 
mice  
CB1
f/f
 mice were obtained by crossing mice carrying the CB1-floxed-neo allele with flipase 
deleter mice, carrying the germ-line expression of the recombinase flipase in order to delete 
the FRT-PGK-Neo selection cassette. Experimental animals were genotyped by PCR, using 
primers G50 (5'-GCT GTC TCT GGT CCT CTT AAA-3'); G51 (5'-GGT GTC ACC TCT GAA 
AAC AGA-3') and G53 (5'-CTC CTG TAT GCC ATA GCT CTT-3'). 
 
 
 
Figure 2. Schematic representation of the CB1 receptor allele. Generation of CB1-
deficient mice (homozygous CB1null/null, called CB1-/-).Wild-type, floxed-neo and null 
allele of CB1, respectively. Black boxes, homology arms; white box, CB1 open reading 
frame; stippled box, PGK-neo cassette; white triangles, loxP sites; dashed bars, probes used 
for Southern blot experiments; small arrows, primers for PCR analyses (Adapted from 
Marsicano et al, 2002) 
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3.2  Drugs 
Rimonabant [SR141716A; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide; Cayman Chemical, USA] was dissolved in vehicle 
solution (one drop Tween-80; 2.5% dimethylsulfoxide in saline) to a final concentration of 3 
mg/kg and injected i.p. at 10 ml/kg body weight, 30 minutes before testing. ß-estradiol 
(Sigma-Aldrich, Germany) was dissolved in 0.5% ethanol : 99.5% propyleneglycol for 
administration via micro-osmotic pumps [model 1002, pumping rate: 0.25μL/hr, total volume: 
90±10μL; Alzet, USA] to final concentration of 36mg/mL (Ström et al, 2012) 
 
3.3 Behavioral Tests 
Specifically for the D1CB1 mice, to minimize the use of animal, they were submitted to a 
battery of behavioral tests, which was divided in three main categories, in the following order: 
(1) low- or mild-stress situation (a) exploratory-based approach avoidance conflict tests: open 
field, elevated plus maze, light/dark, novel object investigation, and novelty- induced 
grooming (b) depressive-like behavior paradigms: sucrose consumption and forced swim test 
(2) social approach: social interaction and social investigation test (3) high-stress situation: 
fear conditioning tests. The order of tests within the battery was designed in such manner that 
mice would be evaluated on what were thought to be least invasive tests before being tested 
on more invasive assays. This design was developed with the assumptions that testing from 
least to most invasive would allow for recovery time (4-5 days) between tests and would 
reduce the likelihood that behavioral responses would be influenced by previous testing 
experience. 
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3.3.1 Anxiety- and fear-like behavioral tests 
Animal tests of anxiety and fear are based on innate animal responses or in leaned association 
with aversive conditions. Many anxiety-like tests are based on exploratory ‘approach–
avoidance’ tasks. They take into account that mice are naturally exploratory species, and 
exploration-based tasks exploit the conflicting tendencies to approach novelty versus avoid a 
potentially dangerous area. The aversive area takes different forms in different tests: open, 
elevated arms (elevated plus-maze), a light compartment (light/dark test) the central area of a 
brightly lit open field (open field test). The second sort of test is based on learned associations 
between a neutral stimulus or area and a harmful stimulus, such as a footshock, whereas 
subsequent presentation of the before-neutral stimulus induces aversive responses even when 
the harmful stimulus is not presents, as observed in the fear conditioning test. As different 
tests may not address ethological significance, it is important to submit animals to a battery of 
test that includes several characteristic of anxiety-like behavior. 
 
Open field test  
Exploratory and locomotor activity of D1CB1
−/−
 and control littermate mice was evaluated in 
the open field (OF) test. The experiment was performed in a squared box (26 cm × 26 cm), in 
which the animal was placed in the central zone of the apparatus equipped with infrared 
beams (TruScan; Coulbourn Instruments, Allentown, PA, USA) and allowed to explore for 30 
min at 300 lux. All sensor rings were connected via interface to a computer equipped with 
TruScan Software Version 99 (Coulbourn Instruments). Boxes and sensor rings (infrared 
beam spacing is 0.76cm) were surrounded by an additional box made of opaque Plexiglas side 
walls (47 cm × 47 cm × 38 cm) without roof and floor. Horizontal locomotion (total, margin, 
or central distance moved) vertical movements (exploratory rearing) and time spent at rest 
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were analyzed during the 30-min monitoring period with a sampling rate of 4 Hz. After each 
session, the apparatus was cleaned with a solution containing neutral soap.  
 
Elevated plus maze test  
The apparatus consisted of two opposite open arms, (30 cm × 5 cm) and two arms with walls 
(30 cm × 5 cm × 14 cm) that were attached to a central platform (5 cm × 5 cm) to form a 
cross. The maze was elevated 50 cm from the floor. Illumination measured at the center of the 
maze was 300 lux. The animal was placed in the center of the maze facing one of the closed 
arms, and observed for 5 min, according to the following parameters: number of entries in the 
open or closed arms and time of permanence in each arm (i.e., the time spent by the animal in 
the open or closed arms). An entry was defined as all four paws having crossed the line 
between an arm and the central area. It is accepted that the anxiolytic effect of a given 
treatment/condition is illustrated by increased parameters in open arms (time and/or number 
of entries). The augmented percentage of entries in open arms over the total entries in both 
arms is a good indicator of reduced anxious-like phenotype as well. Entries in closed arms 
and total entries reflect the motor component of the exploratory activity. In the end of each 
session, the maze floor was carefully wiped with a wet towel. All trials were recorded and 
scored off-line by an experienced observer blind to the genotype, using ANY-MAZE 
(Stoelting).  
  
Novelty-induced grooming test (NGT) 
The mice were placed individually into a clean unfamiliar Plexiglass box (27 cm × 16 cm × 
12 cm) without bedding for 10 min. Three ethological measures of grooming activity were 
scored: latency to start grooming, grooming episodes (washing, general grooming, scratching, 
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licking of paws, or genital grooming), and total time spent grooming. All trials were recorded 
for subsequent video analysis.  
 
Light/dark test 
The light-dark (LD) box was divided in two compartments: (1) one dark compartment (15 cm 
× 20 cm × 38 cm) with black walls and (2) one lit compartment (30 cm × 20 cm × 38 cm) 
with white plastic walls. Both compartments were connected by a 4-cm long tunnel. Light 
intensity was 600 lux in the light compartment and 15 lux in the dark compartment measured 
at floor level. Mice were placed into the corner of the dark compartment at the start of the 
experiment which lasted for 5 min. After each test, the LD box was thoroughly cleaned with 
soap and water. Entries and time spent in the light compartment were assessed by video 
analysis by a trained observer blind to the genotype. These two variables were expressed as 
percentage of the total observation period and the total number of LD transitions, respectively. 
Videos were analyzed using ANY-MAZE (Stoelting). 
 
Novel object investigation test  
The novel object investigation (NOI) test was performed at 30 lux (which provides low 
aversiveness to the environment, and still allowed the assessment of exploration of the 
objects) for 10 min. Experimental subjects were habituated to the test arena (36 cm × 22 cm × 
14 cm, with sawdust bedding material and transparent walls) for 2 days for 10 min (one cage 
per mouse without cleaning or changing of bedding). On the third day, mice were transferred 
into the same test cages and two identical objects (cone made of aluminum: ∅ 6 cm + H 13 
cm) were placed in a symmetrical position at the short walls of the cages. Between animals, 
objects were thoroughly cleaned with water containing detergent to eliminate olfactory cues. 
Objects were heavy enough that a mouse could not displace them. Every trial was video 
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recorded and analyzed using ANY-MAZE (Stoelting). Investigation was defined as follows: 
directing the nose toward the object at a distance of not more than 2 cm and/or touching the 
object with the nose and paws (Jacob et al., 2009). 
 
Fear conditioning task  
For the fear conditioning, two different protocols were used. The first experiment was 
performed in two contexts: (1) the shock context – a cubic-shaped box with a metal grid for 
shock application – and (2) the neutral test context – a cylinder made of transparent Plexiglas, 
lined with wood bedding (Kamprath and Wotjak, 2004). For conditioning (d0), mice were 
placed in the conditioning context. Three minutes later, a tone (80 dB, 9 kHz sine-wave, 10 
ms rising, and falling time) was presented to the animals for 20 s that co-terminated with a 2-s 
scrambled electric footshock of 0.7 mA. Mice were returned to their home cages 60 s later. 
On day 1 (d1), mice were exposed to the neutral context and on day 2 (d2) to the shock 
context for 7 and 3 min, respectively. To test the freezing response to the tone, mice were 
placed in the neutral context, which differed from the conditioning context in material, shape, 
surface texture, and odor of the cleaning solution (Kamprath and Wotjak, 2004). After an 
initial 3 min of habituation, a 180-s permanent tone [9 kHz, 80 dB, sine-wave] was delivered. 
To test the contextual freezing, animals were re-exposed to the shock chamber for 3 min 
without tone presentation and without further shock presentation, and immediately returned to 
their home cages afterward. In the second experiment, mice were conditioned as described for 
the first experiment. On day 1 (d1) and on day 7 (d7), mice were exposed to the 180-s tone in 
the neutral test context. Animals’ behavior was video recorded and analyzed off-line by a 
trained observer blind to the groups (EVENTLOG software, designed by Robert Henderson, 
1986). Freezing behavior was defined as immobility except for respiration movements. 
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3.3.2 Depression-like behavior tests 
Animal models and tests for assessing depression-related behavior in rodents usually involve 
exposure to stressful situations. Of these experimental procedures, the forced swim test (FST) 
(also known as Porsolt’s test; a behavioral despair test) is probably the most widely and most 
frequently. It is  based on the observation that rodents placed in an enclosed filled with water 
will initially engage in vigorous escape-orientated movements, but when they realized that it 
is not possible to escape from this situation, they exhibit increasing bouts of immobility, as if 
they are “giving up the fight”. Another phenotype measured is anhedonia (loss of interest in 
normally pleasurable and rewarding activities), that can be assessed by the simple preference 
for highly palatable solution, such as sucrose, over water. 
 
Forced swim test  
In the forced swim test (FST; Porsolt et al., 1978), mice were individually placed into 
transparent cylinders (height 23.5 cm; diameter 16.5 cm) containing 15 cm water at 25 ± 1°C 
for 6 min. The water was changed after each trial. After vigorous activity, swimming attempts 
cease and the animal adopts a characteristic immobile posture. A mouse is considered 
immobile when it floats in upright position and makes only small movements to keep its head 
above water. The duration of mobility was recorded during the last 4-min of the 6-min testing 
period. All trials were recorded and scored off-line by an experienced observer blind to the 
genotype. 
 
Sucrose consumption test  
During this test, mice are given a free choice between two bottles for 10 h – one filled with 
2.5% sucrose solution and the other with tap water – for two consecutive days (Strekalova and 
Steinbusch, 2010). To prevent possible effects of side preference in drinking behavior, the 
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bottles position was switched in the mid-point of testing. Animals were not food or water-
deprived before the test. For habituation, 1 day prior to the first testing day, animals were 
allowed to drink a 2.5% sucrose solution for 2 h. The consumption in water, sucrose solution, 
and total intake of liquids were estimated simultaneously in the both groups by weighing the 
bottles before and after each trial. The preference for sucrose was calculated as a percentage 
of the consumed sucrose solution from the total amount of liquid drunk, by the formula: 
Sucrose Preference = V(Sucrose solution)/[V(Sucrose solution)+V(Water)]×100%.  
 
3.3.3 Social-related tests 
For these experiments, two different approaches were selected. In the first one, bidirectional 
free-contact was allowed (social interaction test), meaning that regardless of which animal 
initiated the contact there was some interaction between them. On the second task, only the 
test subject was able of initiating contact (social investigation test), which allowed a more 
specific measured of the social intention.  
 
Social interaction test  
Experiments were performed in a new cage (27 cm × 16 cm × 12 cm) with fresh bedding at 5 
lux (i.e., red light). The wall of the cage was extended by 12.5 cm with semi transparent 
plastic. In this test, pairs of unfamiliar mice were placed into the cage for 5 min. Depending 
on the test session, each test subject was paired either with an ovariectomized female (OVX); 
an ovariectomized female with hormonal replacement (OVX + E); or a male mouse of the 
same genotype. The time spent in social interactions (SI; active contact such as sniffing, 
licking, close following, and grooming) and aggressive behavior (fighting and biting, causing 
injury) was recorded for each pair of mice. Each session was video recorded and analyzed off-
line using ANY-MAZE (Stoelting). 
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Social investigation test  
Social investigation (SInv) was performed inside a rectangular box made of white PVC walls 
and with a dark gray PVC floor. The box was divided into three equal compartments (30 cm × 
30 cm × 30 cm) that were interconnected by small opening (6 cm × 5 cm) with guillotine 
doors. Each animal was allowed to free exploration of the apparatus for 10 min (habituation). 
An empty perforated 50 ml falcon tube (length: 11.4; diameter: 2.8 cm
2
; with 22 holes of 0.5 
cm diameter to provide ventilation and olfactory cues to the test animals) was placed in each 
side of the box. This 10 min exposure was designed to familiarize the test subject with the box 
environment. After habituation session, the animal was kept in the center compartment and 
one of the tubes was replaced by a tube containing either an ovariectomized female (OVX); 
an ovariectomized female with hormonal replacement (OVX + E); or male mice. For the next 
10 min test session, the mouse was allowed to explore all three compartments and the time 
spent in contact with the tubes (active contact such as sniffing) was evaluated. All trials were 
recorded and scored off-line by an experienced observer blind to the genotype. 
 
3.4 Statistical Analysis 
Data were analyzed using unpaired t-test or two-way ANOVA. Newman–Keuls test was used 
as post hoc test, if appropriate. Data are presented as mean ± SEM. Statistical significance 
was accepted if p < 0.05. 
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4 RESULTS 
In this first part, it is shown the role of CB1 receptor signaling in the dopamine receptor D1-
expressing neurons on emotional behavior. D1CB1 mice underwent a test battery to access 
different behaviors, which are considered to be related to anxiety, depression and fear- 
responses. All results will be discussed separately in the following sections. 
 
ANXIETY-LIKE BEHAVIOR  
 
Open field test  
 
In the open field test, there was no difference in the exploratory activity between D1CB1
−/−
 
and control group (Figures 3A–F). Both groups showed the same horizontal activity (n= 6-9; 
total distance: t = 1.246; p = 0.2348; central distance: t = 1.501; p = 0.1574, margin distance: t 
= 0.2401; p = 0.8140), total duration of movement (t = 1.217; p = 0.2452), rearing (t = 1.715; 
p = 0.1101), and jumping episodes (t = 1.344; p = 0.2021). This response indicates that in our 
test conditions, genetic deletion of CB1 in neurons expressing D1 receptors did not alter basal 
locomotor activity of mice. 
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Figure 3. Assessment of general locomotor activity of D1CB1
−/−
 mice in the open field 
(OF) test. Conditional D1CB1
−/−
 mutant mice and their respective control littermates were 
tested in an open field for 30 min (n= 6-9). Values are mean ± SEM in terms of horizontal 
activity (A–D) rearing (E) and jumping episodes (F). 
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Elevated plus maze and light/dark test  
 
As described in Figures 4A–D, statistical analysis did not reveal any significant difference 
between D1CB1
−/−
 and control group both in the time spent (n=7-8; t = 0.5568; p = 0.5871) or 
in the number of entries (t = 0.6133; df = 14; p = 0.5502) into open arms of the EPM test. 
Also, there was no difference in the time spent (n= 8-9; t = 0.2827; p = 0.7813) or in number 
of entries (t = 0.9739; df = 15; p = 0.3430) into light compartment of the LD test. No 
locomotion difference was found, considering the total arm entries (t = 0.7276; p = 0.4798) 
and the total LD transitions (t = 0.8154; p = 0.4255) as index. 
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Figure 4. Anxiety-like behaviors of D1CB1
−/−
mice. Conditional D1CB1
−/−
 mutant mice and 
their respective control littermates were tested for 5 min in the elevated plus maze (upper 
panel; n=7-8) or in the light/dark box (lower panel; n= 8-9). Data are presented as mean ± 
SEM regarding open arm entries and open arm time (A) the total arm entries(B), light 
compartment entries and light compartment time (C), and total compartment transitions (D). 
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Novel object investigation 
 
 Unpaired t-test showed that D1CB1
−/− 
and control group, during the 10-min test, spent the 
same amount of time investigating the pair of novel objects (n=8-10; t = 0.5887; p = 0.5643), 
as well as they approached them with the same frequency (t = 0.5705; p = 0.5762; Figure 5).  
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Figure 5. Novel object investigation test (NOI). Conditional D1CB1
−/−
 mutant mice  and 
their respective control littermates were exposed to two novel objects for 10 min (n=8-10). 
Data are presented as mean ± SEM regarding total investigation duration (A) and number of 
approaches (B). 
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Novelty-induced grooming activity test  
 
As described in Figures 6A–C, D1CB1
−/−
 mice performed more grooming episodes (n=8-9; t 
= 2.240; p < 0.05) as well as they spent more time grooming as compared to control animals (t 
= 2.568; p < 0.05). However, the latency to start grooming was not significantly different 
between the two groups (t = 1.170; p = 0.2603). 
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Figure 6. Novelty-induced grooming behavior in D1CB1
−/−
mice (NGT). Conditional 
D1CB1
−/−
 mutant mice and their respective control littermates were tested for the grooming 
activity measure (n=8-9). Data are presented as mean ± SEM regarding latency to start 
grooming (A), number of grooming episodes (B) and total grooming duration (C). *p < 0.05 
as compared to WT mice (unpaired t-test). 
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DEPRESSIVE-LIKE BEHAVIOR  
 
Forced swim test and sucrose consumption  
 
As described in Figure 7, D1CB1
−/−
 mice showed a significant lower sucrose consumption as 
compared to control group on the first (n=10; t = 2.868; p < 0.05), but not on the second 
testing day (t = 0.3575; p = 0.7249). Both, D1CB1
+/+
 and D1CB1
−/−
 mice, showed a high 
percentage of sucrose consumption as compared to the total amount of liquid consumed. In 
the FST, although D1CB1
−/−
 mice showed a decrease in the mobility as compared to control 
animals, the difference between the two genotypes did not reach statistical significance (n=7-
9; t = 1.904; p = 0.0777). 
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Figure 7. Depressive-like behaviors of D1CB1
−/−
 mice. Conditional D1CB1
−/−
 mutant mice 
and their respective control littermates were tested in the sucrose consumption (SC; n=10) 
test (A) or in the forced swim test (FST; n=7-9) paradigm (B). Data are presented as mean ± 
SEM regarding percentage of sucrose consumption or mobility time expressed in seconds. 
*p < 0.05 as compared to WT mice (unpaired t-test). 
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FEAR-LIKE BEHAVIOR 
 
Fear conditioning  
 
As shown in Figure 8A, unpaired t-test revealed that D1CB1
−/−
 showed a significant increase 
on freezing response to the tone at day 1 (n= 8-9; t = 2.497; p < 0.05) and to the context at day 
2 (t = 3.210; p < 0.01) as index of increased auditory-cued and contextual fear responses, 
respectively. When analyzed in 20-s intervals, all mice showed the same initial freezing 
response on day 1. However, whereas control animals showed a rapidly waning freezing 
response during the tone presentation, D1CB1
−/−
 mice showed a deficit in acute fear 
adaptation (B). The second experiment, largely confirmed their phenotype (C, D): D1CB1
−/−
 
mice showed a significant increase on freezing response to the tone on day 1 (t = 4.234; p < 
0.001) and on day 7 (t = 2.923; p < 0.01), which again results from impaired acute fear 
adaptation over the course of tone presentation (D). Freezing before tone presentation on day 
1 was low and indistinguishable between the two groups. 
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Figure 8. Fear memory in D1CB1
−/−
 mice. Auditory-cued (Tone) and contextual (Context) 
fear memory assessed by freezing responses (mean ± SEM) of conditional D1CB1
−/−
 mutant 
mice and their respective control littermates in two independent sets of experiments (A/B, 
C/D; n= 8-9). If not stated otherwise, freezing was averaged over the entire 180 s observation 
periods (A, C) or analyzed in 20 s intervals (B, D). *p < 0.05, **p < 0.01, ***p< 0.001 as 
compared to WT mice (ANOVA for repeated measures followed by Newman–Keuls post hoc 
test). 
  Results  
 
59 
SOCIAL BEHAVIOR  
 
In the second part of this thesis, it is presented results related to the role of CB1 receptor 
localized in different neuronal sub-populations in the modulation of social activity. The 
following results were separeted by social task, where animals were directly or indirectly 
allowed to interact with a male or ovariectomized female stimulus subjects. 
 
Social Interaction 
 
For the social activity, all lines were tested. In the social interaction test, when two free-
moving male mice were confronted in the same cage, none of the tested lines presented 
differences in the contact time compared to their control group (Figure 9), even though 
GABACB1
-/- 
 showed slightly increased social interest (CB1: t=0.29; WT: t=1.20; GluCB1: 
t=1.15;
 
GABACB1: t=2.00; D1CB1
 :
 t=0.25; All  p>0.05). Aggressive behavior was only 
observed in one pair of GluCB1
-/- 
and one pair of GluCB1
+/+
. Therefore, this parameter was 
not further considered. Still in the social interaction test, to verify if the two main opposite 
genotype (GluCB1
 
and
 
GABACB1) and the D1CB1 would present differences in interaction 
when confronted with female subjects, males were introduced to ovariectomized females with 
or without ß-estradiol treatment.  
In case of GluCB1, a 2-way ANOVA (genotype, stimulus subject) revealed significant main 
effects of genotype (F1,28 = 30.72, p < 0.0001) and subject (F2,25 = 26.91, p < 0.0001) as well 
as a significant genotype x subject interaction (F2,25 = 8.563, p < 0.005). Post-hoc tests 
confirmed that GluCB1
-/- 
showed less exploration of OVX females without or with estradiol 
replacement than control group, whereas exploration of male subjects was similar. 
Interestingly, GluCB1
+/+
, but not KO, spent significantly more time investigating the females 
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than the males. For the GABACB1, it was observed significant main effects of genotype (F1,44 
= 8.160, p < 0.01) and subject (F2,41 = 6.907, p < 0.005), but no significant genotype x subject 
interaction (F2,41 = 0.8315, p = 0.442). Thus, GABACB1
-/- 
spent more time in investigating 
social stimuli than GABACB1
+/+
, irrespective of the sex of the stimulus subjects. D1CB1
-/-
 it 
was observed significant main effects of stimulus subject (F2,40 = 16.25 p < 0.01), but no 
significant effect of genotype (F1,43 =0.56, p=0.46 ), nor genotype x subject interaction (F2,40 = 
1.42 p = 0.25). 
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Figure 9. Social Interaction with a male, an OVX female or an OVX female treated with 
ß-estradiol. Effects of pharmacological blockage (SR141716) or genetic deletion of CB1 
receptor on social interaction behavior between a pair of unfamiliar mice - male mice of the 
same genotype/pharmacological treatment, ovariectomized females (female OVX) or 
ovariectomized females with hormonal replacement (female OVX + E). Values are 
represented as means ± S.E.M. *p< 0.05. 
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Social Investigation 
 
In the 3-chamber social investigation test, when the stimulus subject was a male mouse 
(Figure 10), CB1
-/-  
mice presented a lower interest for the social stimulus relative to the 
control group, however in a non-significant manner (n=6-7; genotype: F11,1=1.84; p=0.20; 
genotype x time in contact: F11,1=3.24, p=0.09). Both groups showed preference for the tube 
containing the stimulus mouse compared to the empty one (time in contact: F11,1= 36.16, 
p<0.001). Similarly, animals that received vehicle or SR141716 preferred to explore the tube 
containing the unknown mouse instead of the empty tube (time in contact: F17,1=26.18, 
p<0.001). Yet, differently from the CB1
-/- 
, animals treated with the CB1 receptor 
blocker/inverse agonist exhibited a significant reduction in time spent investigating the social 
stimulus (n=9-10; genotype x time in contact: F1,17=4.52; p<0.05). As observed for the CB1
-/-
 
animals, in the presence of a male mouse stimulus, GluCB1
-/- 
showed no significant difference 
in investigation as compared to the control group (n=10; genotype x time in contact: 
F1,18=0.07; p=0.93). The same applies to GABACB1
-/- 
mice, (n=8-10; genotype x time in 
contact: F1,16=0.60; p=0.45), and to D1CB1
-/- 
(n=9-10; genotype x time in contact: F1,17=1.30; 
p=0.27). All three mutant lines showed preference for the social stimulus when compared to 
the inanimate object. 
In presence of a female stimulus subject (Figure 10), CB1
-/- 
spent significantly less time in 
contact with the social stimulus compared to control littermates (n= 13-16; genotype x time in 
contact: F1,27 = 7.17, p<0.05). WT mice treated with SR141716 also spent less time 
investigating the female stimulus compared to the vehicle group (n=6-7; genotype x time in 
contact: F1,11 =6.53, p<0.05). The same applies to GluCB1
-/- 
(n=8-10; genotype x time in 
contact: F1,16=4.65; p<0.05). GABACB1
-/-
, in contrast,
 
showed the opposite behavior by 
spending significantly more time in contact with the female stimulus (n=11; genotype x time 
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in contact: F1,20=16.05, p<0.01). Yet, D1CB1
-/- 
investigated the OVX female with similar 
intensity as their control group (n=9-10; genotype x time in contact: F1,17=1.85, p>0.05).  
Again, to better understand the role of CB1 receptor on specific neuronal population, D1CB1, 
GABACB1 and GluCB1 mice were presented to a tube containing a female OVX + E. In this 
situation, GluCB1
-/- 
showed reduced interest for the female tube, yet non-significant compared 
to the control group (n=6; genotype x time in contact: F1,10=0.93, p=0.35), oppositely to the 
GluCB1
-/-
, but in the same direction as previously with the OVX females, GABACB1
-/- 
demonstrated increased investigation for the female treated with ß-estradiol (n=10; genotype 
x time in contact: F1,19=5.23, p<0.05). While, D1CB1
-/- 
showed for the first time a significant 
increase in time of investigation when compared to control group (n=9-10; genotype x time in 
contact: F1,18=4.79, p<0.05). 
  Results  
 
64 
 
Figure 10. Social Investigation of social stimulus subject – Effects of pharmacological 
blockage (SR141716) or genetic deletion of CB1 receptor on social investigation of a male 
stimulus mouse; ovariectomized females (female OVX) or ovariectomized females with 
hormonal replacement (female OVX + E) in the 3-chamber box. Values are represented by 
means ± S.E.M. *p< 0.05; Newman–Keuls post hoc test. 
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5 DISCUSSION 
The first half of the present study provide novel evidence that the genetic deletion of 
cannabinoids CB1 receptors in dopamine D1 receptor-expressing neurons is able to affect the 
emotional behavior in mice in highly selective manner. The development of conditional CB1 
mutant mice lacking CB1 receptors specifically from neurons expressing D1 receptors 
(Monory et al., 2007) has been a useful tool to better understand the role of the 
endocannabinoid system in emotional behavior.  
Firstly, it should be reminded that growing evidence indicates that measures of anxiety from 
different tests reflect different states of anxiety. This encouraged the usage of different 
behavioral paradigms such as exploration-based tests and learned fear paradigms, to assess 
different aspects related to several psychiatric disorders in humans, as agoraphobia, social 
phobia or post-traumatic stress disorder (Lister, 1990; File, 1993; Cryan and Holmes, 2005). 
Some of the tests used for this work primarily focus on interest to investigate novel 
environment, others emphasizes social interaction, while a third kind targeted situations that 
involve a strong mnemonic component, such as fear based tests. Even though animal studies 
allow the possibility to directly test the causal relationship between cannabinoid exposure and 
subsequent risk for several psychiatric disorders or to better understand the neurobiological 
background of certain conditions independent of subject-specific factors or previous 
individual history that confound human investigations, it presents some caveats. Animal 
studies do not mimic the complex nature of psychiatric disorder, thus only specific 
phenotypes relevant to a given disorders can be examined. Still, animal models should present 
characteristic that make them valid for use. Any model should be valid if shares structure with 
a behavior or pathology, which means that whenever a relation holds between an animal 
model, a correspondent relation should be seen in the modeled species, usually human 
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(Kaplan and Saccuzzo, 1997). This improves the reliability of the model and obtained results. 
It has been proposed that the validity of a model should be based on face validity, predictive 
validity and construct validity (Willner, 1986). Face validity has many advantages and can be 
easily verified, however, high emphasis on face validity could delay or even prevent the 
development of new animal models because it considers the similarity between the behavior 
observed in an non-human animal and the one observed in human, therefore the usage of such 
an anthropomorphic focus could be a barrier for the use of animals more distant from human 
in the phylogenetic scale (Willner 1986; van der Staay, 2006). Predictive validity considers 
the ability of a model to estimate a behavior outcome, which can be exclusively based on 
empirical evidences without understanding the behavior itself or even its biological 
background. Also, predictive validity is vastly used to evaluate pharmacological properties of 
certain compounds, especially to investigate antidepressant and anxiolytic properties of new 
drugs (Bourin et al, 2002, 2001; Epstein et al, 2006), however in some situations, predictive 
validity shows limitations due to the distinct pharmacodynamics and pharmacokinetic 
properties of each species. Construct validity refers to the theoretical aspects of what the 
model measures, and is consider the most important criterion for animal models. It is based on 
the similarity between the mechanisms underlying animal and human behavior, and requires 
an etiological relationship between the species. Thus, it is theory-driven, where behavioral, 
pathophysiological and neural components are taking into consideration; reflecting the degree 
in which the theory and the model explain the true nature of the symptoms or syndrome 
studied. Construct validity also defines a relationship between dependent and independent 
variables with the theoretical hypothesis tested (Lubow, 2005; van der Staay et al, 2009). It is 
easier to apply this concept in models that investigate “normal behavior” aspects, as in 
anxiety, that in different species it can be induced by a threatening stimulus, considering those 
that can produce disturbance in the subject’s homeostasis. However, it becomes more difficult 
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when considering pathological processes, due to the unknown and complex nature of many 
disorders (Sarter and Bruno, 2002). 
The first novel result of the present study was that D1CB1
−/−
 mice did not show any anxiety-
like phenotype when tested in exploratory behavioral paradigms such as elevated plus-maze, 
light-dark test or novel object investigation. These procedures mostly reflect the conflict 
between exploration and avoidance of a novel environment; thus, the inhibition of exploratory 
behavior observed by the reduced open arms or light compartment entries and novel object 
exploration is commonly associated with high emotionality or anxiety. D1CB1
−/−
 mice also 
did not show any alteration in spontaneous exploration and locomotor behavior. These 
findings are in line with previous data showing no anxiety-like phenotype in mice with total 
CB1 receptors deletion and with specific CB1 receptors deletion on glutamatergic neurons 
(Marsicano et al., 2002; Lafenêtre et al, 2007 Jacob et al., 2009). However, the D1CB1
−/−
 
mice showed increased grooming activity. Grooming is considered a “maintenance” behavior, 
a common species-characteristic movement pattern with readily definable components 
(Bolles, 1960) that serves a range of adaptive functions, including stress reduction and social 
interplay (Kalueff and Tuohimaa, 2005). In rodents, spontaneous grooming behavior may 
occupy as much as 25–40% of the wakeful time, but it is specifically elicited in situations 
(i.e., novelty-induced grooming) where an animal is under a stress-induced conflict or 
frustration. It is also affected by pharmacological treatment, being reduced following 
anxiolytic treatment (Dunn et al., 1981; Gispen and Isaacson, 1981; van Erp et al., 1994; 
Micale et al., 2008). Thus, the present results suggest that if the exposure to novelty cannot be 
controlled by the animals, the novel environment is able to influence the emotionality of 
D1CB1
−/−
 mice. 
The D1CB1
−/−
 mice exhibited a decreased preference for sweet solutions on the first but not 
on the second day of the sucrose preference test under basal conditions, indicating a mild 
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anhedonia-like state. Although anhedonia is commonly associated with depression-like 
behavior phenotype, mutant mice performed as controls in FST, a procedure widely used for 
evaluating behavioral despair in rodents (Cryan and Holmes, 2005). Thus, the modulation of 
depressive-like behaviors may be mediated by distinct neuronal circuits in D1CB1
−/−
 mice 
evaluated in a task-specific or dependent manner. On the other hand, the lower sucrose 
preference test was only evident upon the first confrontation with the novel taste (day 1) and 
disappeared on the next day, suggesting a significant contribution of neophobia. Interestingly, 
D1CB1
−/−
 mice showed sustained auditory-cued and contextual fear responses, thus 
resembling the phenotype of impaired fear adaptation observed in mice with complete 
deletion of CB1 receptors (Marsicano et al., 2002; Kamprath et al., 2006) or selective deletion 
from principal neurons of the forebrain (Kamprath et al., 2009). Since Monory et al. (2007) 
showed that the deletion of CB1 in D1-expressing neurons did not alter the analgesic effects 
of THC, it can be excluded the possibility that the phenotype of D1CB1
−/−
 mice in the fear 
conditioning paradigms could be due to different nociceptive thresholds.  
Currently, it is not precisely known the mechanism behind the CB1 receptors modulation of 
D1 receptors-mediated emotional behavior. However, due to their coexpression, it is tempting 
to assume that a direct or indirect receptor–receptor interaction, via intracellular signaling 
pathways, might be involved (Glass et al., 1997; Gangarossa et al., 2011). Previous studies 
showed D1 receptor encoding gene (Drd1a) associated with Cre-recombinase is robust in the 
major projections areas of the dopaminergic system, including striatum, nucleus accumbens, 
olfactory tubercles and prefrontal cortex. Lower expression was observed in layer VI of the 
cortex, hippocampus, thalamic and hypothalamic nuclei (Lemberger et al, 2007). To better 
study the role of D1 receptor in different pathologies, a mutant mouse line using used Cre-
mediated recombination to ablate neurons expressing the Drd1a gene during development 
was developed (Drago et al, 1998; Wong et al, 2000; Padungchaichot et al, 2000); however 
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most animals died before completing 1 week. Those that survive until 3 weeks old displayed 
hyperkinetic syndrome with gait abnormality, as observed in basal ganglia diseases. Recently, 
some studies use a Cre-mediated strategy to ablate Drd1a-expressing neurons after 
birth.These animals present a better survival rate and showed a relatively mild distonia 
phenotype (Gantois et al, 2007). 
Still in the hypothesis of interaction between D1 and CB1 receptors, Martín et al. (2008) 
showed in rats that pharmacological CB1 receptors blockade or activation could facilitate or 
inhibit animal behavior, respectively; and this latter effect was absent in D1 receptors knock-
out mice, demonstrating a D1 receptors dependence on CB1-mediated actions. Thus, in the 
highly aversive situations of fear conditioning paradigms, where a strong stimulus as a 
footshock was delivered, the endocannabinoid signaling failed. This happens due to the CB1 
deletion that negatively modulates the D1 receptors emotional-related behavior, leading to an 
impaired fear adaptation.  
In the second part of the present study, it was evaluated the involvement of CB1 receptors in 
social behavior in mice. For that purpose, direct contact between two animals was 
investigated, with the attempt to create a more ethological situation. Given previous reports 
about social interaction after pharmacological blockage or genetic deletion of CB1 receptor 
(Jacob et al, 2009; Häring et al, 2011, Litvin et al 2013) it was surprising not to observe any 
treatment / genotype differences. One explanation for the discrepant findings might be the 
previously observed interaction between aversiveness of the test situation and involvement of 
CB1 receptors signaling in social behavior (Jacob et al, 2009). In the present study the 
emotional load was maintained at a minimum by using less aversive conditions like red light. 
Higher light intensity, however, would have confounded our interpretation of “social 
intention” by differences in anxiety levels (Jacob et al, 2009). Also, these experiments, for all 
mutant lines and treatment, failed to observed differences in aggression, differently than 
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reported for the resident-intruder test where GluCB1
-/- 
showed increased aggression (Häring et 
al, 2011) – mice did not show any territorial / aggressive behavior in the novel environment, 
independent of the genotype. While testing the speficic mutante mice lines (D1CB1, 
GABACB1 and GluCB1) on direct contact with females (OVX and OVX + E), D1CB1
-/- 
showed same levels of interaction as control littermates. Also, GABACB1
-/- 
presented a 
similar phenotype as observed in the interaction between two males, they showed increased, 
yet not significant, in time of interaction. On the other hand, GluCB1
-/-
 demonstrated reduced 
levels of interaction in both female conditions (OVX and OVX + E). This could be related to 
the level of salience provocated by female subjects that are not observed during a less 
interested pairing.  
Continuing on the involvement of CB1 receptors in social behavior, animals were submitted 
to the 3-chamber social investigation test, where the test subject had the option of 
investigating or not the stimulus animal in comparison with exploration of an inanimate 
object located in another compartment. When mice were presented with a male mouse as 
stimulus subject, all groups showed a higher interest for the social stimulus compared to the 
empty tube. However, only animals treated with SR141716 showed significantly reduced 
exploration of the social stimulus when compared with vehicle-treated control. Yet, in the 
presence of a more interesting stimulus subject, such as an OVX female mouse, all groups 
differed from their control, except for the D1CB1
−/−
. Again, SR141716 treated animals 
showed a reduction in time investigating the social stimulus; the same was observed for total 
CB1
-/- 
and GluCB1
-/-
. This suggests that activation of CB1 receptors in glutamatergic neurons 
is involved in the promotion of sexual interest. The opposite was observed for GABACB1
-/-
, 
which presented an increase in social interest for the female stimulus. When tested with an 
OVX + E female, GABACB1 and GluCB1 presented the same pattern of behavior, with 
GABACB1
-/-
 showing higher time investigating the OVX + E female, whereas GluCB1
-/-
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showed a tendency to reduced investigation time towards the stimulus female. Interestingly, 
in the presence of the OVX + E female, D1CB1
-/- 
showed an increased investigation towads 
the stimulus mouse, a phenotype more related to GABACB1 animals. Therefore, CB1 in 
glutamatergic versus GABAergic neurons control sexual interest in an opposite manner, 
similar to exploration of novel objects (Lafenêtre et al, 2009; Häring et al, 2011), active 
versus passive avoidance (Metna-Laurent et al, 2012) and cannabinoid-induced anxiolytic 
versus anxiogenic effects (Rey et al, 2012), while CB1 in D1 expressing neurons involment 
depends on the value or intensity of the situation. The sex dependency of differences in social 
interest is remarkable since it was used ovariectomized females, which may not be the most 
arousing stimulus for a male subject. However, Pankevich et al (2004) showed that even 
though males generally prefer to investigate female in estrous cycle, odor of ovariectomized 
females still promotes interest for investigation when compared to a neutral odor. Still, the 
opposite situation (i.e. female investigating male stimulus subject) is rarely investigated, 
which provides an interesting area for future studies. These results corroborate with previous 
studies (Häring et al, 2011; Jacob et al, 2009) that showed the different involvement of CB1 
receptor depending on its localization. An important point to highlight in the current study is 
that differences observed were dependent on the gender of the stimulus subject, i.e. male vs 
female mice. 
Several studies reported increased anxiety-related behaviors after impaired CB1 receptors 
signaling only when aversive stimulus cannot be avoided (Haller et al., 2004, 2009; Thiemann 
et al., 2007; Kamprath et al., 2009; Jacob et al, 2009). However, little is known about how the 
endocannabinoid system modulation of the dopaminergic system could be involved in this 
effect. It is accepted that the endocannabinoid system modulates several neurotransmitter 
systems (glutamatergic, GABAergic, and dopaminergic) at multiple levels (Piomelli, 2003; 
Katona and Freund, 2008). In the brain, where exogenously administered and endogenously 
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released cannabinoids exert most of their behavioral effects, the CB1 receptors are expressed 
at different levels at different neuronal subpopulations. More specifically, they are present at 
very high levels in GABAergic interneurons, where they mediate cannabinoid-dependent 
inhibition of GABA release, and to a minor extent, in glutamatergic terminals (Marsicano and 
Lutz, 1999). In the glutamatergic neuronal subpopulation, they play a pivotal role in both 
neuroprotection and fear extinction in highly aversive situations, through the modulation of 
glutamate release, further confirming that the fear-alleviating effects of CB1 became evident 
primarily under highly aversive conditions (Monory et al., 2006; Kamprath et al., 2009; 
Moreira and Wotjak, 2010). Several lines of evidence suggest that dopamine is released in 
several brain regions such as the amygdala and prefrontal cortex under stress conditions. By 
acting on D1- or D2-like receptors, dopamine is involved in physiological processes 
facilitating affective behaviors and emotional learning (LeDoux, 2000). Although, 
coexpression of the cannabinoid CB1 and D1 receptors supports the idea of the cannabinoid–
dopaminergic system cross-talk, as in forebrain basal ganglia and piriform cortex, the exact 
role of D1 receptors is not fully understood. Nevertheless, the present data add a new facet to 
the cross-talk between different neurotransmitter systems (i.e. GABAergic, glutamatergic and 
dopaminergic) and the endocannabinoid systems, within the attention being draw to different 
levels of social interaction. Several animal studies investigated the participation of the 
cannabinoid system in sexual interest and reproductive processes. They observed that direct or 
indirect CB1 receptor activation significantly impairs sexual-related behavior (Shrenker and 
Bartke 1985; Ferrari et al. 2000; Hill and Gorzalka, 2006), indicating reduction in sexual 
motivation. However, human studies suggested a facilitatory effect of cannabis on subjective 
indices of sexual function, which may be related to altered sensation and/or perception or 
indirectly enhanced through cannabis-induced disinhibition and reduction in anxiety levels 
(Hill and Gorzalka, 2006; Klein et al, 2012). Currently, it is proposed that the biphasic effect 
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produced by CB1 receptor activation is dependent on the balance between the receptors 
populations located either on GABAergic or glutamatergic neurons (Moreira et al, 2012; Rey 
et al, 2012). Meaning, high dose of cannabinoid produces anxiogenic-like behavior by CB1 
receptor activation on GABAergic neurons; whereas, activation of CB1 receptors located in 
glutamatergic neurons by low dose of cannabinoid produce an anxiolytic-like effect (Rey et 
al, 2012).  
Considering that the neural circuits regulating emotions and social behavior are highly 
interconnected, it is not surprising that changes in anxiety levels would influence social 
interactions. Disturbances in emotional regulation can lead to deficits in social behavior and 
excessive aggression (Davidson et al., 2000). Abnormalities in sexual drive are also affected 
by emotional alterations, leading to situations of anxious arousal and aggression or lack of 
sexual interest and anhedonia (Ace, 2007; Laurent and Simons, 2009), corresponding to 
anxiety and depression, respectively (Kalmbach et al, 2012). In animal studies, social 
investigation of a female subject can reflect positive hedonic behavior. Accordingly, 
diminished interest in pleasurable activities (i.e., anhedonia) predicts depressive-like disorders 
(Cryan and Holmes, 2005; Micale et al, 2013 Willner, 1986). In contrast, contact with a male 
subject typically evoked behaviors characterized as competitive (territorial or partner 
dominance), that are highly related to anxiety-like states (Cryan and Holmes, 2005; Paré, 
2000). 
However, it cannot be ruled out the involvement of different pathways as well as the potential 
compensatory mechanisms occurring during embryonic or early postnatal development, 
which represents a limitation of experiments with mutant mice in general. Since the 1980s, 
much of today’s basic biomedical research, including neuropsychiatric research, make intense 
use of genetic mouse models as a powerful tool for investigating gene function in vivo. 
However, a lot of attention must be given to its potential limitations. To start, the function of a 
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gene essential for embryonic or early postnatal development cannot be studied in adulthood. 
Next, the disruption of ubiquitously expressed genes might result in rather complex 
phenotypes with too much unclear outcomes for a good understanding of the specific function 
of a gene. Particularly in the case of psychiatric disorders, it is compulsory to address the 
function of a gene of interest in the central nervous system or even more precisely in specific 
neuronal or glial cell populations. Also, early ablation of a gene might activate compensatory 
mechanisms that possibly mask or blur the direct effects of the gene of interest. In addition, 
difficulty that occurs in conjunction with the original gene targeting strategies is the 
methodologically unavoidable introduction of positive selection markers, which are used to 
enrich for homologous recombination events and often for gene disruption. These selection 
markers, comprising their own regulatory elements necessary for efficient transcription, have 
been demonstrated to interfere with the expression of the target gene and with genes adjacent 
to the target site (Olson et al. 1996; Meyers et al. 1998; Matthaei, 2007; Deussing, 2013).  
The most common method, and the one used in this work, to obtain tissue-specific control of 
gene deletion is the CreLoxP system modified from bacteriophage. Briefly, LoxP sites are 
short DNA sequences that are recognized by a specific DNA recombinase enzyme called Cre 
(cyclization recombination or causes recombination) that deletes any DNA between the two 
sequences. An exon in the gene of interest is flanked by these LoxP (floxed) sites and the 
modified gene is introduced into its correct location in embryonic stem cells by homologous 
recombination. The stem cells are injected into mouse blastocysts and mice generated in 
which the gene is ‘floxed’ but fully functional until it is inactivated by the Cre recombinase 
due to the removal of the exon. This is achieved by breeding the ‘floxed’ mice with a mouse 
transgenic for the Cre recombinase usually under the control of a tissue-specific promoter (Gu 
et al. 1994, Rajewsky et al. 1996; Kwan, 2002; Matthaei, 2004). The result is deletion of the 
gene in a specific tissue. A major problem with this method is the ‘position’ effect, whereby 
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Cre is expressed non-specifically in other tissues, or the promoter driving Cre is active early 
during development so that the gene is ablated at the wrong time or in the wrong tissue. A 
further difficulty, that has not been enough addressed, is that the mammalian genome contains 
many ‘pseudo’ LoxP sites (Thyagarajan et al. 2000) that potentially could be recombined by 
Cre recombinase with totally unknown effects. Also, many transgenic cre strains exhibit “off-
target” activity. For well-characterized promoters, however, traditional transgenesis might be 
an ideal option as it allows the flexibility to incorporate a fragment of promoter sequence with 
known functionality. Provide temporal control of Cre expression through the use of an 
inducible promoter that has been modified to be ‘off’ until the mice are treated with the 
inducer (i.e. tamoxifen) is a great improvement to the technique (Kellendonk et al. 1996, 
Zheng et al. 2002), although side-effects in other tissues, such as in neurons, may continue to 
be a problem (Hendry et al. 1987). It would also be an improvement to have a regulatory 
system that would allow the reliable switching ‘on’ and ‘off’ of endogenous genes in a 
repeatedly reversible manner, especially considering that the major problem with the Cre 
recombinase system is that it is not reversible (Matthaei, 2007). Ideally, a system to test the 
effects of a gene deletion should incorporate complete reversibility, totally tissue specific and 
not modify the host genome or be modified by the host genome. Currently none of the 
commonly used methods satisfy these requirements since they rely on the use of transgenic 
mice with their inherent limitations. Nevertheless, none of the common psychiatric disorders 
is the consequence of a single null mutation. As in many other common disease areas, 
psychiatric research encounters the challenge that susceptibility to this type of diseases arises 
from the complex interaction of many genes or of genetic variants of a relatively small effect 
size with largely unknown environmental factors rather than from a single gene. All these 
points should be taken into account when modeling psychiatric disorders or when evaluating 
the potential underlying disease mechanisms (Deussing, 2013). Even considering all caveats 
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from these techniques, simple deletions of gene function will continue to have a place in 
various situations as will transgenic mice using minimal promoters. However, it is imperative 
to understand the limitations of these systems so that appropriate controls can be included and 
correct conclusions can be made (Hagg 1999; Matthaei, 2007). Also, so far, research 
involving genetic mouse models has significantly contributed to the field of neurobiology in 
general and to our understanding of psychiatric disorders in particular. 
Another approach recently used to better understand modulatory function of the CB1 receptor 
in neuronal circuits, is the conditional rescue mouse line generated by a the loxP-flanked stop 
cassette (Stop-CB1 allele) controlled by its endogenous promoter, which allows selective 
reactivation of the CB1 receptor in specific cell populations (Ruehle et al, 2013). Before the 
rescue process, mice lack CB1 receptor protein similar to CB1 receptor-null mutants. They 
also reproduced behavior and electrophysiological phenotypes described for CB1 receptor-
null mutant animals (Marsicano et al., 2002, 2003; Haller et al., 2004).  While animals with 
rescue of the CB1 receptor throughout the whole organism did not differ from WT animals in 
any of the tested procedures, indicating the validity of this experimental approach. Thus, this 
newly generated mouse line can be a valuable tool to investigate sufficient CB1 receptor 
function in any given cell type to which Cre recombinase can be delivered specifically, to 
improve the knowledge about different subpopulations role and the involvement of CB1 
receptors in different situations.  
In conclusion, the present work provided direct evidence for a cross-talk between 
dopaminergic D1 receptors and endocannabinoid system in terms of controlling negative 
affect, suggesting that a specific reduction of endocannabinoid signaling in neurons 
expressing dopamine D1 receptors is able to affect acute fear adaptation. It also demonstrated 
an opposite role of CB1 receptors on glutamatergic versus GABAergic neurons in regulation 
of social interaction with female, but not male conspecifics. The present data imply that 
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selective enhancement of endocannabinoid signaling at glutamatergic synapses may promote 
sexual interest, rendering it an interesting option for the treatment of psychiatric diseases 
related with its loss. 
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Cannabinoid receptor type 1 receptors on GABAergic vs.
glutamatergic neurons differentially gate sex-dependent
social interest in mice
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Abstract
Abnormalities in social behavior are found in almost all psychiatric disorders, such as anxiety, depression, autism, and schizo-
phrenia. Thus, comprehension of the neurobiological basis of social interaction is important for a better understanding of numer-
ous pathologies and improved treatments. Several findings have suggested that an alteration of cannabinoid receptor type 1
(CB1) receptor function could be involved in the pathophysiology of such disorders. However, the role of CB1 receptors is still
unclear, and their localisation on different neuronal subpopulations may produce distinct outcomes. To dissect the role of CB1
receptors in different neuronal populations, we used male knockout mice and their respective control littermates [total deletion
(CB1/); specific deletion on cortical glutamatergic neurons (Glu-CB1/) or on GABAergic interneurons (GABA-CB1/), and
wild-type (WT) mice treated with the CB1 antagonist/inverse agonist SR141716A (3 mg/kg). Mice were required to perform differ-
ent social tasks – direct social interaction and social investigation. Direct interaction of two male mice was not modified in any
group; however, when they were paired with females, Glu-CB1/ mice showed reduced interaction. Also, exploration of the male
stimulus subject in the three-chamber social investigation test was almost unaffected. The situation was completely different when
a female was used as the stimulus subject. In this case, Glu-CB1/ mice showed reduced interest in the social stimulus, mimick-
ing the phenotype of CB1/ or WT mice treated with SR141716A. GABA-CB1/ mice showed the opposite phenotype, by
spending more time investigating the social stimulus. In conclusion, we provide evidence that CB1 receptors specifically modulate
the social investigation of female mice in a neuronal subtype-specific manner.
Introduction
Cannabis is known to affect psychological states in humans (and
animals). For this reason, it is the most frequently used recreational
drug, mainly influencing emotional processes (Murray et al., 2007).
However, the effects of cannabinoids appear in a biphasic manner
(Viveros et al., 2005), as observed in several behaviors, including
motivational processing (Maldonado & Rodrıguez de Fonseca,
2002; Ruehle et al., 2011; Moreira et al., 2012), locomotion and
exploration (Haller et al., 2004), novelty-seeking (Lafenêtre et al.,
2009), and feeding behavior (Bellocchio et al., 2010). The wide
distribution of cannabinoid receptor type 1 (CB1) in the central ner-
vous system (Marsicano & Lutz, 1999) and its location in different
neural subpopulations (Monory et al., 2007) increase the difficulties
in understanding the mechanisms underlying its biphasic effect. This
is particularly challenging because the endocannabinoid system
controls the activation of both inhibitory (GABA) and excitatory
(glutamate) neurotransmission (Monory et al., 2006).
Alterations in the endocannabinoid system are observed in several
psychiatric disorders, especially those with emotion-related dysfunc-
tions as a core symptom. In those, social disruption is observed – con-
ditions such as social withdrawal, increased aggressiveness, decreased
affiliative behavior and social cognition and loss of sexual interest are
described in schizophrenia, autism, anxiety, and major depression
(American Psychiatric Association, 2000). With regard to social
aspects, rodents, like humans, show a large repertoire of social inter-
actions with conspecifics, characterised by high levels of complexity
in the type and number of interactions (File & Seth, 2003; Crawley
et al., 2007; Choleris et al., 2009). Such similarities between humans
and animals underscore the potential translational value of studies on
social behavior in mice with respect to the clinical situation.
Although several CB1 receptor mutants and pharmacological
approaches have been used to study the contribution of the endocann-
abinoid system to the control of emotions (Moreira & Wotjak, 2010;
Micale et al., 2013a), the cellular substrates of such responses with
regard to the specific neuronal subpopulations involved are still
largely unexplored. Likewise, little is known about the role played by
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CB1 receptors in the repertoire of different social behaviors. With the
development of total (CB1/) (Zimmer et al., 1999; Marsicano
et al., 2002; Martin et al., 2002) and conditional mutant mice lacking
the CB1 receptor on either GABAergic (GABA-CB1/) or glutama-
tergic (Glu-CB1/) neurons (Monory et al., 2006), we are starting to
understand the role of CB1 receptors on different neuronal popula-
tions in emotional behavior (Jacob et al., 2009; H€aring et al., 2011).
Hence, we subjected male mice with pharmacological blockade or
ubiquitous respective cell-specific genetic deletion of CB1 receptors
to different social behavior tests. For the social interaction test, we
placed pairs of unfamiliar mice in a novel environment for bidirec-
tional investigation. The direct contact allowed assessment of social
investigation and aggressive behavior at the same time. To assess the
interest in social stimuli, we confronted the experimental subjects
with a social (a tube containing a male or an ovariectomised female
with or without estradiol replacement) and a non-social (empty) stim-
ulus in the three-chamber social investigation task. This allowed us to
distinguish between general social interest (male stimulus) and sexual
interest (female stimulus).
Materials and methods
Animals
Adult male mice (aged 8–12 weeks) were used. Mice (n = 5–11 per
group) were bred in our breeding facility (Max-Planck Institute of
Biochemistry, Martinsried, Germany), and transferred to our experi-
mental building. Mice were housed singly and maintained in stan-
dard conditions with food and water available ad libitum under a
12-h inverse light–dark cycle (lights off at 09:00 h) for at least
14 days before the experiments were started. Total and conditional
CB1 receptor mutant mice were obtained and genotyped by poly-
merase chain reaction (PCR) with specific primers, as previously
described (Marsicano et al., 2002; Monory et al., 2006; Jacob et al.,
2009). We used mice with total CB1 receptor knockout (CB1/;
from heterozygous breeding pairs) [PCR primers: G50 (50-GCT
GTC TCT GGT CCT CTT AAA-30); G51 (50-GGT GTC ACC TCT
GAA AAC AGA-30); and G54-neo-null 30 (50-CCT ACC CGG
TAG AAT TAG CTT-30)], and mice with CB1 receptor knockout
on cortical glutamatergic neurons [Glu-CB1/; mice with condi-
tional deletion of CB1 receptors on glutamatergic neurons were
obtained as described previously (Monory et al., 2006)]. Briefly,
NEX-Cre mice were crossed with CB1f/f mice to obtain CB1f/f;Nex-
Cre mice, from breeding pairs where only the fathers expressed Cre-
recombinase [PCR primers: G50 (50-GCT GTC TCT GGT CCT
CTT AAA-30); G51 (50-GGT GTC ACC TCT GAA AAC AGA-30);
G53 (50-CTC CTG TAT GCC ATA GCT CTT-30); G100 (50-CGG
CAT GGT GCA AGT TGA ATA-30), and G101 (50-GCG ATC
GCT ATT TTC CAT GAG-30)]. We also used mice with CB1
receptor knockout on forebrain GABAergic neurons [GABA-CB1/
; mice with conditional deletion of CB1 receptors on GABAergic
neurons were obtained as described previously (Monory et al.,
2006)]. Briefly, Dlx5/6-Cre mice were crossed with CB1f/f mice to
obtain CB1f/f;Dlx5/6-Cre mice, from breeding pairs where only the
fathers expressed Cre-recombinase [PCR primers: G50 (50-GCT
GTC TCT GGT CCT CTT AAA-30); G51 (50-GGT GTC ACC TCT
GAA AAC AGA-30); G53 (50-CTC CTG TAT GCC ATA
GCT CTT-30); G100 (50-CGG CAT GGT GCA AGT TGA ATA-30);
and G101 (50-GCG ATC GCT ATT TTC CAT GAG-30)]. Control
littermates of knockout mice were also used, along with wild-type
(WT) mice for pharmacological treatment (CB1f/f = WT) [PCR
primers: G50 (50-GCT GTC TCT GGT CCT CTT AAA-30); G51
(50-GGT GTC ACC TCT GAA AAC AGA-30); and G53 (50-CTC
CTG TAT GCC ATA GCT CTT-30)]. Mice of a given experiment
and line were derived from at least four different litters. All stimulus
subjects were from a C57BL/6N background. For the social behavior
experiments, ovariectomised females were used. Females were ovari-
ectomised at least 15 days before the beginning of experiments.
Some females also received b-estradiol for 1 week before the experi-
ments started (see below). All behavioral experiments were performed
during the active (dark) phase of mice, between 09:30 h and 17:00 h.
Drugs
Rimonabant [SR141716A; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-
(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; Cayman
Chemical, Ann Arbor, MI, USA] was dissolved in vehicle solution
(one drop of Tween-80; 2.5% dimethylsulfoxide in saline) to a final
concentration of 3 mg/kg, and injected intraperitoneally at 10 mL/kg
body weight, 30 min before testing. b-Estradiol (Sigma-Aldrich,
Steinheim, Germany) was dissolved in 0.5% ethanol/99.5% propyl-
eneglycol for administration via micro-osmotic pumps (Model 1002;
pumping rate, 0.25 lL/h; total volume, 90  10 lL; Alzet, Cuper-
tino, CA, USA) to a final concentration of 36 lg/mL (Str€om et al.,
2012).
Behavioral tests
During experiments and video analysis, experimenters were blind to
the genotype. All behavioral tests took place in an experimental room
with the same light–dark cycle and environmental conditions (i.e.
humidity and temperature) as in the housing facility. Laboratory ani-
mal care and experimental procedures were in compliance with the
European Union recommendations for the care and use of laboratory
animals (86/609/EEC). All experimental procedures were approved
by the Committee on Animal Health and Care of the State of Upper
Bavaria (AZ55.2-1-54-2532-44-09 and AZ55.2-1-54-2532-142-12).
Social interaction test
The social interaction experiment was performed as previously
described (Terzian et al., 2011). Briefly, all experiments were per-
formed in a new cage (27 9 16 9 12 cm) with fresh bedding at
5 lux (i.e. red light). The wall of the cage was extended by 12.5 cm
with semi-transparent plastic. In this test, pairs of unfamiliar mice
were placed into the cage for 5 min. Depending on the test session,
each test subject was paired either with an ovariectomised female, an
ovariectomised female treated for 1 week with b-estradiol, or a male
mouse of the same genotype. The time spent in social interactions
(active contact such as sniffing, licking, close following, and groom-
ing) and aggressive behavior (fighting and biting, causing injury) was
recorded for each pair of mice. Each session was video-recorded, and
analysed off-line with ANY-MAZE (Stoelting, Wood Dale, IL, USA).
Three-chamber social investigation test
The three-chamber social investigation task was conducted as previ-
ously described (Terzian et al., 2011). The three-chamber apparatus
consists of a PVC rectangular box divided into three equal compart-
ments (30 9 30 9 30 cm) interconnected by small openings
(6 9 5 cm) that could be closed with guillotine doors. Mice were
tested under 5 lux (i.e. red light). During the habituation phase, each
mouse freely explored the apparatus for 10 min, and empty
perforated 50-mL Falcon tubes (length, 11.4 cm; diameter, 2.8 cm2;
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22 holes of diameter 0.5 cm were used to provide ventilation and
olfactory cues to the test mice) were placed in each side of the box.
After the habituation session, the test mouse was kept in the center
compartment, and one of the tubes was replaced by a tube contain-
ing a stimulus C57BL/6N mouse – an adult male, an ovariectomised
female, or an ovariectomised female treated for 1 week with b-estra-
diol. In this second stage, the mouse had 10 min to explore all three
compartments, and the time spent in direct active contact (with the
tubes) was recorded. Independent groups were exposed to the male
or female stimulus subjects. Each session was video-recorded, and
analysed off-line with ANY-MAZE (Stoelting).
Data analysis
Data were analysed with an unpaired t-test or two-way ANOVA (geno-
type/treatment; time in contact) for repeated measures (time in con-
tact with the tube containing the social stimulus vs. time spent in the
empty tube). The Newman–Keuls test was used as a post hoc test, if
appropriate. Data are presented as means  standard errors of the
mean (SEMs). Statistical significance was accepted if P < 0.05.
Results
In the social interaction test, where two freely moving male mice were
in the same cage, none of the tested lines showed differences from the
control group in contact time (CB1/, t = 0.29; WT, t = 1.20; Glu-
CB1/, t = 1.15; Fig. 1), even though GABA-CB1/ mice showed
slightly increased social interest; however, this difference failed to
reach statistical significance (GABA-CB1/, t = 2.00, P > 0.05;
Fig. 1). Aggressive behavior was observed in only one pair of Glu-
CB1/ mice and one pair of Glu-CB1+/+ mice. Therefore, this param-
eter was not considered further. However, in the social interaction test,
to verify whether the two main opposite genotypes (Glu-CB1 and
GABA-CB1, the terms ‘Glu-CB1’ and ‘GABA-CB1’ refer to the dif-
ferent groups related to their location of CB1 deletion, involving both
knockout (-/-) and control (+/+) groups) would show differences in
interaction when confronted with female subjects, males were intro-
duced to ovariectomised females with or without b-estradiol treat-
ment. In the case of Glu-CB1, a two-way ANOVA (genotype; stimulus
subject) revealed significant main effects of genotype (F1,28 = 30.72,
P < 0.0001) and subject (F2,25 = 26.91, P < 0.0001), as well as a sig-
nificant genotype 9 subject interaction (F2,25 = 8.563, P < 0.005).
Post hoc tests confirmed that Glu-CB1/ mice showed less explora-
tion of ovariectomised females without or with b-estradiol replace-
ment than the control group, whereas exploration of male subjects was
similar. Interestingly, Glu-CB1+/+ mice, but not Glu-CB1/ mice,
spent significantly more time investigating the females than the males.
For GABA-CB1, significant main effects of genotype (F1,44 = 8.160,
P < 0.01) and subject (F2,41 = 6.907, P < 0.005) were observed, but
no significant genotype 9 subject interaction (F2,41 = 0.8315,
P = 0.442). Thus, GABA-CB1/ mice spent more time in investigat-
ing social stimuli than GABA-CB1+/+ mice, irrespective of the sex of
the stimulus subjects.
In the three-chamber social investigation test, when the stimulus
subject was a male mouse (Fig. 2), CB1/ mice showed less inter-
est in the social stimulus than did the control group, but the differ-
ence was not significant manner (n = 6–7; genotype, F11,1 = 1.84,
P = 0.20; genotype 9 time in contact, F11,1 = 3.24, P = 0.09).
Both groups showed a preference for the tube containing the stimu-
lus mouse as compared with the empty tube (time in contact,
F11,1 = 36.16, P < 0.001). Similarly, mice that received vehicle or
SR141716A preferred to explore the tube containing the unknown
mouse rather than the empty tube (time in contact, F17,1 = 26.18,
P < 0.001). However, mice treated with the CB1 receptor blocker/
inverse agonist showed a significant reduction in time spent investi-
gating the social stimulus (n = 9–10; genotype 9 time in contact,
F1,17 = 4.52, P < 0.05).
As observed for the CB1/ mice, in the presence of a male
mouse stimulus, Glu-CB1/ mice showed no significant difference
in investigation from the control group (n = 10; genotype 9 time in
contact, F1,18 = 0.007, P = 0.93). The same was found for GABA-
CB1/ mice (n = 8–10; genotype 9 time in contact, F1,16 = 0.60,
P = 0.45). Both mutant lines showed a preference for the social stim-
ulus as compared with the inanimate object (statistics not shown).
In presence of an ovariectomised female stimulus subject (Fig. 2),
CB1/ mice spent significantly less time in contact with the social
stimulus than did control littermates (n = 13–16; genotype 9 time
in contact, F1,27 = 7.17, P < 0.05). WT mice treated with
SR141716A also spent less time investigating the female stimulus
than did the vehicle group (n = 6–7; genotype 9 time in contact,
F1,11 = 6.53, P < 0.05). The same was found for Glu-CB1
/ mice
(n = 8–10; genotype 9 time in contact, F1,16 = 4.65, P < 0.05).
Fig. 1. Direct social interaction: effects of pharmacological blockage
[SR141716A (SR)] or genetic deletion of CB1 receptors on social interaction
between a pair of unfamiliar mice – male mice of the same genotype/receiving
the same pharmacological treatment, ovariectomised females (OVX), or ovari-
ectomised females with hormone replacement (OVX + E). Values are
means  SEMs. *P < 0.05. Numbers next to each group represent the number
of animals per group (n) for each experiment. Newman–Keuls post hoc test.
Veh, vehicle.
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GABA-CB1/ mice, in contrast, showed the opposite behavior, by
spending significantly more time in contact with the female stimulus
(n = 11; genotype 9 time in contact, F1,20 = 16.05, P < 0.01).
To further substantiate the role of CB1 receptors in the two oppo-
site neuronal populations, new batches of GABA-CB1 and Glu-CB1
mice were presented with a tube containing an ovariectomised
female treated for 1 week with b-estradiol. In this situation,
GluCB1/ mice showed reduced interest in the female tube, but
the difference from the control group was not significant (n = 6;
genotype 9 time in contact, F1,10 = 0.93, P = 0.35). GABA-CB1
/
 showed increased investigation of the ovariectomised female trea-
ted for 1 week with b-estradiol (n = 10; genotype 9 time in con-
tact, F1,18 = 5.23, P < 0.05).
Discussion
The present study evaluated the involvement of CB1 receptors in
social behavior in mice. For this purpose, we first investigated direct
contact between two mice, in an attempt to create a more ethological
situation. Given previous reports about social interaction after phar-
macological blockage or genetic deletion of CB1 receptors (Jacob
et al., 2009; H€aring et al., 2011; Litvin et al., 2013), we were sur-
prised to not observe any treatment/genotype differences between
two males of the same genotype. One explanation for the discrepant
findings might be the previously observed relationship between aver-
siveness of the test situation and the involvement of CB1 receptor
signaling in social behavior (Jacob et al., 2009). In the present
study, we kept the emotional load to a minimum by using less aver-
sive conditions, such as red light. Higher light intensity, however,
would have confounded our interpretation of ‘social intention’ by
differences in anxiety levels (Jacob et al., 2009). We also failed to
observed differences in aggression. Other than that reported for the
resident–intruder test, where Glu-CB1/ mice showed increased
aggression (H€aring et al., 2011), mice did not show any territorial/
aggressive behavior in the novel environment, independently of the
genotype. When both mutated lines (GABA-CB1 and Glu-CB1)
Fig. 2. Social investigation of social stimulus subject: effects of pharmacological blockage [SR141716A (SR)] or genetic deletion of CB1 receptor on social
investigation of a male stimulus mouse by ovariectomised females (OVX) or ovariectomised females with hormone replacement (OVX + E) in the three-cham-
ber box. Graphs represent different mutant mice and treatment with SR141716, with respective control groups. Values are means  SEMs. *P < 0.05. Numbers
next to each group represent the number of animals per group (n) for each experiment. Newman–Keuls post hoc test. Veh, vehicle.
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were tested upon direct contact with females (ovariectomised
females or ovariectomised females treated for 1 week with b-estra-
diol), GABA-CB1/ mice showed a similar phenotype as observed
in the interaction between two males; that is, they showed a non-sig-
nificant increase in interaction. Glu-CB1/ mice, in contrast,
showed reduced levels of interaction with both groups of females.
We relate the sex-dependent differences in free social interaction
shown by GluCB1/ mice to different levels of salience provoked
by female and male stimulus subjects.
In free social interaction, interaction times are determined not only
by the test, but also by the stimulus subjects. This potentially con-
founding factor could be circumvented in the second experiment, the
three-chamber social investigation test, where the stimulus subject
was exposed in a Falcon tube. This time, the test mice had the option
of investigating or not investigating the stimulus mouse in compari-
son with exploration of an inanimate object located in another com-
partment. When mice were presented with a male mouse as the
stimulus subject, all groups showed higher interest in the social stimu-
lus than in the empty tube. However, only mice treated with
SR141716A showed significantly reduced exploration of the social
stimulus as compared with vehicle-treated controls. In the presence of
a more interesting stimulus subject, such as an ovariectomised female
mouse, all groups differed from their controls. Again, SR141716A-
treated mice showed a reduction in time spent investigating the social
stimulus; the same was observed for CB1/ and Glu-CB1/ mice.
This suggests that activation of CB1 receptors in glutamatergic neu-
rons is involved in the promotion of sexual interest in female stimulus
subjects. The opposite was observed for GABA-CB1/ mice, which
showed an increase in social interest in the female stimulus subject.
When tested with the ovariectomised female treated for 1 week with
b-estradiol, GABA-CB1 and Glu-CB1 mice showed the same pattern
of behavior, with GABA-CB1/ mice spending more time and
GluCB1/ mice less time in investigating the female. Therefore,
CB1 receptors in glutamatergic and in GABAergic neurons control
sexual interest in an opposite manner, similarly to exploration of
novel objects (Lafenêtre et al., 2009; H€aring et al., 2011), active vs.
passive avoidance (Metna-Laurent et al., 2012), and cannabinoid-
induced anxiolytic vs. anxiogenic effects (Rey et al., 2012). The sex
dependency of differences in social interest is remarkable, as we used
ovariectomised females, which may not constitute the most arousing
stimulus for a male subject. However, Pankevich et al. (2004)
showed that, even though males generally prefer to investigate
females in the estrous cycle, the odor of ovariectomised females still
promotes interest in investigation as compared with a neutral odor.
However, the opposite situation (i.e. a female investigating a male
stimulus subject) is rarely investigated, which provides an interesting
area for future studies.
Our results are in agreement with previous studies (Jacob et al.,
2009; H€aring et al., 2011) showing the differential involvement of
CB1 receptors, depending on their localisation. An important point to
highlight in the current study is that we observed such differences
according to the sex of the stimulus subject, i.e. male vs. female mice.
Endocannabinoids are known to modulate several neurotransmitter
systems at different levels of complexity (Piomelli, 2003). In the cen-
tral nervous system, CB1 receptors are expressed at different levels in
different neuronal subpopulations – higher expression levels in GAB-
Aergic interneurons, where they mediate cannabinoid-dependent inhi-
bition of GABA release; and lower expression levels in glutamatergic
terminals (Marsicano & Lutz, 1999). In the latter neuronal subpopula-
tion, they modulate glutamate release, influencing fear and anxiety
levels in threatening situations (Monory et al., 2006; Kamprath et al.,
2009; Hill et al., 2010; Moreira & Wotjak, 2010). It is also important
to note that conditional CB1 receptor mutants could show different
phenotypes from those observed in CB1/ animals (Jacob et al.,
2009; Bellocchio et al., 2010; H€aring et al., 2011; Terzian et al.,
2011). Even though the majority of CB1 receptors in the brain are
located on GABAergic neurons, many behaviors observed after CB1
receptor ablation are related to action upon those located on glutama-
tergic neurons (Hill et al., 2010; Rey et al., 2012). Further studies
are necessary to identify the main structures implicated in the altera-
tions in social interest observed in the present study.
Several animal studies have investigated the participation of the
cannabinoid system in sexual interest and reproductive processes.
They found that direct or indirect CB1 receptor activation signifi-
cantly impairs sex-related behavior (Shrenker & Bartke, 1985; Fer-
rari et al., 2000; Gorzalka & Hill, 2006), indicating a reduction in
sexual motivation. However, human studies have suggested a facili-
tatory effect of cannabis on subjective indices of sexual function,
which may be related to altered sensation and/or perception, or indi-
rect enhancement through cannabis-induced disinhibition and reduc-
tion in anxiety levels (Gorzalka & Hill, 2006; Klein et al., 2012).
Currently, it is proposed that the biphasic effect produced by CB1
receptor activation is dependent on the balance between the receptor
populations located either on GABAergic or glutamatergic neurons
(Rey et al., 2012); a high dose of cannabinoid produces anxiogenic-
like behavior by CB1 receptor activation on GABAergic neurons,
whereas activation of CB1 receptors located on glutamatergic neu-
rons by a low dose of cannabinoid produces an anxiolytic-like effect
(Rey et al., 2012).
Considering that the neural circuits regulating emotions and
social behavior are highly interconnected, it is not surprising that
changes in anxiety levels influence social interactions. Disturbances
in emotional regulation can lead to deficits in social behavior and
excessive aggression (Davidson et al., 2000). Abnormalities in sex-
ual drive are also affected by emotional alterations, leading to situa-
tions of anxious arousal and aggression, or lack of sexual interest
and anhedonia (Ace, 2007; Laurent & Simons, 2009), correspond-
ing to anxiety and depression, respectively (Kalmbach et al., 2012).
In animal studies, social investigation of a female subject can
reflect positive hedonic behavior. Accordingly, diminished interest
in pleasurable activities (i.e. anhedonia) predicts depressive-like dis-
orders (Willner, 1991; Cryan & Holmes, 2005 Micale et al.,
2013b). In contrast, contact with a male subject typically evoked
behaviors characterised as competitive (territorial or partner domi-
nance), which are highly related to anxiety-like states (Pare, 2000;
Cryan & Holmes, 2005).
Together, the findings of this study demonstrate opposite roles of
CB1 receptors on glutamatergic and on GABAergic neurons in the
regulation of social interaction with female, but not male, conspecif-
ics. Our data imply that selective enhancement of endocannabinoid
signaling at glutamatergic synapses may promote sexual interest,
making it an interesting option for the treatment of psychiatric dis-
eases related to its loss, such as depression.
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.S.  Guimaraesd,e,∗
Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG,
1270-901, Brazil
Graduate School of Systemic Neuroscience/Ludwig Maximilian Universität, Großhadernerstr. 2, Martinsried 82152, Germany
Max  Planck Institute of Psychiatry, Kraepelinstrasse 2-10, Munich 80804, Germany
Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14049-900, Brazil
Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14049-900,
razil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 23 September 2013
eceived in revised form 4 February 2014
ccepted 18 March 2014
eywords:
ndovanilloids
a  b  s  t  r  a  c  t
The  Transient  Receptor  Potential  Vanilloid  Type-1  (TRPV1)  was  first  characterized  in primary  afferent
fibers  as  a  receptor  for capsaicin  (the  pungent  ingredient  of  chili  peppers).  Later  on,  this  cation-permeable
ion  channel  was also  described  in  the  central  nervous  system,  where  its main  putative  endogenous
ligand is N-arachidonoyl  ethanolamide  (an endocannabinoid,  also  known  as  anandamide).  Recent  results
employing  genetic,  pharmacological  and  histochemical  techniques  indicate  that  TRPV1  tonically  modu-
late  anxiety,  fear  and  panic  responses  in  brain  regions  related  to defensive  responses,  such  as  the  dorsalndocannabinoids
nandamide
nxiety
ear
periaqueductal  gray,  the hippocampus  and  the  medial  prefrontal  cortex.  Genetic  deletion  or  antago-
nism  of  this  ion channel  induces  anxiolytic-like  effects  in several  animal  models.  The  main  mechanism
responsible  for TRPV1-mediated  effects  on  anxiety  seems  to  involve  facilitation  of  glutamatergic  neuro-
transmission.  In  addition,  there  is  evidence  for interactions  with  other  neurotransmitter  systems,  such
as  nitric  oxide  and  endocannabinoids.
© 2014  Elsevier  Ltd. All  rights  reserved.ontents
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.1. Structure and function
Capsaicin (8-methyl-N-vanillyl-6-nonenamide), the main pun-
ent constituent of the native American plant Capsicum sp,
opularly known as the hot chili pepper, was first isolated and
enominated by Thresh in 1846 (Szallasi and Blumberg, 1990b). Ini-
ial studies showed that it could induce a burning pain perception
Bernstein et al., 1981; Stjarne et al., 1989) and skin hyperalgesia
Bartho et al., 1990; Baumann et al., 1991). These effects result from
timulation and depolarization of primary afferent sensory neurons
Holzer, 1991) followed by the release of pro-inflammatory media-
ors (Southall et al., 2003). After repeated administration, however,
hese capsaicin-induced responses show a rapid desensitization
Dray, 1992; Green, 1989; Hayes et al., 1984).
Biochemical and electrophysiological studies indicated that cap-
aicin facilitates excitability and electrical conduction in sensory
nmyelinated C-fibers and neural cell bodies by increasing sodium
nd calcium permeability (Erdelyi et al., 1987; Marsh et al., 1987;
ood et al., 1988). Capsaicin-induced calcium influx results in exo-
ytosis of excitatory amino acids and other neuromodulators such
s substance P (Go and Yaksh, 1987; Li et al., 2004; Marinelli et al.,
002, 2003; Sasamura et al., 1998). In addition, it was initially
bserved that capsaicin can also bind to specific sites in the periph-
ral terminals of thin-myelinated A fibers (Chung et al., 1985;
iura and Sakamoto, 1987; Matsumiya et al., 1983; Szolcsanyi et al.,
988). This subset of bipolar neurons is involved in the devel-
pment of chronic pain. Their cellular bodies are located in the
orsal root (DRG), nodose and trigeminal ganglion, from where they
end terminals that make synapses with second-order neurons in
he central nervous system (CNS; Chad et al., 1983; Holzer, 1991;
zallasi, 1995; Williams and Zieglgansberger, 1982).
It was later found that capsaicin effects were antagonized in
 competitive way by a drug named capsazepine (Walpole et al.,
994). This fact, together with its biological effects, led to the pro-
osal of an orphan “capsaicin receptor” in mammalian organisms.
his receptor was indeed identified by autoradiographic stud-
es using [3H] resiniferatoxin (RTX), a potent capsaicin analog,
n tissues of several species, including humans (Acs et al., 1994;
zallasi, 1994; Szallasi and Blumberg, 1990a,b). Since capsaicin
nd RTX share a vanillyl group as the key structural recognition
ite the receptor was initially denominated “vanilloid” (Szallasi
nd Blumberg, 1990b). In 1997 the vanilloid receptor was  cloned
n rat cells from the DRG and demonstrated to be a subtype of
on-selective cation channels related to the Transient Receptor
otential (TRP) family of ion channels (Caterina et al., 1997). This
eceptor was named by the authors as ‘vanilloid receptor subtype
’ (VR1). It was later renamed by the IUPHAR Nomenclature Com-
ittee the ‘Transient Receptor Potential Vanilloid Type 1’ (TRPV1;
lapham et al., 2005). Structurally, it is composed by four subunits,
ach having six-transmembrane-spanning domains and a short
ydrophobic pore between the fifth and sixth segments (Ramsey
t al., 2006; Wu et al., 2010).
TRPV1 channels can be activated by several stimuli in addition
o capsaicin, including noxious heat, low pH (Caterina et al., 1997;
ominaga et al., 1998) and inflammatory mediators (Moriyama
t al., 2005; Tang et al., 2004; Vyklicky et al., 1998). Lipid endoge-
ous agonists of these receptors have also been proposed and
amed endovanilloids. The most studied endovanilloid is, by
ar, anandamide (N-arachidonoyl ethanolamine), an arachidonicPlease cite this article in press as: Aguiar, D.C., et al., Modulation of def
(TRPV1) Channels. Neurosci. Biobehav. Rev. (2014), http://dx.doi.org/1
cid derived neuromodulator. Anandamide is primarily known
s the endogenous agonist at the CB1 receptors, being the first
escribed endocannabinoid/endovanilloid (Di Marzo et al., 2001;
mart and Jerman, 2000; Zygmunt et al., 2000). Other proposed PRESS
avioral Reviews xxx (2014) xxx–xxx
endovanilloids are N-arachidonoyl dopamine (Huang et al.,
2002; Toth et al., 2003), N-oleoyl dopamine (Chu et al., 2003)
and some products of lipoxygenases, such as 12-HPETE (12-
hydroperoxyeicosatetraenoic acid) and leukotriene B4 (Hwang
et al., 2000). Due to their lipophilic nature, these TRPV1 agonists
are able to freely cross the cell membrane and interact with the
intracellular binding site of the receptor (De Petrocellis et al., 2001;
Jung et al., 1999).
1.2. Brain localization
In addition to their presence in sensory neurons and some
tissues such as the respiratory and urinary bladder epithelium
(Szallasi et al., 1993; Ahmed et al., 2009; Watanabe et al., 2005),
skin, mast cells (Stander et al., 2004) and the enteric system (Horie
et al., 2005; Matsumoto et al., 2011), a large number of stud-
ies employing [3H]RTX autoradiography, immunohistochemistry,
electron microscopy, electrophysiology and molecular biological
(western blot, RT-PCR and in situ hybridization) techniques, as
well as genetically-modified mice, indicated that TRPV1 receptors
are located in several CNS regions, including the dorsal horn of
the spinal cord (Acs et al., 1994; Szallasi and Blumberg, 1991),
hindbrain, midbrain and forebrain areas, being present not only
in neurons but also in astrocytes (Toth et al., 2005). These stud-
ies are summarized in Table 1. Some studies, however, have failed
to detect the presence of TRPV1 channels in the CNS (Benninger
et al., 2008; Caterina et al., 1997; Szallasi, 1995; Tominaga et al.,
1998). Corroborating these latter findings, a recent study using a
sophisticated genetic strategy to visualize TRPV1, complemented
with the use of TRPV1 knockout mice, was  also unable to detect
the expression of these receptors in most of the brain areas ana-
lyzed except for a discrete expression in few regions that include
areas within and adjacent to the caudal hypothalamus and rostral
midbrain (Cavanaugh et al., 2011). How much these contradic-
tory results depend on methodological issues needs to be further
clarified. Only the generation of brain-specific TRPV1 deficient
mouse mutants may  ultimately resolve this puzzle. In addition,
its cellular localization (e.g., pre- versus post-synaptic) in specific
neuronal populations needs to be further investigated. Finally, fur-
ther quantitative experiments need to be performed to compare
TRPV1 expression across different regions of the CNS. Anyhow,
as reviewed below, even if the expression of TRPV1 channels in
the brain is much lower than in other areas such as the DRG
(Cavanaugh et al., 2011; Sanchez et al., 2001), pharmacological,
electrophysiological and behavioral studies strongly indicate that
brain-located TRPV1 plays an important role on the control of emo-
tional responses.
2. TRPV1 channels modulate defensive behavior: systemic
and genetic studies
The development of pharmacological tools has been instrumen-
tal for studying the involvement of TRPV1 channels in diverse
physiological processes. Among them, capsazepine (a thiourea
derivate), one of the first antagonists to be discovered, was  ini-
tially employed to investigate the involvement of these channels
in defensive responses. This compound, however, lacks selectivity,
since it can also bind to voltage-gated calcium channels and nico-
tinic acetylcholine receptors. The capsaicin halogenated derivate,
6-iodo-nordihydrocapsaicin, is a more selective and potent (4-
fold) antagonist than capsazepine (Appendino et al., 2003). Finally,ensive behavior by Transient Receptor Potential Vanilloid Type-1
0.1016/j.neubiorev.2014.03.026
cinnamide analogs, such as SB-366791, also exhibit a very high
selectivity to TRPV1 channels (for a review, see Szallasi et al., 2003).
Regarding their effects in defensive responses, an initial
study employed systemic injection of capsazepine and observed
Please cite this article in press as: Aguiar, D.C., et al., Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1
(TRPV1) Channels. Neurosci. Biobehav. Rev. (2014), http://dx.doi.org/10.1016/j.neubiorev.2014.03.026
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Table  1
Studies supporting the presence of TRPV1 receptors in mammalian brain regions.
Brain region Subregion Localization Co-expression Species Reference
Amygdala
NS NS NS M Roberts et al. (2004)
Central NS NS R Mezey et al. (2000)
Basolateral/lateral NS NS M Zschenderlein et al. (2011)
Basal Ganglia
Striatum NS NS R, M de Lago et al. (2004), Maccarrone et al. (2008),  Mezey et al.
(2000), Sasamura et al. (1998) and Tzavara et al. (2006)
Substantia nigra NS NS R Musella et al. (2009, 2010)
NS CB1 M Cristino et al. (2006)
Pre-synaptic CB1 R Marinelli et al. (2007)
Caudate putamen NS NS M Roberts et al. (2004)
NS CB1 M Cristino et al. (2006)
Globus palidus NS CB1 M Cristino et al. (2006)
Nucleus accumbens Post-synaptic NS M Grueter et al. (2010)
Ventral Tegmental Area NS NS R Marinelli et al. (2005)
BNST NS Post-synaptic CB1 R Puente et al. (2011)
Cerebellum
NS NS NS H, MK, R Cortright et al. (2001), Hayes et al. (2000), Mezey et al.
(2000), Sanchez et al. (2001), Sasamura et al. (1998),
Schumacher et al. (2000), Szabo et al. (2002) and Toth et al.
(2005)
Cerebellar cortex NS NS M Roberts et al. (2004)
NS CB1 M Cristino et al. (2006)
Cortex
NS NS NS R Mezey et al. (2000), Sanchez et al. (2001), Sasamura et al.
(1998), Schumacher et al. (2000)
Post-synaptic NS R Toth et al. (2005)
Parietal NS NS H, R, M Mezey et al. (2000) and Sun et al. (2013)
Somatosensory NS NS MK Szabo et al. (2002)
NS TRPV2 R Liapi and Wood (2005)
Somatomotor NS TRPV2 R Liapi and Wood (2005)
NS NS MK Szabo et al. (2002)
Frontal NS NS H, R, M Hayes et al. (2000) and Roberts et al. (2004)
Prelimbic Probably post-synaptic Not found R Fogaca et al. (2012)
Entorhinal NS NS M Cavanaugh et al. (2011)
Parietal NS NS R, M Mezey et al. (2000) and Roberts et al. (2004)
Piriform NS NS R, M Roberts et al. (2004) and Szabo et al. (2002)
Retrosplienal NS NS M Roberts et al. (2004)
Insular NS TRPV2 R Liapi and Wood (2005)
Cingulate NS TRPV2 R Liapi and Wood (2005)
NS NS R Steenland et al. (2006)
Habenula Medial, lateral NS NS R Mezey et al. (2000)
Hippocampus
NS NS NS H, R, M Cavanaugh et al. (2011), Hayes et al. (2000), Sanchez et al.
(2001), Sasamura et al. (1998), Schumacher et al. (2000)
Dentate gyrus NS NS H, R, M Roberts et al. (2004) and Sun et al. (2013)
Post-synaptic NS R, M Toth et al. (2005)
NS CB1 M Cristino et al. (2006)
CA1 Post-synaptic NS R, H Roberts et al. (2004), Sun et al. (2013) and Toth et al. (2005)
NS NS R, M Al-Hayani et al. (2001), Marsch et al. (2007), Roberts et al.
(2004) and Li et al. (2008)
NS CB1 M Cristino et al. (2006)
Pre-synaptic NS M Gibson et al. (2008)
CA2 NS NS M,  H Roberts et al. (2004) and Sun et al. (2013)
NS CB1 M Cristino et al. (2006)
CA3 NS CB1 M Cristino et al. (2006)
NS NS M Cristino et al. (2008) and Roberts et al. (2004)
Hypothalamus
– NS NS R Sasamura et al. (1998) and Schumacher et al. (2000)
Suprachiasmatic and
anterior
NS NS R Mezey et al. (2000)
Supraoptic Pre-synaptic NS R, M Yokoyama et al. (2010)
Medial-basal NS NS MK Szabo et al. (2002)
Medial NS NS R, H, M Acs et al. (1994) and Roberts et al. (2004)
Periventricular, ventral
medial
NS NS M Roberts et al. (2004)
Dorsomedial NS NS M,  R Cavanaugh et al. (2011), Mezey et al. (2000) and Roberts
et al. (2004)
Posterior NS NS M,  R Cavanaugh et al. (2011)
Arcuate NS NS M,  R, MK  Mezey et al. (2000), Roberts et al. (2004) and Szabo et al.
(2002)
Preoptic area NS NS R, H, MK Acs et al. (1994), Hori et al. (1988) and Szabo et al. (2002)
Pre-synaptic NS R Karlsson et al. (2005)
Paraventricular NS NS R, M Mezey et al. (2000) and Roberts et al. (2004)
Locus
coeruleus
NS NS NS MK,  H, M,  R Acs et al. (1994), Hajos et al. (1987), McGaraughty et al.
(2003), Mezey et al. (2000), Roberts et al. (2004) and Szabo
et al. (2002)
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Table 1 (Continued)
Brain region Subregion Localization Co-expression Species Reference
Probably pre-synaptic NS R Marinelli et al. (2002)
Pre-synaptic NS R Li et al. (2004)
NS CB1 M Cristino et al. (2006)
Olfactory bulb NS NS NS R, M Sanchez et al. (2001) and Sasamura et al. (1998)
Olive Inferior NS NS R Mezey et al. (2000)
Periaqueductal
gray matter
NS NS NS M Cavanaugh et al. (2011) and Roberts et al. (2004)
NS CB1 M Cristino et al. (2006)
Dorsolateral Pre-synaptic NS R, M Xing and Li (2007)
Ventral NS NS R McGaraughty et al. (2003)
Dorsal NS NS R McGaraughty et al. (2003)
NS CB1 R Casarotto et al. (2012)
Ventrolateral Probably pre-synaptic CB1 R, M Maione et al. (2006)
Raphe
NS NS NS M,  R McGaraughty et al. (2003) and Roberts et al. (2004)
Dorsal NS NS R Cavanaugh et al. (2011) and Mezey et al. (2000)
Reticular formation NS NS NS R, H, MK Acs et al. (1994), Mezey et al. (2000) and Szabo et al. (2002)
Several Nuclei Cochlear, mammillary,
suprammamillary,
interpeduncular, olfactory,
intrafascicular
NS NS R, M Cavanaugh et al. (2011), Mezey et al. (2000) and Roberts
et al. (2004)
Septum
Dorsal, fimbrial septal nucleus NS NS R Mezey et al. (2000)
Lateral, medial septal nucleus NS NS M,  R Mezey et al. (2000) and Roberts et al. (2004)
Solitary tract
nucleus
NS NS NS R Guo et al. (1999) and Mezey et al. (2000)
NS P2X3 R Guo et al. (1999)
Pre-synaptic NS R Doyle et al. (2002)
Superior
colliculus
NS NS NS M,  R Roberts et al. (2004)
Probably pre-synaptic NS M Maione et al. (2009a)
Thalamus
– NS NS R Sasamura et al. (1998)
Paracentral, central lateral,
ventromedial, medial
habenular, zona incerta
NS NS M Roberts et al. (2004)
Paraventricular NS NS R, M Mezey et al. (2000) and Roberts et al. (2004)
Centromedian and midline NS NS R Mezey et al. (2000)
Ventral NS NS MK,  H, R Acs et al. (1994) and Roberts et al. (2004)
Reticular NS NS M Roberts et al. (2004)
NS CB1 M Cristino et al. (2006)
Ventral posterolateral,
laterodorsal thalamic nucleus
ventrolateral
NS CB1 M Cristino et al. (2006)
N
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Trigeminal tract NS NS NS 
S: Not Shown; R: Rat; M:  Mouse; MK:  Monkey; H: Human.
nxiolytic-like effects in rats submitted to the elevated plus maze
EPM), suggesting that tonic activation of these receptors facili-
ates anxious states (Kasckow et al., 2004). This result has been
ecently confirmed by a study showing that, besides being anxio-
ytic by itself, i.c.v. injected capsazepine potentiates the effects of
n anxiolytic benzodiazepine in the social interaction test in mice
Manna and Umathe, 2011).
Experiments investigating the phenotype of knockout animals
lso point to TRPV1 channel as an important modulator of fear and
nxiety-related responses. TRPV1-KO mice explore more the open
rms of the EPM and the lit compartment of the light-dark box,
n comparison to wild-type littermate, indicating reduced anxiety-
ike behavior. Moreover, deletion of this channel results in impaired
tress sensitization as well as decreased cue and contextual fear
onditioning (Marsch et al., 2007). Thus, the genetic approach con-
erges with pharmacological data suggesting that TRPV1 tonically
ontrols both innate and learned defensive responses.
. Brain sites involved in TRPV1 modulation of defensivePlease cite this article in press as: Aguiar, D.C., et al., Modulation of def
(TRPV1) Channels. Neurosci. Biobehav. Rev. (2014), http://dx.doi.org/1
esponses
Although the aforementioned results indicate that pharma-
ological or genetic interference with TRPV1 channels modifiesR Guo et al. (1999) and Mezey et al. (2000)
defensive-like responses, it was  only recently that the brain
sites involved in these effects began to be investigated. As dis-
cussed below, studies using intra-cerebral injections of TRPV1
agonists/antagonists show that these channels modulate normal
defensive responses both to potential (anxiety) or clearly threaten-
ing stimuli (fear; Blanchard and Blanchard, 2008) in brain areas that
include the medial prefrontal cortex (mPFC), the ventral hippocam-
pus (vHPC) and the midbrain periaqueductal gray (PAG) (Canteras
et al., 2010; McNaughton and Corr, 2004; Millan, 2003).
3.1. TRPV1 and the medial prefrontal cortex
The mPFC, particularly its ventral portion (vmPFC), coordinates
defensive behaviors (Bishop, 2007; Vertes, 2006) via its connections
with limbic structures that include the bed nucleus of stria termi-
nalis (BNST), amygdaloid complex, ventral hippocampus, medial
thalamus and brainstem (Peters et al., 2009). Intra-vmPFC injection
of the TRPV1 antagonist capsazepine decreased anxiety in the EPM
and Vogel conflict (VCT) tests and attenuated the expression of con-ensive behavior by Transient Receptor Potential Vanilloid Type-1
0.1016/j.neubiorev.2014.03.026
textual fear conditioning in rats (Rubino et al., 2008; Aguiar et al.,
2009; Terzian et al., 2014). This anxiolytic effect was confirmed
with 6-iodo-nordihydrocapsaicin (Fogaca et al., 2012; Terzian et al.,
2014), a more potent and selective TRPV1 antagonist (Appendino
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Table  2
Pharmacological targeting of TRPV1 receptors in animal tests of anxiety.
Administration
route
Drug (dose range tested)
[effective doses]
Possible
mechanism
Animal model Effect on defensive
behaviors
Species References
i.p. Olvanil (0.2–5.0 mg/kg) [0.2, 1
and 5 mg/kg]
TRPV1 agonist EPM ↑ Rat Kasckow et al. (2004)
i.c.v. Capsaicin (1–100 g) [10 and
100 g]
TRPV1 agonist Social interaction
test
↑ Mice Manna and Umathe (2011)
i.c. (mPFC) Methanandamide (0.1–10 g)
[10 ga]
CB1 and TRPV1
agonist
EPM ↑ Rat Rubino et al. (2008)
i.c. (mPFC) Capsaicin (1–10 g and 1 nmol)
[5 and 10 g, 1 nmol]
TRPV1 agonist EPM, contextual
fear conditioning
↑ Rat Rubino et al. (2008) and
Terzian et al. (2014)
i.c. (dHPC) Capsaicin (0.003, 0.03 and
0.3 g) [0.003 and 0.03 g]
TRPV1 agonist EPM ↑ Rat Hakimizadeh et al. (2012)
i.c. (dPAG) Capsaicin (0.01, 0.1 and 1 nmol)
[0.1 and 1 nmol]
TRPV1 agonist EPM ↑ Mice Mascarenhas et al. (2013)
i.c. (dlPAG) Capsaicin (0.01, 0.1 and 1 nmol)
[1 nmol]
TRPV1 agonist EPM and VCT ↓b Rat Terzian et al. (2009)
i.p. Capsazepine (1–10 g/kg) [1, 5
and 10 g/kg]
TRPV1
antagonist
EPM ↓ Rat Kasckow et al. (2004)
i.p. SB366791 (0.1–2.5 mg/kg)
[1 mg/kg]
TRPV1
antagonist
EPM ↓ Mice Micale et al. (2009)
i.p. AA-5-HT (0.1–5 mg/kg) [0.1, 0.5,
1  and 2.5 mg/kg]
TRPV1
antagonist and
FAAH inhibitor
EPM ↓ Mice Micale et al. (2009)
i.c. (BLA) AA-5-HT (0.25–0.5 nmol) [0.25
and 0.5 nmol]
TRPV1
antagonist and
FAAH inhibitor
EPM ↓ Rat John and Currie (2012)
i.c.v. Capsazepine (100 g) TRPV1
antagonist
Social interaction
test
↓ Mice Manna and Umathe (2011)
i.c. (mPFC) Capsazepine (10 g) TRPV1
antagonist
EPM ↓ Rat Rubino et al. (2008)
i.c. (mPFC) Capsazepine (1, 10 and 60 nmol)
[1, 10 and 60 nmol]
TRPV1
antagonist
EPM, VCT and
contextual fear
conditioning
↓ Rat Aguiar et al. (2009) and Terzian
et al. (2014)
i.c. (mPFC) 6-I-CPS (3 nmol) TRPV1
antagonist
EPM, VCT and
contextual fear
conditioning
↓ Rat Fogaca et al. (2012) and
Terzian et al. (2014)
i.c. (vHPC) Capsazepine (0.2–2 nmol)
[2 nmol]
TRPV1
antagonist
EPM ↓ Rat Santos et al. (2008)
i.c. (dHPC) AMG  9810 (0.003, 0.03 and
0.3 g) [0.03 and 0.3 g]
TRPV1
antagonist
EPM ↓ Rat Hakimizadeh et al. (2012)
i.c. (dlPAG) Capsazepine (1–60 nmol)
[60 nmol in the ETM, EPM or VCT
and 1, 10, 30 or 60 nmol in dlPAG
chemical or electrical
stimulation]
TRPV1
antagonist
ETM, EPM, VCT and
escape induced by
dPAG electrical or
chemical (NMDA,
NO) stimulation
↓ Rat Almeida-Santos et al. (2013),
Casarotto et al. (2012), Lisboa
and Guimaraes (2012) and
Terzian et al. (2009)
i.c. (dPAG) SB366791 (1 nmol) TRPV1
antagonist
Escape induced by
dPAG electrical
stimulation
↓ Rat Casarotto et al. (2012)
i.p.: intraperitoneal, i.c.v.: intracerebroventricular, i.c.: intracerebral, dlPAG: dorsolateral periaqueductal gray, dPAG: dorsal periaqueductal gray, ETM: elevated T-maze, EPM:
elevated plus-maze, mPFC: medial prefrontal cortex, vHPC: ventral hippocampus, dHPC: dorsal hippocampus, BLA: basolateral amygdala, AA-5HT: N-arachidonoyl-serotonin,
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-I-CPS: 6-iodonordihydrocapsaicin, SB366791: N-(3-Methoxyphenyl)-4-chlorocin
a Anxiolytic at 0.1 g.
b Desensitization of TRPV1 receptors?
t al., 2003; Table 2). Capsazepine was also able to reverse the
nxiogenic-like effect induced by higher doses of anandamide in
ats (Rubino et al., 2008).
.2. TRPV1, the ventral hippocampus, BNST and amygdaloid
omplex
Specific lesions of the ventral hippocampus (vHPC), BNST and
mygdaloid complex attenuate anxiety-like behaviors (Bannerman
t al., 2004; Bertoglio et al., 2006; Engin and Treit, 2007; Pentkowski
t al., 2006). These regions are proposed to cooperate with the
mPFC to regulate emotional responses (Bannerman et al., 2004;
jelstrup et al., 2002; Verwer et al., 1997). Similar to the vmPFC,
lockade of TRPV1 channels in the vHPC was  anxiolytic in ratsPlease cite this article in press as: Aguiar, D.C., et al., Modulation of def
(TRPV1) Channels. Neurosci. Biobehav. Rev. (2014), http://dx.doi.org/1
ested in the EPM (Santos et al., 2008). Capsaicin was  recently
hown to modify long-term potentiation (LTP), the physiologi-
al correlate of fear memories (Sigurdsson et al., 2007), in slices
btained from the lateral amygdala of mice (Zschenderlein et al.,e, VCT: Vogel conflict test; NO: nitric oxide.
2011). TRPV1channels are also involved in long-term depression
(LTD) induced by anandamide in the BNST of rats (Puente et al.,
2011). Since these regions are related to defensive behavior and
aversive conditioning learning (Canteras et al., 2010), TRPV1 could
modulate anxiety and fear learning mechanisms. However, the
effects of TRPV1-related drugs injected into the amygdala or BNST
on anxiety responses remain to be investigated.
3.3. TRPV1, the periaqueductal gray and panic-like behavior
The PAG is proposed to control emotional coping strategies
(Blanchard et al., 2005; McNaughton and Corr, 2004). Among its
regional subdivisions, the dorsal portion (dPAG), particularly the
dorsolateral column (dlPAG), is part of a neural defensive systemensive behavior by Transient Receptor Potential Vanilloid Type-1
0.1016/j.neubiorev.2014.03.026
that coordinates freezing, flight and fight behaviors in threaten-
ing situations, such as the presence of a predator (Blanchard and
Blanchard, 2008; Canteras and Blanchard, 2008). Several pieces
of evidence indicate that this region is closely associated with
 ING ModelN
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anic attacks (Del-Ben and Graeff, 2009; Gray and McNaughton,
000; Schenberg et al., 2001). For example, electrical stimula-
ion of the dPAG in humans induces symptoms similar to a panic
ttack (Schenberg et al., 2001), such as feelings of intense fear
nd imminent death, together with autonomic arousal (Nashold
t al., 1969). Corroborating this finding, neuroimaging studies show
ncreased dPAG activity in panic patients (Del-Ben and Graeff, 2009)
r healthy volunteers exposed to a proximal threatening stimu-
us such as predator exposure (Mobbs et al., 2007). In rodents,
lectrical or chemical stimulation of the dPAG causes intense
ight responses accompanied by autonomic changes (Beckett and
arsden, 1995; Krieger and Graeff, 1985; Schenberg et al., 2001),
hich are attenuated by systemic or local administration of pan-
colytic drugs (Hogg et al., 2006; Jenck et al., 1995; Moreira
t al., 2013; Schenberg et al., 2001; Schutz et al., 1985). Taken
ogether, these findings suggest that local electrical or chemi-
al stimulation of the dPAG is a putative model of panic attacks
Moreira et al., 2013; Schenberg et al., 2001). Moreover, these panic-
ike responses can be modulated by several neurotransmitters
ncluding serotonin, GABA, glutamate and nitric oxide (Guimaraes
t al., 1991; Moreira and Guimaraes, 2004; Schenberg et al.,
001).
Considering that several studies indicate the presence of TRPV1
n the PAG (Cavanaugh et al., 2011; Cristino et al., 2006; Maione
t al., 2006; McGaraughty et al., 2003; Roberts et al., 2004; Xing
nd Li, 2007), we have recently started to investigate the possible
ole of dlPAG-located TRPV1 channels in defensive responses. In
ine with our initial hypothesis, intra-dlPAG administration of cap-
azepine in rats reduced anxiety-like behavior in the EPM and the
CT (Terzian et al., 2009). In this study, however, a similar anxiolytic
ffect was observed after intra-dlPAG administration of capsaicin,
hich could have involved TRPV1 desensitization (De Petrocellis
t al., 2011). Contrasting with this latter result, anxiogenic effects
f capsaicin have been reported in mice after dlPAG administration
Mascarenhas et al., 2013).
We  have also investigated TRPV1 antagonists in animal tests
ssociated with panic attacks. Local injection of capsazepine and
he selective TRPV1 antagonist, SB366791, attenuated panic-like
ehavior induced by electrical stimulation of the dorsal PAG in rats
Casarotto et al., 2012). This result was reproduced in three other
ests: escape responses induce by (i) local injection of the excit-
tory amino acid N-methyl-d-aspartate (NMDA) or (ii) the nitric
xide donor SIN-1, and (iii) exposure to the open arms of the ele-
ated T-maze (Almeida-Santos et al., 2013; Lisboa and Guimaraes,
012). Taken together, these results indicate that, under threaten-
ng situations, TRPV1 channels facilitate defensive responses in the
lPAG.
. Mechanisms of TRPV1 interference in defensive behavior
The anti-aversive effects of TRPV1 antagonists in the dlPAG
trongly resemble those described for antagonists of gluta-
ate ionotropic receptors (NMDA and non-NMDA) (Aguiar
nd Guimaraes, 2011; Guimaraes et al., 1991; Molchanov and
uimaraes, 2002; Resstel et al., 2008; Tonetto et al., 2009). Mod-
fication of glutamate-mediated synaptic transmission (Feinmark
t al., 2003; Gibson et al., 2008; Kauer and Gibson, 2009) has been
roposed as the main mechanism by which TRPV1 channels influ-
nce several physiological conditions, including neural plasticity
Bennion et al., 2011; Chavez et al., 2010; Gibson et al., 2008;
rueter et al., 2010; Li et al., 2008; Marsch et al., 2007), descendingPlease cite this article in press as: Aguiar, D.C., et al., Modulation of def
(TRPV1) Channels. Neurosci. Biobehav. Rev. (2014), http://dx.doi.org/1
odulation of nociception (McGaraughty et al., 2003) and facilita-
ion of aversive states (Terzian et al., 2009).
Early electrophysiological data obtained in rat brain slices of
he hypothalamus, substantia nigra or locus coeruleus showed PRESS
avioral Reviews xxx (2014) xxx–xxx
that TRPV1 stimulation evokes glutamate release (Marinelli et al.,
2002, 2003; Sasamura et al., 1998). Corroborating these findings, an
increase in glutamatergic synaptic transmission was also observed
after capsaicin infusion into the dPAG, an effect that was  prevented
by TRPV1 antagonists (Xing and Li, 2007). These results agree with
findings suggesting that TRPV1 channels are present in glutamater-
gic terminals in the PAG and adjacent colliculi (Cristino et al.,
2006; Maione et al., 2006, 2009a, 2009b; McGaraughty et al., 2003;
Starowicz et al., 2007). Anandamide can also tonically facilitate glu-
tamate release through TRPV1 activation in the substantia nigra
(Marinelli et al., 2003). Indeed, it has recently been reported that,
when anandamide degradation was inhibited along cannabinoid
type 1 (CB1) blockade, glutamatergic activity increases in the PAG
through a presynaptic TRPV1 mechanism (Kawahara et al., 2011).
In addition to presynaptic, post-synaptic effects of TRPV1
channels on glutamate-mediated neurotransmission can also be
important. Actually, it was  recently shown that the long-term
depression (LTD) induced in the nucleus accumbens by mGluR-5
activation depends on postsynaptic TRPV1 activation by anan-
damide (Grueter et al., 2010). Similar results have been reported
in the dentate gyrus (Chavez et al., 2010). Also, in the BNST an
increased anandamide release induced by glutamate-mediated
activation of mGluR-5 could act on post-synaptic TRPV1 to induce
LTD (Puente et al., 2011). In this region TRPV1 channels were
present for the most part in dendrites next to the synaptic cleft
(Puente et al., 2011). Anandamide has a lower affinity for TRPV1
than CB1 receptors (Piomelli, 2003), and facilitation of glutamate
release by TRPV1 activation might be related to the bell-shaped
dose–response curves observed with high doses of anandamide
and other cannabinoids (Moreira et al., 2007, 2012; Campos and
Guimaraes, 2009; Rubino et al., 2008). In line with this, we hypoth-
esized that the lack of anxiolytic-like effects observed with higher
doses of anandamide injected into the dlPAG of rats was due
to TRPV1-mediated facilitation of glutamatergic neurotransmis-
sion. Accordingly, local blockade of NMDA receptors unveiled the
anxiolytic-like effect of higher doses of this substance, which was
prevented by a CB1 receptor antagonist (Fogaca et al., 2013).
Considering that anandamide can bind to both TRPV1 and
CB1, we  also hypothesized the existence of a reciprocal interac-
tion between these two  receptors in the modulation of panic-like
responses. At electrophysiological and neurochemical levels,
TRPV1 and CB1 mediate opposite responses regarding neural fir-
ing and glutamate release (Kawahara et al., 2011). Accordingly,
we found that local TRPV1 antagonism or CB1 activation increases
the current threshold to induce panic-like behaviors after electri-
cal stimulation of the dlPAG (Casarotto et al., 2012). Furthermore,
CB1 antagonism prevented the anti-panic effects of TRPV1 antag-
onists. We  also observed that these receptors are co-expressed
in synaptic terminals in the dlPAG (Casarotto et al., 2012). Simi-
lar reciprocal interactions have been observed in the modulation
of anxiety-like behavior in rats tested in the EPM and VCT after
anandamide administration into the vmPFC (Fogaca et al., 2012).
Based on these observations, we  put forward a hypothesis that
anandamide, CB1 and TRPV1 could behave as a set-point system
in the modulation of panic-like responses (Moreira et al., 2012;
Moreira and Wotjak, 2010). We  proposed that anandamide, which
can tonically activate both receptors, has its actions entirely shift to
CB1 after TRPV1 blockade. This would change the balance, result-
ing in CB1-mediated anti-aversive effects of TRPV1 antagonists.
One premise of this hypothesis is that anandamide could simul-
taneously activate both receptors, which is supported by their
co-localization in the PAG and other brain regions. Therefore, theensive behavior by Transient Receptor Potential Vanilloid Type-1
0.1016/j.neubiorev.2014.03.026
mechanisms though which TRPV1 modulate defensive responses
seem to be tightly linked to the functioning of the endocannabi-
noid system (Di Marzo, 2008; Moreira et al., 2012; Moreira and
Wotjak, 2010).
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Fig. 1. Possible mechanisms involved in TRPV1-mediated effects in defensive
responses. Activation of TRPV1 receptors by anandamide facilitates glutamate (open
circles) release, which drives defensive responses in anxiety-related regions such as
the vmPFC and dlPAG. However, recent evidence suggests that other neurotrans-
mitters, including NO, and GABA, are also involved in the modulatory influence of
these receptors in anxiety (see main text for details). 2AG: 2-arachidonoyl glycerol,
ADC: adenylyl cyclase, CB1: cannabinoid type-1 receptor, DGL: diacylglycerol lipase,
GC: guanylyl cyclase, mGlu5: glutamate metabotropic type-5 receptor, NMDA: N-
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Petrocellis et al., 2011). Also, the possible side effects of acute andethyl-d-aspartate receptor, nNOS: neuronal nitric oxide synthase, NO: nitric oxide,
L: N-acylphosphatidylethanolamine-hydrolyzing phospholipase.
Although most of the evidence reviewed so far suggests that
RPV1 channels interfere with defensive responses by facilitation
f glutamate release, the role of these receptors is probably more
omplex and could involve other neurotransmitters such as nitric
xide (NO). In the CNS, NO is synthesized by the neuronal nitric
xide synthase (nNOS) (Bredt and Snyder, 1994). This enzyme is
ctivated by calcium influx trough NMDA receptors, indicating a
lose relationship between NO and glutamate-mediated neuro-
ransmission (Bredt and Snyder, 1994). Recent electrophysiological
ata by Zschenderlein et al. (2011) suggest that anandamide sti-
ulates NO synthesis via TRPV1. NO could then act presynaptically
s a retrograde messenger and enhance the release of glutamate
Zschenderlein et al., 2011). Corroborating a possible TRPV1-NO-
lutamate interaction, systemic administration of capsaicin in rats
ncreased NO synthesis in the paraventricular nucleus of hypothala-
us, medial amygdala and dlPAG, brain regions related to defensive
esponses (Okere et al., 2000a, 2000b; Okere and Waterhouse,
006). Therefore, TRPV1 could modulate aversive responses by
acilitating the glutamate/NMDA receptor/NO pathway. To test this
ypothesis we verified if defensive responses induced by increasing
O action in the dlPAG of rats would be blocked by pretreatment
ith a TRPV1 antagonist. In accordance to our expectations, local
njection of capsazepine prevented the defensive reaction induced
y the NO donor 3-morpholinosylnomine hydrochloride (SIN-1) in
his brain region (Lisboa et al., 2013). This result is in line with
hat obtained in a previous study showing that the flight reac-
ions induced by SIN-1 in the dlPAG depend on glutamate release
Moreira et al., 2004). Moreover, similar to the effects observed
ith TRPV1 antagonists, local blockade of NMDA receptors in the
lPAG turned a high, ineffective dose of anandamide, into an anx-
olytic one (Fogaca et al., 2013). Together, these findings suggest
hat NO and endovanilloids interact to control glutamate-mediated
efensive responses (Fig. 1).
Some authors have also proposed that TRPV1 can interfere with
ABAergic neurotransmission (Bennion et al., 2011; Maccarrone
t al., 2008). However, this interference has been found in pro-Please cite this article in press as: Aguiar, D.C., et al., Modulation of def
(TRPV1) Channels. Neurosci. Biobehav. Rev. (2014), http://dx.doi.org/1
esses involving synaptic plasticity and there is still controversy if
hey depend on a direct effect on GABA neurons or if TRPV1 recep-
ors facilitate GABAergic neurotransmission indirectly through a PRESS
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glutamate-mediated mechanism (Chavez et al., 2010; Gibson et al.,
2008; Maione et al., 2009a). Linking this latter proposal with
the endocannabinoid system, a recent electrophysiological study
using ventrolateral PAG slices suggested that local TRPV1 acti-
vation, by facilitating glutamate release, activates post-synaptic
metabotropic type-5 glutamate receptor (mGlu-5) and increases
2-arachidonoyl glycerol (2-AG) formation (Liao et al., 2011). This
endocannabinoid would then act presynaptically on CB1 recep-
tors to decrease GABA release (Fig. 1). This would disinhibit the
vlPAG and activate the descending pain inhibitory pathway. This
result suggests that TRPV1 and CB1 interact to control not only
glutamate but also GABA-mediated neurotransmission and may
help to explain why, although sharing endogenous ligands such as
anandamide, these receptors seem to play opposite roles in several
physiological responses, including those related to fear and anxiety
(Di Marzo, 2008; Moreira et al., 2012; Moreira and Wotjak, 2010).
At the present most studies have investigated the effects
of single, acute interference with TRPV1 channels on defensive
responses. However, TRPV1 channels can undergo plastic changes
after prolonged exposure to aversive stimuli such as chronic
pain. For example, de Novellis and co-workers (2011) showed
that neuropathic pain induced by spinal nerve ligation causes an
increase in extra-cellular glutamate in the vmPFC accompanied by
up-regulation of fatty acid amide hydrolase (FAAH, the enzyme
responsible for anandamide hydrolysis) and TRPV1 channels (de
Novellis et al., 2011). Increased expression of TRPV1 channels dur-
ing chronic pain has also been described in the periphery (Akbar
et al., 2010). Although the mechanisms involved in these changes
are unknown, a recent study in rats showed that repeated corti-
costerone administration or exposure to a psychological stressor
(water avoidance, 1 h daily) for 10 days resulted in visceral hyper-
algesia and increased and decreased expression of TRPV1 and CB1
receptors, respectively, in DRG neurons. The stress effects were
prevented by co-treatment with the glucocorticoid receptor (GR)
antagonist RU-486. In vitro incubation of DRG neurons with cor-
ticosterone produced similar results (Hong et al., 2011). Together,
these results suggest that stress exposure, by enhancing cortico-
sterone levels and activating GRs, changes the balance between
TRPV1 and CB1 receptors, increasing the former and decreasing
the latter. Other stressful interventions such as exposure to volatile
anesthetics may  also result in TRPV1 sensitization (Cornett et al.,
2008; Harrison and Nau, 2008; Zschenderlein et al., 2011). These
results highlight the importance of further investigating the plastic
changes of the endovanilloid system under chronic conditions such
as repeated drug administration or prolonged exposure to aversive
situations.
5. Conclusions
Several pieces of evidence suggest that TRPV1 channels promote
defensive responses. The underlying mechanisms of this effect
seem to involve facilitation of glutamate actions in specific brain
areas that include the dlPAG, vmPFC and vHPC. Key questions, how-
ever, remain to be answered, including TRPV1 role in other brain
regions related to defensive responses, such as the amygdala and
BNST, its differential involvement in physiological versus patho-
logical anxiety and its multiple interactions with other transmitter
systems. Its endogenous ligands and their release mechanisms
under acute and repeated aversive situations also remain to be
determined. An additional aspect to be considered is the poten-
tial clinical use of TRPV1 desensitization by capsaicin analogs (Deensive behavior by Transient Receptor Potential Vanilloid Type-1
0.1016/j.neubiorev.2014.03.026
chronic administration of TRPV1-related drugs remain to be further
investigated. TRPV1 channels play an important role in body tem-
perature regulation (Moran et al., 2011) and its antagonists cause
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yperthermia in laboratory animals (Gavva et al., 2008). Accord-
ngly, human studies indicated that hyperthermia could be a side
ffect of these drugs (Gavva et al., 2007; Krarup et al., 2011). Thus,
n important step toward therapeutic applications would be devel-
ping compounds that are able to block specific sites of TRPV1
hannels, without interfering with its modulatory role upon body
emperature (Moran et al., 2011).
Finally, TRPV1 should also be considered for the development
f drugs that interfere with endocannabinoids. Compounds that
nhibit the anandamide-hydrolyzing enzyme, FAAH, have anxio-
ytic properties by enhancing the actions of this endocannabinoid
pon CB1 receptors (Kathuria et al., 2003; Moreira et al., 2008).
heir effects, however, are partially occluded by the parallel action
f anandamide upon TRPV1. In this way, simultaneous blockade
f FAAH and TRPV1 induced by drugs such as N-arachidonoyl-
erotonin (AA-5-HT) represents an interesting strategy to increase
nandamide levels and redirect its action entirely to CB1 receptors,
esulting in a more robust anxiolytic effect (Micale et al., 2009).
Thus, drug development in this field could be based either on
elective blockade of TRPV1 or rely upon interactions between this
on channel and the endocannabinoid system. If their putative side
ffects are circumvented, drugs targeting TRPV1 could represent a
ew and promising strategy for the treatment of anxiety disorders.
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Abstract
Rationale Contextual fear is evoked by re-exposing an animal
to an environment that has been previously paired with an
aversive or unpleasant stimulus. It can be assessed by freezing
and cardiovascular changes such as increase in mean arterial
pressure and heart rate. A marked increase in neuronal activity
is associated with contextual fear conditioning, especially in
limbic structures involved with defense reactions, such as the
ventral portion of medial prefrontal cortex.
Objective Given the fact that transient receptor potential
vanilloid type 1 (TRPV1) receptors could be involved in the
expression of defensive behavior, the present work tested the
hypothesis that TRPV1 manipulation in the ventromedial pre-
frontal cortex (vMPFC) modulates the expression of contextu-
al conditioned fear.
Methods Male Wistar rats received bilateral microinjections
into the vMPFC of the TRPV1 receptor antagonists capsazepine
(1, 10, and 60 nmol/200 nL) or 6-iodonordihydrocapsaicin
(3 nmol/200 nL), and the TRPV1 agonist capsaicin (1 nmol/
200 nL) preceded by vehicle or 6-iodonordihydrocapsaicin be-
fore re-exposure to the experimental chamber for 10 min, 48 h
after conditioning in two different protocols distinct by their
aversiveness.
Results Both antagonists reduced the freezing and cardiovas-
cular responses in the high aversive protocol. Capsaicin caused
an increase in fear-associated responses that could be blocked
by 6-iodonordihydrocapsaicin.
Conclusions Our results indicate that TRPV1 receptors locat-
ed in the vMPFC have a tonic involvement in the modulation
of the expression of contextual fear conditioning.
Keywords Contextual fear . TRPV1 receptors . Prefrontal
cortex . Cardiovascular system . Rats
Introduction
Contextual fear responses are evoked when an animal is re-
exposed to an environment previously paired with an electric
footshock (Blanchard and Blanchard 1969; Fanselow 1980;
LeDoux et al. 1988; Resstel et al. 2008a, c). It is characterized
by freezing and cardiovascular responses such as mean arterial
pressure (MAP) and heart rate (HR) increases. Different shock
intensities can be applied to better understand the relation be-
tween fear responses and environment aversiveness, i.e., higher
shock intensities are usually used to overload the subject, thus the
search for manner to reduce or alleviate the aversive response;
less aversive shock intensities can be used to avoid the ceiling
effect and investigate how a certain system could be involved in
the fear expression and the potential enhancer effect of some
drugs (Quigley et al. 1994; Baldi et al. 2004; Lisboa et al. 2010).
Fear-related responses are associated with increased neu-
ronal activity in the ventral portion of medial prefrontal cortex
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(vMPFC) (Beck and Fibiger 1995). This region comprises
infralimbic (IL) and prelimbic (PL) cortices (Verberne and
Owens 1998; Resstel and Correa 2006) that are involved with
cardiovascular, neuroendocrine, and behavioral responses, in-
cluding those elicited by contextual fear conditioning
(Frysztak and Neafsey 1994; Schulkin et al. 2005; Sierra-
Mercado et al. 2006; Radley et al. 2009; Tavares et al. 2009).
A study using immunohistochemistry and in situ hybridi-
zation was the first to describe the existence of transient
receptor potential type 1 (TRPV1)-expressing neurons in the
brain (Mezey et al. 2000). Next, it was unveiled that their pro-
depolarization characteristic led to neural firing—mainly on
glutamatergic transmission (Starowicz et al. 2007; Xing and Li
2007; Kawahara et al. 2011). These cation-permeable channel
receptors were first described in peripheral afferent fibers
related to nociceptive processes (Caterina et al. 1997). Also,
its activation is usually followed by receptor desensitization
(Szallasi and Blumberg 1999; Szallasi and Di Marzo 2000).
Since their first description, the presence of TRPV1 receptors
has been recognized in several regions, including those in-
volved in defensive behavior expression (Mezey et al. 2000;
Sanchez et al. 2001; Roberts et al. 2004; Toth et al. 2005).
More specifically, recent studies have described the specific
expression of TRPV1 receptors in both portions of vMPFC,
PL, and IL (de Novellis et al. 2011; Giordano et al. 2012).
Kasckow et al. (2004) suggested for the first time the pos-
sible involvement of TRPV1 receptors on emotional responses,
by submitting animals to an anxiety model after systemic
injection of the TRPV1 antagonist capsazepine. After that,
Rubino et al. (2008) demonstrated that administration of an
analogue of the TRPV1 agonist anandamide into the prefrontal
cortex produces biphasic effects—in high dose-promoted
anxiogenic-like behavior in animals submitted to the elevated
plus maze which was blocked by capsazepine. Also, TRPV1
knockout mice present reduced anxiety-like behavior and im-
paired fear conditioning (Marsch et al. 2007). Our group also
showed reduction in anxiety level after local blockade of
TRPV1 receptors in different brain regions (Aguiar et al.
2009; Terzian et al. 2009; Fogaça et al. 2012), thus supporting
the hypothesis that TRPV1 receptors play a role in defensive
behavior. Although capsazepine has been employed in most
part of these studies as TRPV1 receptor antagonist, its selec-
tivity is limited and shows several off-target effects. For this
reason, amore selective antagonist was employed in the present
work (6-iodonordihydrocapsaicin; Appendino et al. 2003).
Considering the abovementioned evidence, the present
work aimed to evaluate the pharmacological role of TRPV1
receptors located in the vMPFC during contextual fear expres-
sion. For this reason, we administrated two different TRPV1
antagonists and one TRPV1 agonist to rats submitted to fear
conditioning protocols with different levels of aversiveness
that would enable a bidirectional manipulation of the vanilloid
system—where a high aversive protocol allows a substantial
activation of TRPV1 receptors and a more clear result after its
blockade, and a less aversive protocol still permits an increase
in the system activation after pharmacological treatment with
the agonist capsaicin. Our results demonstrated that depending
on the aversiveness level, TRPV1 receptors located in the
vMPFC have a partial or complete influence on the expression
of contextual fear responses.
Materials and methods
Animal preparation
Seventy-two maleWistar rats weighing 230–270 g were used.
Animals were maintained in the Animal Care Unit of the
Department of Pharmacology, School of Medicine of
Ribeirão Preto, University of São Paulo. Rats were housed
individually in plastic cages with free access to food and water
and under a 12-h light/dark cycle (lights on at 0630 hours).
The Institution’s Animal Ethics Committee approved housing
conditions and experimental procedures.
Seven days before the first context exposure (habituation),
rats were anesthetized with tribromoethanol (250 mg/kg, IP).
After local anesthesia with 2 % lidocaine, the skull was
surgically exposed, and stainless steel guide cannulae (26G)
were implanted bilaterally into the vMPFC using a stereotaxic
apparatus (Stoelting, Wood Dale, Illinois, USA) as described
by Lisboa et al. (2010). Coordinates for cannulae implantation
were selected from the rat brain atlas of Paxinos and Watson
(1997). Cannulae were fixed to the skull with dental cement
and one metal screw. After surgery, the animals received a
poly-antibiotic (Pentabiotico®, Fort Dodge, Brazil), with strep-
tomycins and penicillins, to prevent infection and the nonste-
roidal anti-inflammatory flunixine meglumine (Banamine®,
Schering Plough, Brazil) for postoperative analgesia.
One day before the re-exposure to the context, rats were
anesthetized with tribromoethanol and a catheter (a 4 cm PE-
10 segment heat-bound to a 13-cm PE-50 segment, Clay
Adams, Parsippany, New Jersey, USA) was inserted into the
abdominal aorta through the femoral artery for cardiovascular
recording. The catheter was tunneled under the skin and
exteriorized on the animal’s dorsum.
Drugs
Capsazepine and capsaicin (TOCRIS, Ellisville, Missouri,
USA) were dissolved in dimethyl sulfoxide (DMSO), as pre-
viously described (Terzian et al. 2009). The doses
(capsazepine, 1, 10, and 60 nmol/200 nL; capsaicin, 1 nmol/
200 nL) were chosen based on previous results from our
group. 6-Iodonordihydrocapsaicin (6-iodo, TOCRIS,
Ellisville, Missouri, USA) dose of 3 nmol/200 nL was pre-
pared in DMSO (100 %). The dose of 6-iodo was selected
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based on the study of Appendino et al. (2003) and Fogaça
et al. (2012). All solutions were prepared immediately before
use.
Fear conditioning
Habituation, conditioning, and re-exposure were carried out in
25×22×22 cm footshock chambers. The chambers had a grid
floor composed of 18 stainless steel rods (2 mm in diameter),
spaced 1.5 cm apart and wired to a shock generator (Insight,
Brazil). The chamber was cleaned with 70 % ethanol, before
and after each animal. The procedure started 1 week after
guide cannulae implantation. It consisted of one 10-min ha-
bituation session to the footshock chamber (no shock presen-
tation). The conditioning session (shock presentation) was
performed 24 h after the habituation session, which consisted
of six electric 1.5 mA/3 s footshocks (Resstel et al. 2008a, b)
delivered at 20 s to 1 min intervals, starting 3 min after placing
the animal into the chamber.
An additional group of animals was submitted to a different
conditioning protocol to obtain reduced conditioned fear re-
sponses as described before (Baldi et al. 2004; Lisboa et al.
2010). In this condition, three electric footshocks of 0.85 mA/
3 s were delivered at 20 s to 1 min intervals.
Twenty-four hours after the conditioning session, for both
protocols, a catheter was implanted into the femoral artery for
cardiovascular recording. Forty-eight hours after the condi-
tioning, cardiovascular and behavioral (freezing) responses to
context were evaluated in the re-exposure session.
In this re-exposure session, the animal was placed for
10 min to the same chamber but without any shock presenta-
tion. Animals were transferred from the animal room to the
procedure room (a different room was used for conditioning)
in their home box. MAP and HR were recorded using an HP-
7754A amplifier (Hewlett Packard, Palo Alto, CA, USA)
connected to a signal acquisition board (Biopac M-100,
Goleta, CA, USA) and computer-processed. Rats were tested
one at a time. After connecting the animal to the setup, drugs
were administrated into the vMPFC, and 5 minutes before re-
exposure to the context, MAP and HR baseline were recorded
in the home box. Two 33G needles (Small Parts, Miami
Lakes, FL, USA) 1-mm longer than the guide cannula and
connected to a 10-μL syringe (7002-H, Hamilton Co., Reno,
NV, USA) through PE-10 tubing were used. The needles were
carefully inserted into the guide cannulae, and the solutions
were infused over a 30-s period with a rate of 400 nL/min.
They remained in place for an additional 20-s period to
prevent reflux. The re-exposure session started 10 min after
injection.
Freezing was evaluated during the re-exposure session by
an experimenter blind to the treatment located 30 cm from the
experimental chamber. It was defined as the complete absence
of movement except for breathing, while the animal assumed
a characteristic tense posture (Fanselow 1980; Resstel et al.
2006, 2008c).
Experimental design
In the first experiment, all animals were randomly assigned to
treatment groups. Each animal received 200 nL bilateral in-
jections into the vMPFC of capsazepine (1, 10, or 60 nmol), 6-
iodo (3 nmol), or vehicle. The animals were tested 10 min
after the microinjection.
In the second experiment, to evaluate the effects of TRPV1
receptor activation in the vMPFC in a less aversive conditioning
protocol, each animal received two bilateral injections of 200 nL
into the vMPFC of the drugs or vehicle. The experimental
groups were as follows: vehicle+vehicle (n=6), vehicle+
capsaicin (1 nmol, n=5), 6-iodo (3 nmol)+vehicle (n=5), or
6-iodo (3 nmol)+capsaicin (1 nmol, n=5). The interval between
the first and second microinjection was 5 min, and the animals
were tested 10 min after the last microinjection.
Histology
After the behavioral tests, the rats were anesthetized with
urethane, and 200 nL of 1 % Evans blue dye was bilaterally
injected into the vMPFC as a marker of injection sites. After
this procedure, the animals were perfused through the left
ventricle of the heart with isotonic saline followed by 10 %
formalin solution. The brains were removed and, after a min-
imum period of 5 days immersed in a 10 % formalin solution,
50-μm sections were obtained in a Cryostat (Cryocut 1800,
Leica). The injection sites were identified in diagrams from the
Paxinos andWatson’s atlas (Paxinos andWatson 1997) and are
illustrated in Fig. 1.
Data analysis
MAP and HR values were continuously recorded in the home
cage during the 5-min period prior and the 10-min period
during re-exposure to the context. Data were expressed as
means ± SEM of MAP or HR changes (ΔMAP and ΔHR,
respectively) sampled at 60-s intervals. Average points sam-
pled during the 5-min before re-exposure were used as control
baseline value. MAP and HR changes were analyzed using
two-way analysis of variance (ANOVA) with treatment as
main independent factors and time as repeated measurement.
When interaction between the factors was observed, the main
independent factors were compared at specific times using the
Bonferroni’s post hoc test.
Freezing was expressed as percentage of the whole test
period. Freezing was analyzed using one-way or two-way
ANOVA with treatment as the main independent factor
followed by the Bonferroni’s post hoc test or Student’s t test.
p<0.05 was assumed as statistically significant.
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Results
Schematic diagram indicating the injection sites of vehicle and
drugs and photomicrographs showing a representative bilat-
eral injection site in the IL and PL regions of vMPFC are
presented in Fig. 1.
Effects of the capsazepine microinjected into the vMPFC
on behavioral and cardiovascular responses to contextual fear
conditioning
The administration of capsazepine (10 and 60 nmol) into the
vMPFC significantly reduced the freezing (F3,30=30.75,
p<0.001) of conditioned animals (n=10/group) but not the dose
of 1 nmol (n=6, p>0.05), when compared with vehicle-treated
conditioned animals (n=8, Fig. 2a, left panel).Moreover, a dose
dependencywas demonstrated by nonlinear regression analysis,
showing a significant correlation between capsazepine doses
and attenuation of the freezing (r2=0.71, df=23, p<0.05,
Fig. 2a, right panel), confirming a dose-dependent effect.
The bilateral injection of capsazepine into the vMPFC had
no effect on basal levels of both MAP (F3,30=0.87, p>0.05)
and HR (F3,30=0.92, p>0.05) when compared to vehicle
control group. The re-exposure to a context previously paired
with footshocks induced a marked and sustained increase in
both MAP (F14,450=104.4, p<0.001) and HR (F14,450=84.2,
p<0.001) during the 10 min of session. Capsazepine (10 and
60 nmol) attenuated the cardiovascular response increases of
conditioned animals (MAP: F3,450=130.5, p<0.001, and HR:
F3,450=108.4, p<0.01), but not the dose of 1 nmol (p>0.05),
when compared with vehicle-treated animals (Fig. 2b, left
panels). Again, a nonlinear regression analysis showed a
significant correlation between capsazepine doses and attenu-
ation of both MAP (r2=0.7, df=23, p<0.05) and HR
(r2=0.65, df=23, p<0.05) (Fig. 2b, right panels).
The capsazepine effects (10 and 60 nmol doses) were
similar when it was administered in PL (n=5) or IL (n=5) of
conditioned rats (freezing: F1,16=0.03, p>0.05; MAP:
F3,240=0.76, p>0.05; and HR:F3,240=0.058, p>0.05). In these
two areas, capsazepine reduced these responses (IL—freezing:
F2,15=37.4, p<0.001; MAP: F2,225=75.2, p<0.001; and HR:
F2,225=88.3, p<0.001; PL—freezing: F2,15=17.5, p<0.001;
MAP: F2,225=101.5, p<0.001; andHR: F2,225=91.3, p<0.01).
Finally, no changes on behavioral or cardiovascular re-
sponses were observed when capsazepine (10 or 60 nmol)
was microinjected into structures surrounding the vMPFC of
animals (n=8; freezing, p>0.05; MAP, p>0.05; and HR,
p>0.05, respectively).
Fig. 1 a Photomicrographs of a coronal brain section showing bilateral
microinjections sites in the IL and PL regions of vMPFC. b Diagram-
matic representation based on the rat brain atlas of Paxinos and Watson
(1997) indicating the injection sites in the IL (black circles) and IP (white
circles). Animals with drug injection sites outside the vMPFC were
represented by gray circles. Cg1 cingulate cortex area 1, PL prelimbic
cortex, IL infralimbic cortex, DP dorsal peduncular córtex, cc corpus
callosum, IA interaural
Fig. 2 Effects of bilateral injection of 200 nL of vehicle or capsazepine
(CPZ, 1, 10, or 60 nmol) in conditioned animals (n=6–10) during
chamber exposition a on the percentage of time spent freezing behavior
(left panel) and nonlinear regression analysis of percentage of time spent
freezing (right panel). b Time course of mean arterial pressure (ΔMAP)
and heart rate (ΔHR) increases (right panels), and nonlinear regression
analysis of mean values of mean arterial pressure (ΔMAP) and heart rate
(ΔHR) increases. Values are represented by means ± SEM. *p<0.05 and
**p<0.01 compared to vehicle group, Bonferroni’s post hoc test
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Effects of 6-iodonordihydrocapsaicin microinjected
into the vMPFC on behavioral and cardiovascular responses
to contextual fear conditioning
To confirm the involvement of vMPFC-TRPV1 receptors on
expression of contextual fear conditioning, we administrated
the selective TRPV1 receptor antagonist, 6-iodo (3 nmol) into
the vMPFC of a new group of animals. The administration of
6-iodo into the vMPFC significantly reduced the freezing of
conditioned animals (n=5, t=8.6, p<0.001) when compared
with vehicle-treated animals (n=5, Fig. 3a). Also, 6-iodo
attenuated the increase in cardiovascular response of condi-
tioned animals (MAP: F1,120= 83.6, p<0.001 and HR:
F1,120=66.4, p<0.001) when compared with the control group
(Fig. 3b), without affecting the basal levels of MAP (t=0.16,
p>0.05) and HR (t=0.07, p>0.05).
Effects of the capsaicin microinjected into the vMPFC
on behavioral and cardiovascular responses to contextual fear
conditioning in a less aversive protocol
The group conditioned with a less aversive conditioning pro-
tocol (n=5) spent less time freezing (48±3.4% vs 80.3±2.5%,
t=7.6, p<0.001) and presented reduced cardiovascular re-
sponses (MAP=F1,120=89.2, p<0.001 and HR=F1,120=81.3,
p<0.001) during the re-exposure to the context in comparison
to the group submitted to the more aversive conditioning
protocol (n=5).
Compared with vehicle-treated animals (n=5), the admin-
istration of capsaicin (1 nmol) into the vMPFC of conditioned
animals submitted to the less aversive conditioning protocol
(n=5) increased freezing (F1,16=10.3, p<0.001) and cardio-
vascular responses (MAP: F3,240=107.9, p<0.001 and HR:
F3,240=127.1, p<0.001; Fig. 4). The bilateral injection of
capsaicin into the vMPFC had no effect on basal levels of
both MAP (F3,19=0.07, p>0.05) and HR (F3,19=0.1, p>0.05)
when compared to the vehicle control group.
In this less aversive conditioning protocol, the bilateral ad-
ministration of 6-iodo (3 nmol, n=5) had no effects on both
freezing (F1,16=2.2, p>0.05) and cardiovascular responses
(MAP:F3,240=0.03, p>0.05 andHR:F3,240=0.1, p>0.05) when
compared to the vehicle-treated group. However, the pre-
treatment with 6-iodo blocked the effects of capsaicin in increas-
ing both freezing (F1,16=11, p<0.001) and cardiovascular re-
sponses (MAP: F3,240=82.8, p<0.001 and HR: F3,240=98.7,
p<0.001).
Discussion
The present study demonstrated that TRPV1 receptors located
into the vMPFC are involved in the expression of contextual fear
conditioning. This involvement seems to be tonically mediated,
since TRPV1 blockade is sufficient to decrease fear-related
freezing and cardiovascular responses. Corroborating these re-
sults, another important finding is that direct activation of
TRPV1 receptors by capsaicin can increase conditioned fear
response, an effect that was blocked by pretreatment with
TRPV1 antagonist.
Fig. 3 a Effects of bilateral injection of 200 nL of vehicle or 6-
iodonordihydrocapsaicin (6-iodo, 3 nmol) in conditioned animals (n=5
per group) on the percentage of time spent freezing behavior. b Time
course of the effects of bilateral microinjection of 200 nL of vehicle 6-
iodonordihydrocapsaicin (6-iodo, 3 nmol) recorded in conditioned ani-
mals (n=5 per group) onmean arterial pressure (ΔMAP, upper panel) and
heart rate (ΔHR, lower panel) increases. Values are represented bymeans ±
SEM. *p<0.05 compared to vehicle group, Student’s t test, Bonferroni’s
post hoc test
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Intra-vMPFC administration of capsazepine attenuated the
expression of contextual fear conditioning in a dose-
dependent manner, suggesting the involvement of local
TRPV1 receptors in this response. However, capsazepine
may have a nonspecific action in addition to its effects on
TRPV1 receptors, which is characterized by inhibition of
calcium current via blockade of voltage-dependent calcium
channels usually associated with TRPV1 receptors activation
(Docherty et al. 1997). Therefore, to confirm TRPV1 recep-
tors involvement in the expression of contextual fear con-
ditioning, we microinjected the selective TRPV1 receptor
antagonist 6-iodo (Appendino et al. 2003; Fogaça et al.
2012). The bilateral administration of 6-iodo was able to
reduce both behavior and autonomic responses evoked by
exposure to an aversive context, as observed after
capsazepine administration. Binding studies described that
6-iodo has two- to tenfold higher affinity than capsazepine
for TRPV1 receptors, without affinity for voltage-
dependent calcium channels (Appendino et al. 2003).
Thus, the present findings about 6-iodo, together with
those obtained with capsazepine, indicate that TRPV1
receptors in vMPFC are involved on the modulation of
contextual fear conditioning expression.
Previous studies described the differences between IL and
PL, areas that comprise the vMPFC, in the modulation of
cardiovascular and behavioral responses in several models
and different treatments (Jaskiw and Weinberger 1990;
Frysztak and Neafsey 1991, 1994; Jinks and McGregor
1997; Vidal-Gonzalez et al. 2006; Tavares et al. 2009;
Sierra-Mercado et al. 2011). Therefore, to inquire if the
TRPV1 receptors in both the PL and IL cortex could modulate
the expression of contextual fear differently, animals that
received a dose of 10 or 60 nmol of the TRPV1 receptor
antagonist capsazepine were separated according to the site
of microinjection into two groups, PL and IL. It must be
acknowledged that in some occasions, it is difficult to separate
IL and PL, especially when dealing with injection volume
spreading through the tissue. The same effects of TRPV1
receptor antagonism on contextual fear conditioning were
observed when capsazepine was administrated in PL or IL.
Moreover, the bilateral administration of TRPV1 receptor
antagonist into structures surrounding the vMPFC, which
are near to both areas, did not affect the expression of contex-
tual fear conditioning. Therefore, it is less probable that the
effects of drugs would be due to their spread from the site of
injection to one unspecific point, in this case, located between
the IL and PL. These results are in agreement with other
observations that the IL or PL has the same influence on both
cardiovascular and behavior responses (Owens and Verberne
2001; Resstel and Correa 2005, 2006; Resstel et al. 2008a,b,c;
Lisboa et al. 2010; Ferreira-Junior et al. 2012). Moreover,
studies showed that IL and PL had the same role in defensive
responses to contextual fear conditioning, including cardio-
vascular responses (Corcoran and Quirk 2007; Lisboa et al.
2010; Resstel et al. 2006). Thus, our findings show a homo-
geneous influence of the vMPFC subarea TRPV1 receptors on
contextual fear conditioning expression.
Fig. 4 a Effects of bilateral injection of 200 nL of vehicle or 6-
iodonordihydrocapsaicin (6-iodo, 3 nmol) followed by a second injection
of vehicle or capsaicin (CPS, 1 nmol) in conditioned animals (n=5 each
group) on the percentage of time spent in freezing behavior. b Time
course of the effects of bilateral microinjection of vehicle or 6-
iodonordihydrocapsaicin (6-iodo, 3 nmol) followed by a second injection
of vehicle or capsaicin (CPS,d 1 nmol) recorded in conditioned animals
(n=5 each group) on mean arterial pressure (ΔMAP, upper panel) and
heart rate (ΔHR, lower panel) increases. Values are represented bymeans ±
SEM. *p<0.05 compared to vehicle group; *p<0.05 compared to cap-
saicin group. Student’s t test, Bonferroni’s post hoc test
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The participation of TRPV1 receptors is proposed to de-
pend on the environment aversiveness (Marsch et al. 2007).
Corroborating this proposal, in higher shock conditions, both
capsazepine (10 and 60 nmol) and 6-iodo (3 nmol) were able
to reduce freezing and cardiovascular responses associated
with fear expression, which indicates the active participation
of TRPV1 receptors in high-threatening situations.
Meanwhile, when a lower shock intensity was given, the same
dose of 6-iodo (3 nmol) was no longer capable to reduce fear-
related responses. Also, in the low-shock protocol, TRPV1
receptors activation by capsaicin increased the fear responses,
an effect that was prevented by pretreatment with a TRPV1
antagonist. This suggests that, under this condition, the
endovanilloid system in this area is not fully engaged.
Altogether, these results indicate that the role of the
endovanilloid system depends on environmental conditions.
They agree with the findings observed in TRPV1 knockout
animals, where differences between the mutant and the wild-
type animals were only observed under aversive conditions in
several behavioral tests but not under standard conditions
(Marsch et al. 2007). In this case, TRPV1 KO animals
presented less anxiety and fear levels compared to the wild-
type, although their extinction capability was maintained.
Considering the prefrontal cortex, previous works have
extensively shown its participation in aversive responses
(Frysztak and Neafsey 1994; Resstel and Correa 2006).
More recently, studies evaluating vMPFC interplay between
cannabinoid and vanilloid system demonstrated that both
systems play a role in suppressing and promoting fear/
anxiety behavior, respectively. Rubino et al. (2008) demon-
strated that inhibition of local TRVP1 was sufficient to reduce
anxiety-like behavior in the elevated plus maze, which was
also reported by Aguiar and collaborator (2009). Furthermore,
in the first study, TRPV1 antagonist was capable of abolishing
the anxiogenic-like affect observed after methanandamide
treatment.
On another hand, increased endogenous tone by rising
levels of anandamide or NADA (N-arachidonyl dopamine)
could also activate both TRPV1 and the cannabinoid type 1
(CB1) receptors in different extents (Di Marzo et al. 2001; Di
Marzo 2010). Whereas higher levels of these compounds
would result in a predominant drive towards TRPV1 recep-
tors, the pharmacological blockade or genetic ablation of these
receptor causes a shift of activation onto CB1 receptor direc-
tion (Casarotto et al. 2011; Moreira et al. 2011), which has
been shown to reduce aversive responses in different animal
models (Lisboa et al. 2010; Rubino et al. 2008; Pamplona
et al. 2006).
Recent pieces of evidence have also shown that TRPV1
receptors are able to modulate the glutamate releases in the
central nervous system (Karlsson et al. 2005; Sikand and
Premkumar 2007). Moreover, the antagonism of local vMPFC
glutamatergic NMDA receptors reduces the contextual fear
conditioning responses (Resstel et al. 2008b). Therefore, block-
ade of TRPV1 could culminate in a sort of indirect antagonist of
glutamatergic neurotransmissions in the vMPFC. These results
and our present findings suggest that endovanilloids could play
amajor role on the expression of contextual fear conditioning by
controlling glutamatergic synaptic transmission in the vMPFC
by activation of TRPV1 receptors.
In conclusion, our work demonstrated the involvement of
TRPV1 receptor located in the vMPFC in fear expression. The
results also suggest that the vanilloid system is tonically
activated during threatening situations accordantly with the
situation aversiveness. Together, these results suggest that
vanilloid system could be a possible target for pharmacolog-
ical treatment of anxiety disorders.
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BEHAVIORAL NEUROSCIENCE
in several neurophysiological responses. More specifically, it has 
been suggested that CB1R signaling modulates DAergic pathways 
by influencing directly or indirectly the activity of DAergic neu-
rons through either post- or pre-synaptic mechanisms (Laviolette 
and Grace, 2006). However, both the mechanisms through which 
DAergic and EC signaling cross-talk and the role played by the 
dopamine D1 receptor positive neurons still remain unclear. The 
dopamine D1 receptors (D1Rs), which belong to the “D1-like” 
group, are expressed in brain regions involved in aversive learning 
and memory such as nucleus accumbens, hippocampus, and amyg-
dala. (Kamei et al., 1995; Bernabeu et al., 1997; El-Ghundi et al., 
2001; Nagai et al., 2007). Interestingly, the colocalization of CB1Rs 
with D1Rs indicates that these receptors may interact by potentially 
modifying their respective functions with important behavioral and 
pharmacological consequences (Hermann et al., 2002).
Although the use of complete CB1 knock-out mice together 
with pharmacological approaches suggest that ECS controls fear 
and anxiety primarily under highly aversive situations (Moreira 
and Wotjak, 2010), the cellular substrates of these effects with 
regard to specific neuronal subpopulation involved (i.e., dopamine 
receptor D1-expressing neurons) is still largely unexplored, except 
INTRODUCTION
In the central nervous system (CNS), endogenous cannabinoids 
compounds activate cannabinoid CB1 receptors (CB1Rs), which 
are located pre-synaptically in several brain regions such as pre-
frontal cortex, hippocampus, amygdala, and basal ganglia. They 
act as inhibitory retrograde signaling messengers at glutamatergic 
and GABAergic synapses, modulating the release of several neuro-
transmitters such as acetylcholine or dopamine (DA) (Marsicano 
and Lutz, 1999; Piomelli, 2003). Thus, the endocannabinoid system 
(ECS), through its neuromodulating activity, could be involved in 
several physiological functions as memory processing, pain percep-
tion, locomotion, and inflammation; additionally, its dysregulation 
could underlie several pathological conditions known to accom-
panying psychiatric disorders (Di Marzo, 2008).
The role of the dopaminergic (DAergic) neurotransmitter sys-
tem in the processing of emotional behavior is well established 
and supported by several preclinical and clinical data showing 
that DA, acting on D1- or D2-like receptors, is one of the most 
important neuromodulators of fear and anxiety (LeDoux, 2000). 
A DAergic and EC interaction at different anatomical levels (i.e., 
amygdala, nucleus accumbens and striatum) seems to be involved 
The dopamine and cannabinoid interaction in the modulation 
of emotions and cognition: assessing the role of cannabinoid 
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D1R (D1–CB1−/−) in order to answer this question. To elucidate the behavioral effects of CB1R 
deficiency in this specific neuronal subpopulation, we subjected D1–CB1−/− mice to a battery 
of behavioral tests which included exploration-based tests, depressive-like behavioral tests, 
social behavior, and fear-related memory paradigms. D1–CB1−/− did not show any difference 
in the exploration-based paradigms such as open field, elevated plus maze, or novel object 
investigation test, except for an increase in novelty-induced grooming. By contrast, they showed 
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for a  specific contribution of principal neurons of the forebrain 
(Kamprath et al., 2009). Thus, conditional CB1 knock-out ani-
mals, lacking CB1Rs specifically in D1R positive neurons provide 
an important tool to answer these questions.
Based on the above premises, this study was undertaken to 
investigate the role of CB1R signaling in the dopamine receptor 
D1-expressing neurons in affecting emotional behavior. For this 
purpose, conditional CB1 mutant mice, lacking CB1Rs expres-
sion in neurons containing dopamine D1Rs (D1–CB1−/−; Monory 
et al., 2007), were submitted to a battery of behavioral tests, which 
included exploration-based tests, depressive-like behavioral tests, 
and fear-related memory paradigms. Since it has been hypothesized 
that ECS is a relevant modulator of dopamine D1Rs-mediated 
behaviors including social activity (Martín et al., 2008; Zenko et al., 
2011), we also evaluated the phenotype of these mice in social 
approach tests.
MATERIALS AND METHODS
ANIMALS
Male mice at the age of 8–16 weeks were used throughout the 
experiments. Conditional D1–CB1 knock-out mice (D1–CB1−/− 
or KO) and their respective wild-type (WT) littermate controls 
(D1–CB1+/+ or WT) were generated and genotyped as previously 
described (Monory et al., 2007). Animals (n = 6–10 per group) 
were single housed and maintained in standard conditions with 
food and water ad libitum under a 12-h inverse light–dark (LD) 
cycle (lights off at 9 a.m.) for at least 14 days before starting the 
experiments. All behavioral experiments were performed dur-
ing the active (dark) phase of mice between 9:30 a.m. and 5 p.m. 
Experimenters were always blind to the genotype. All behavioral 
tests took place in an experimental room with the same LD cycle 
and environmental conditions (i.e., humidity, temperature) as in 
the housing facility. All experiments were carried out according 
to the European Community Council Directive 86/609/EEC and 
efforts have been made to minimize animal suffering and reduce 
the number of animals used.
BEHAVIORAL TESTING
Novelty-induced grooming test
Grooming behavior was observed under the same environmental 
conditions as previously described (Kalueff and Tuohimaa, 2005). 
The mice were placed individually into a clean unfamiliar Plexiglass 
box (27 cm × 16 cm × 12 cm) without bedding for 10 min. Three 
ethological measures of grooming activity were scored: latency to 
start grooming, grooming episodes (washing, general grooming, 
scratching, licking of paws, or genital grooming), and total time 
spent grooming. All trials were recorded for subsequent video 
analysis.
Open field test
Exploratory activity of D1–CB1−/− and WT mice was evaluated in 
the open field (OF) test, as previously described (Jacob et al., 2009). 
The experiment was performed in a squared box (26 cm × 26 cm), 
in which the animal was placed in the central zone of the apparatus 
equipped with infrared beams (TruScan; Coulbourn Instruments, 
Allentown, PA, USA) and allowed to explore for 30 min at 300 lux. 
All sensor rings were connected via interface to a computer equipped 
with TruScan Software Version 99 (Coulbourn Instruments). Boxes 
and sensor rings were surrounded by an additional box made of 
opaque Plexiglas side walls (47 cm × 47 cm × 38 cm) without roof 
and floor. Horizontal locomotion (total, margin, or central distance 
moved) vertical movements (exploratory rearing) and time spent 
at rest were analyzed during the 30-min monitoring period with a 
sampling rate of 4 Hz. After each session, the apparatus was cleaned 
with a solution containing neutral soap.
Elevated plus maze test
The apparatus consisted of two opposite open arms, (30 cm × 5 cm) 
and two arms with walls (30 cm × 5 cm × 14 cm) that were attached 
to a central platform (5 cm × 5 cm) to form a cross. The maze was 
elevated 50 cm from the floor (Pellow et al., 1985). Illumination 
measured at the center of the maze was 300 lux. The animal was 
placed in the center of the maze facing one of the closed arms, and 
observed for 5 min, according to the following parameters: number 
of entries in the open or closed arms and time of permanence in 
each arm (i.e., the time spent by the animal in the open or closed 
arms). An entry was defined as all four paws having crossed the line 
between an arm and the central area. It is accepted that the anxio-
lytic effect of a drug treatment is illustrated by increased parameters 
in open arms (time and/or number of entries; Pamplona et al., 
2011: for pharmacological validation of our current set-up). The 
augmented percentage of entries in open arms over the total entries 
in both arms is a good indicator of reduced anxious-like phenotype 
as well. Entries in closed arms and total entries reflect the motor 
component of the exploratory activity. On removal of each mouse, 
the maze floor was carefully wiped with a wet towel. All trials were 
recorded on a HDD using a video-camera and then scored off-line 
by an experienced observer by means of a video/computer system 
ANY-MAZE (Stoelting).
Light/dark test
Set-up and test procedure were essentially the same as previously 
described (Jacob et al., 2009). The LD box was divided in two com-
partments: (1) one dark compartment (15 cm × 20 cm × 38 cm) with 
black walls and (2) one lit compartment (30 cm × 20 cm × 38 cm) 
with white plastic walls. Both compartments were connected by a 
4-cm long tunnel. Light intensity was 600 lux in the light compart-
ment and 15 lux in the dark compartment measured at floor level. 
Mice were placed into the corner of the dark compartment at the 
start of the experiment which lasted for 5 min. After each test, 
the LD box was thoroughly cleaned with soap and water. Entries 
and time spent in the light compartment were assessed by video 
analysis by a trained observer. These two variables were expressed 
as percentage of the total observation period and the total number 
of LD transitions, respectively.
Novel object investigation test
The novel object investigation (NOI) test was performed at 30 lux 
(which still allowed the assessment of exploration of the objects) 
for 10 min. Experimental subjects were habituated to the test arena 
(36 cm × 22 cm × 14 cm, with sawdust bedding material and trans-
parent walls) for 2 days for 10 min (one cage per mouse without 
cleaning or changing of bedding). On the third day, mice were 
transferred into the same test cages and two identical objects (cone 
Terzian et al. D1–CB1 knock-out mice and emotional behavior
Frontiers in Behavioral Neuroscience www.frontiersin.org August 2011 | Volume 5 | Article 49 | 2
to free exploration of the apparatus for 10 min (habituation). An 
empty perforated 50 ml falcon tube was placed in each side of the 
box. This 10 min exposure was designed to familiarize the subject 
mouse with the testing environment. After habituation session, the 
animal was kept in the center compartment and one of the tubes 
was replaced by a tube containing an ovariectomized female. For 
the next 10 min session, the mouse was allowed to explore all three 
compartments and the time spent in the SInv (active contact such 
as sniffing) was recorded.
Fear conditioning task
The set-up has been described and displayed in detail before 
(Kamprath and Wotjak, 2004; Plendl and Wotjak, 2010). Two dif-
ferent protocols were programmed and carried out. The first experi-
ment was performed in two contexts: (1) the neutral test context 
– a cylinder made of transparent Plexiglas, lined with wood shav-
ings – and (2) the shock context – a cubic-shaped box with a metal 
grid for shock application. For conditioning (d0), mice were placed 
in the conditioning context. Three minutes later, a tone (80 dB, 
9 kHz sine-wave, 10 ms rising, and falling time) was presented to 
the animals for 20 s that coterminated with a 2-s scrambled elec-
tric footshock of 0.7 mA. Mice were returned to their home cages 
60 s later. On day 1 (d1), mice were exposed to the neutral context 
and on day 2 (d2) to the grid context for 7 and 3 min, respectively. 
Briefly, mice were placed in the test context, which differed from 
the conditioning context in material, shape, surface texture, and 
odor of the cleaning solution. After an initial 3 min of habituation, 
a 180-s permanent tone [9 kHz, 80 dB, sine-wave] was delivered. 
To test the contextual freezing, animals were re-exposed to the 
shock chamber for 3 min without tone presentation and without 
further shock application, and immediately returned to their home 
cages afterward.
In the second experiment, mice were conditioned as described 
for the first experiment. On day 1 (d1) and on day 7 (d7), mice 
were exposed to the 180-s tone in the neutral test context. Animals’ 
behavior was video recorded by small CCD cameras (Conrad 
Electronics, Hirschau, Germany) and rated off-line by a trained 
observer (EVENTLOG, designed by Robert Henderson, 1986). 
Freezing behavior was defined as immobility except for respira-
tion movements.
EXPERIMENTAL DESIGN
Behavioral experiments were conducted in two screens to reduce 
the number of animals used for the study with separate cohorts 
of animals for every screen (Table 1). If not stated otherwise, the 
different screens were accomplished with 4–5 days in between 
two consecutive tests. Animals were submitted to a battery of 
behavioral tests, which was divided in three main categories, in 
the following order: (1) low- or mild-stress situation (a) explora-
tory-based approach avoidance conflict tests: open field, elevated 
plus maze, light/dark, novel object investigation, and novelty-
induced grooming (b) depressive-like behavior paradigms: 
sucrose consumption and forced swim test (2) social approach: 
social interaction and social investigation test (3) high-stress 
situation: fear conditioning (FC) tests. The order of tests within 
the battery was designed in such manner that mice would be 
evaluated on what were thought to be least invasive tests before 
made of aluminum: ∅ 6 cm + H 13 cm) were placed in a sym-
metrical position at the short walls of the cages. Between animals, 
objects were thoroughly cleaned with water containing detergent to 
eliminate olfactory cues. Objects were heavy enough that a mouse 
could not displace them. Every trial was video recorded and ana-
lyzed using ANY-MAZE (Stoelting). Investigation was defined as 
follows: directing the nose toward the object at a distance of not 
more than 2 cm and/or touching the object with the nose and paws 
(Jacob et al., 2009).
Sucrose consumption test
During this test, mice are given a free choice between two bottles 
for 10 h – one filled with 2.5% sucrose solution and the other with 
tap water – for two consecutive days (Strekalova and Steinbusch, 
2010). To prevent possible effects of side preference in drinking 
behavior, the bottles position was switched in the mid-point of 
testing. Animals were not food or water-deprived before the test. 
For habituation, 1 day prior to the first testing day, animals were 
allowed to drink a 2.5% sucrose solution for 2 h. The consumption 
in water, sucrose solution, and total intake of liquids were estimated 
simultaneously in the both groups by weighing the bottles before 
and after each trial. The preference for sucrose was calculated as a 
percentage of the consumed sucrose solution from the total amount 
of liquid drunk, by the formula: Sucrose Preference = V(Sucrose 
solution)/[V(Sucrose solution)+V(Water)]×100%.
Forced swim test
The forced swim test (FST) employed here was essentially similar to 
that described elsewhere (Porsolt et al., 1978). Mice were individually 
placed into transparent cylinders (height 23.5 cm; diameter 16.5 cm) 
containing 15 cm water at 25 ± 1°C for 6 min. The water was changed 
after each trial. After vigorous activity, swimming attempts cease and 
the animal adopts a characteristic immobile posture. A mouse is 
judged to be immobile when it floats in upright position and makes 
only small movements to keep its head above water. The duration 
of mobility was recorded during the last 4-min of the 6-min test-
ing period. All trials were recorded for subsequent off-line analysis.
Social interaction test
The procedure was adopted from (Smit-Rigter et al., 2010). 
Experiments were performed in a new cage (27 cm × 16 cm × 12 cm) 
with fresh bedding at 5 lux (i.e., red light) or 700 lux (light intensity 
measured at the level of test cages). The lid of the new cage was 
removed and the walls elongated by 12.5 cm of semi transparent 
plastic. Briefly, pairs of unfamiliar mice of the same genotype (n = 7 
pairs of D1–CB1−/− and WT) were placed into the cage for 5 min. 
The time spent in social interactions (SI; active contact such as 
sniffing, licking, close following, and grooming) was recorded for 
each pair of mice. Each session was video recorded and analyzed 
off-line using ANY-MAZE (Stoelting).
Social investigation test
Social investigation (SInv) task was conducted as previously 
described with slight modifications (Crawley et al., 2007). It took 
place in a rectangular box made of white PVC walls and with a dark 
gray PVC floor. The box was divided into three equal compartments 
(30 cm × 30 cm × 30 cm) that were interconnected by small open-
ing (6 cm × 5 cm) with guillotine doors. Each animal was allowed 
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difference was found, considering the total arm entries (t = 0.7276; 
df = 14; p = 0.4798) and the total LD transitions (t = 0.8154; df = 15; 
p = 0.4255) as index.
Novel object investigation
Unpaired t-test showed that D1–CB1−/− and WT mice, during the 
10-min test, spent the same amount of time investigating the pair 
of novel objects (t = 0.5887; p = 0.5643), as well as they approached 
them with the same frequency (t = 0.5705; p = 0.5762; Figure 3).
Novelty-induced grooming activity test
As described in Figures 4A–C, D1–CB1−/− mice performed more 
grooming episodes (t = 2.240; p < 0.05; df = 15) as well as they spent 
more time grooming as compared to WT animals (t = 2.568; p < 0.05; 
df = 15). However, the latency to start grooming was not significantly 
different between the two groups (t = 1.170; p = 0.2603; df = 15).
being tested on more invasive assays. This design was developed 
with the assumptions that testing from least to most invasive 
would allow for recovery time between tests and would reduce 
the likelihood that behavioral responses would be influenced by 
previous testing experience.
STATISTICAL ANALYSIS
Data were analyzed using unpaired t-test or two-factor ANOVA by 
means of Sigma Stat 3.5 (Systat Software Inc., San Jose, CA, USA). 
Newman–Keuls test was used as post hoc test, if appropriate. Data 
are presented as mean ± SEM. Statistical significance was accepted 
if p < 0.05.
RESULTS
EXPLORATORY AVOIDANCE CONFLICT TESTS
Open field test
In the OF test, there was no difference in the exploratory activity 
between D1–CB1−/− and WT mice (Figures 1A–F). Both groups 
showed the same horizontal activity (total distance: t = 1.246; 
p = 0.2348; central distance: t = 1.501; p = 0.1574, margin distance: 
t = 0.2401; p = 0.8140), total duration of movement (t = 1.217; 
p = 0.2452), rearing (t = 1.715; p = 0.1101), and jumping episodes 
(t = 1.344; p = 0.2021). This response indicates that in our test 
conditions, genetic deletion of CB1 in neurons expressing D1Rs 
did not alter basal locomotor activity of mice.
Elevated plus maze and light/dark test
As described in Figures 2A–D, statistical analysis did not reveal 
any significant difference between D1–CB1−/− and WT mice both 
in the time spent (t = 0.5568; df = 14; p = 0.5871) or in the number 
of entries (t = 0.6133; df = 14; p = 0.5502) into open arms of the 
EPM test. Also, there was no difference in the time spent (t = 0.2827; 
df = 15; p = 0.7813) or in number of entries (t = 0.9739; df = 15; 
p = 0.3430) into light compartment of the LD test. No locomotion 
FiguRe 1 | Assessment of general locomotor activity of D1–CB1−/− mice 
in the open field (OF) test. Conditional D1–CB1−/− mutant mice (KO) and their 
respective wild-type (WT) littermates were tested in an open field for 30 min. 
Values are mean ± SEM in terms of locomotor activity (A–D) rearing (e) and 
jumping episodes (F).
Table 1 | Comprehensive behavioral test battery of D1–CB1 knock-
out mice.
Test Age (weeks) Days n Results
FiRsT gROup
OF 8–10 1 6–9 Figures 1A–F
EPM 8–10 5 7–8 Figures 2A, B
LD 9–11 9 8–9 Figures 2C,D
SI 9–11 13 6–8 Figures 6A,B
FST 10–12 20 7–9 Figure 5B
FC 11–13 27 8–9 Figures 7A,B
seCOND gROup
NGT 8–10 2 8–9 Figures 4A–C
NOI 8–10 1 8–10 Figure 3
SC 8–10 5 10 Figure 5A
SInv 9–11 9 9–10 Figures 6C,D
FC 11–13 27 9–10 Figures 7C,D
n, Animal number; OF, open field; EPM, elevated plus maze; LD, light/dark; SI, 
social interaction; FST, forced swim test; FC, fear conditioning; NOI, novel object 
investigation; SC, sucrose consumption; SInv, social investigation; NGT, novelty-
induced grooming test.
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Social investigation
Figures 6C,D describe the time and the number of active approaches 
toward the empty falcon tube vs. the tube containing the ovariec-
tomized female. Two-way ANOVA analyses (factor 1: object, factor 
2: genotype) revealed a main effect of object (number of interac-
tion: F
1,34
 = 35.588; p < 0.001; time of interaction: F
1,34
 = 25.023; 
p < 0.001), but no main effect of genotype (number of interac-
tion: F
1,34
 = 0.0182; p = 0.893; time of interaction: F
1,34
 = 1.402; 
p = 0.245) or a object × genotype interaction (number of inter-
action: F
1,34
 = 0.839; p = 0.366; time of interaction: F
1,34
 = 1.780; 
p = 0.191), indicating that mice of both genotype display a prefer-
ence for the ovariectomized female. Additional t-test was performed 
separately for each genotype. D1–CB1−/− and WT mice showed 
higher interest for the tube containing the female, as described by 
the significant increase of time of investigation (WT: t = 3.782; 
p < 0.01; D1–CB1−/−: t = 3.489; p < 0.01) and by number of inter-
actions (WT: t = 3.904; p < 0.01; D1–CB1−/−: t = 4.459; p < 0.001).
Fear conditioning
As shown in Figure 7A, unpaired t-test revealed that D1–CB1−/− 
showed a significant increase on freezing response to the tone at 
day 1 (t = 2.497; p < 0.05) and to the context at day 2 (t = 3.210; 
p < 0.01) as index of increased auditory-cued and contextual fear 
responses, respectively. When analyzed in 20-s intervals, all mice 
DEPRESSIVE-LIKE BEHAVIOR
Forced swim test and sucrose consumption
As described in Figure 5, D1–CB1−/− mice showed a significant 
lower SC as compared to WT mice on the first (t = 2.868; p < 0.05), 
but not on the second testing day (t = 0.3575; p = 0.7249). 
However, WT and D1–CB1−/− mice showed a high percentage 
of SC as compared to the total amount of liquid consumed. 
In the FST, although D1–CB1−/− mice showed a decrease in the 
mobility as compared to WT animals, the difference between the 
two genotypes did not reach statistical significance (t = 1.904; 
p = 0.0777).
SOCIAL ACTIVITY TESTS
Social interaction
As described in Figures 6A,B, two-way ANOVA (factor 1: light 
intensity, factor 2: genotype) revealed a main effect of light intensity 
(F
1,13
 = 14.656; p < 0.01) genotype (F
1,13
 = 6.366; p < 0.05) and a 
light intensity × genotype interaction (F
1,13
 = 10.904; p < 0.01) for 
time of interaction. There were also a main effect of light intensity 
(F
1,13
 = 18.472; p < 0.01) genotype (F
1,13
 = 5.285; p < 0.05) and a 
light intensity × genotype interaction (F
1,13
 = 12.947; p < 0.01) for 
the frequency of interaction. Post hoc analysis showed that in the 
less aversive environment (0 lux), D1–CB1−/− expressed a lower SI 
during the 5-min test than WT mice as described by the decreased 
number and time of interactions (p < 0.05). WT approached the 
low level of performance seen in D1–CB1−/− under aversive condi-
tions (700 lux).
FiguRe 2 | Anxiety-like behaviors of D1–CB1−/− mice. Conditional 
D1–CB1−/− mutant mice (KO) and their respective wild-type (WT) littermates 
were tested for 5 min in the elevated plus maze (upper panel) or in the light/
dark box (lower panel). Data are presented as mean ± SEM regarding open 
arm entries and open arm time (A) the total arm entries (B), light 
compartment entries and light compartment time (C), and total compartment 
transitions (D).
FiguRe 3 | Novel object investigation test. Conditional D1–CB1−/− mutant 
mice (KO) and their respective wild-type (WT) littermates were exposed to 
two novel objects for 10 min. Data are presented as mean ± SEM regarding 
total investigation duration (A) and number of approaches (B).
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tion over the course of tone presentation (Figure 6D). Freezing 
before tone presentation on day 1 was low and indistinguishable 
between the two groups.
DISCUSSION
In the present study we provide first evidence that the genetic dele-
tion of cannabinoids CB1Rs in dopamine D1Rs-expressing neurons 
is able to affect the emotional behavior in mice in highly selective 
manner. Several studies reported increased anxiety-related behav-
iors after impaired CB1R signaling only when aversive stimulus 
cannot be avoided (Haller et al., 2004, 2009; Thiemann et al., 2007; 
Kamprath et al., 2009). However, little is known about how ECS 
modulation of the DAergic system could be involved in this effect.
It is accepted that ECs modulate several neurotransmitter systems 
(glutamatergic, GABAergic, and DAergic) at multiple levels (Piomelli, 
2003). In the brain, where exogenously administered (∆9-tetrahydro-
cannabinol [THC]) and endogenously released cannabinoids exert 
most of their behavioral effects, the CB1Rs are expressed at different 
levels at different neuronal subpopulations. More specifically, they 
are present at very high levels in GABAergic interneurons, where 
they mediate cannabinoid-dependent inhibition of GABA release, 
and to a minor extent, in glutamatergic terminals (Marsicano and 
Lutz, 1999). In the glutamatergic neuronal subpopulation, they play 
a pivotal role in both neuroprotection and fear extinction in highly 
aversive situations, through the modulation of glutamate release, 
further confirming that the fear-alleviating effects of CB1 became 
evident primarily under highly aversive conditions (Monory et al., 
2006; Kamprath et al., 2009; Moreira and Wotjak, 2010).
Several lines of evidence suggest that DA is released in several 
brain regions such as the amygdala and prefrontal cortex under 
stress conditions. By acting on D1- or D2-like receptors, DA is 
involved in physiological processes subserving affective behaviors 
and emotional learning (LeDoux, 2000). Although, coexpression of 
the cannabinoid CB1Rs and D1Rs supports an ECS–DAergic system 
cross-talk, as in forebrain basal ganglia and piriform cortex, the 
exact role of D1Rs is not fully understood. Thus, the development 
of conditional CB1 mutant mice, in which the CB1Rs are specifically 
deleted in neurons expressing D1Rs (Monory et al., 2007) has been 
an useful tool to understand their role in the emotional behavior.
It should be recalled that growing evidence indicates that meas-
ures of anxiety from different tests could reflect different states of 
anxiety. This prompted us to use different behavioral paradigms 
such as exploration-based tests and social paradigms, that primar-
ily focus on reciprocal SI and on the preference for social novelty, 
respectively, as well as tasks involving a strong mnemonic compo-
nent, such as fear based tests, to assess different aspects that could 
mimic symptoms of human anxiety disorders as agoraphobia, social 
phobia or post traumatic stress disorder (Lister, 1990; File, 1992; 
Cryan and Holmes, 2005).
The first novel result of the present study was that D1–CB1−/− mice 
did not show any anxiety-like phenotype when tested in exploratory 
behavioral paradigms such as EPM, LD, or NOI. These procedures 
mostly reflect the conflict between exploration and avoidance of a 
novel environment; thus, the inhibition of exploratory behavior given 
by the reduced open arms or light compartment entries and novel 
object exploration is commonly associated with high emotionality or 
anxiety. D1–CB1−/− mice also failed to show alteration in spontaneous 
showed the same initial freezing response on day 1. However, 
whereas WT mice showed a rapidly waning freezing response 
during the tone presentation, D1–CB1−/− mice showed a deficit 
in acute fear adaptation (Figure 6B). The second experiment, 
largely confirmed their phenotype (Figures 6C,D): D1–CB1−/− 
mice showed a significant increase on freezing response to the 
tone on day 1 (t = 4.234; p < 0.001) and on day 7 (t = 2.923; 
p < 0.01), which again results from impaired acute fear adapta-
FiguRe 4 | grooming behavior in D1–CB1−/− mice. Conditional D1–CB1−/− 
mutant mice (KO) and their respective wild-type (WT) littermates were tested 
for the grooming activity measure. Data are presented as mean ± SEM 
regarding latency to start grooming (A), number of grooming episodes (B) and 
total grooming duration (C). *p < 0.05 as compared to WT mice (unpaired t-test).
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FiguRe 5 | Depressive-like behaviors of D1–CB1−/− mice. Conditional 
D1–CB1−/− mutant mice (KO) and their respective wild-type (WT) littermates 
were tested in the sucrose consumption test (A) or in the forced swim test 
(FST) paradigm (B). Data are presented as mean ± SEM regarding percentage of 
sucrose consumption or mobility time expressed in seconds. *p < 0.05 as 
compared to WT mice (unpaired t-test).
FiguRe 6 | social behaviors in D1–CB1−/− mice. Conditional D1–CB1−/− mutant 
mice (KO) and their respective wild-type (WT) littermates were tested in the social 
interaction (A,B) or in the social investigation (C,D) test. Data are presented as 
mean ± SEM regarding time in interaction and number of interactions. E1: empty 
tube 1; E2: empty tube 2; F1: tube with female. *p < 0.05, **p < 0.01, ***p < 0.01 
(Newman–Keuls post hoc test or unpaired t-test).
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cedure widely used for evaluating behavioral despair in rodents 
(Cryan and Holmes, 2005). Thus, the modulation of depressive-
like behaviors in D1–CB1−/− mice evaluated in different tasks may 
be mediated by distinct neuronal circuits. On the other hand, the 
lower SC was only evident upon the first confrontation with the 
novel taste (day 1) and disappeared on the next day, suggesting a 
significant contribution of neophobia. In fact, a weak- to moderate 
anxiety-like phenotype of D1–CB1−/− mice became evident when 
the animals were tested under low (0 lux) aversive conditions in 
an unavoidable situation (i.e. SI test), where the WT control mice 
demonstrated social approach (intense interaction). These findings 
suggest that the deletion of CB1Rs specifically in D1Rs-expressing 
neurons elicited SI impairments, similarly to those observed in mice 
lacking CB1 in cortical glutamatergic neurons (Jacob et al., 2009). 
By contrast, it did not affect the preference for social novelty with 
female stimulus.
Interestingly, D1–CB1−/− mice showed sustained auditory-cued 
and contextual fear responses, thus resembling the phenotype of 
impaired fear adaptation observed in mice with complete deletion 
of CB1Rs (Marsicano et al., 2002; Kamprath et al., 2006) or selec-
tive deletion from principal neurons of the forebrain (Kamprath 
et al., 2009). Since Monory et al. (2007) showed that the deletion of 
exploration and locomotor behavior. These findings are in line with 
previous data showing no anxiety-like phenotype in mice with total 
CB1Rs deletion and with specific CB1Rs deletion on glutamatergic 
neurons (Marsicano et al., 2002; Jacob et al., 2009). However, the D1–
CB1−/− mice showed increased grooming activity. Grooming is con-
sidered a “maintenance” behavior, a common species-characteristic 
movement pattern with readily definable components (Bolles, 1960) 
that serves a range of adaptive functions, including stress reduction 
and social interplay (Kalueff and Tuohimaa, 2005). In rodents, spon-
taneous grooming behavior may occupy as much as 25–40% of the 
wakeful time, but it is specifically elicited in situations (i.e., NGT) in 
which an animal is in stress-induced conflict or frustration, as well 
as being reduced following anxiolytic treatment (Dunn et al., 1981; 
Gispen and Isaacson, 1981; van Erp et al., 1994; Micale et al., 2008). 
Thus, our results suggest that if the exposure to novelty cannot be 
controlled by the animals, the novel environment is able to influence 
the emotionality of D1–CB1−/− mice.
The D1–CB1−/− mice exhibited a decreased preference for sweet 
solutions on the first but not on the second day of the SC test under 
basal conditions, indicating a mild anhedonia-like state. Although 
anhedonia is commonly associated with depression-like behavior 
phenotype, mutant mice performed normally in the FST, a pro-
FiguRe 7 | Fear memory in D1–CB1−/− mice. Auditory-cued (Tone) and 
contextual (Context) fear memory assessed by freezing responses 
(mean ± SEM) of conditional D1–CB1−/− mutant mice (KO) and their 
respective wild-type (WT) littermates in two independent sets of 
experiments (A/B, C/D). If not stated otherwise, freezing was averaged 
over the entire 180 s observation periods (A,C) or analyzed in 20 s intervals 
(B,D). *p < 0.05, **p < 0.01, ***p < 0.001 as compared to WT mice 
(unpaired t-test).
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Opposing Roles for Cannabinoid Receptor Type-1 (CB1) and
Transient Receptor Potential Vanilloid Type-1 Channel
(TRPV1) on the Modulation of Panic-Like Responses in Rats
Plı́nio C Casarotto1, Ana Luisa B Terzian2,3, Daniele C Aguiar4, Hélio Zangrossi1, Francisco S Guimarães1,
Carsten T Wotjak2 and Fabrı́cio A Moreira*,4
1Department of Pharmacology, School of Medicine of Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil; 2Max Planck Institut
für Psychiatrie, Research Group Neuronal Plasticity, Munich, Germany; 3Graduate School of Neuroscience, Ludwig Maximilians Universität,
Munich, Germany; 4Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte,
MG, Brazil
The midbrain dorsal periaqueductal gray (dPAG) has an important role in orchestrating anxiety- and panic-related responses. Given the
cellular and behavioral evidence suggesting opposite functions for cannabinoid type 1 receptor (CB1) and transient receptor potential
vanilloid type-1 channel (TRPV1), we hypothesized that they could differentially influence panic-like reactions induced by electrical
stimulation of the dPAG. Drugs were injected locally and the expression of CB1 and TRPV1 in this structure was assessed by
immunofluorescence and confocal microscopy. The CB1-selective agonist, ACEA (0.01, 0.05 and 0.5 pmol) increased the threshold for
the induction of panic-like responses solely at the intermediary dose, an effect prevented by the CB1-selective antagonist, AM251
(75 pmol). Panicolytic-like effects of ACEA at the higher dose were unmasked by pre-treatment with the TRPV1 antagonist capsazepine
(0.1 nmol). Similarly to ACEA, capsazepine (1 and 10 nmol) raised the threshold for triggering panic-like reactions, an effect mimicked by
another TRPV1 antagonist, SB366791 (1 nmol). Remarkably, the effects of both capsazepine and SB366791 were prevented by AM251
(75 pmol). These pharmacological data suggest that a common endogenous agonist may have opposite functions at a given synapse.
Supporting this view, we observed that several neurons in the dPAG co-expressed CB1 and TRPV1. Thus, the present work provides
evidence that an endogenous substance, possibly anandamide, may exert both panicolytic and panicogenic effects via its actions at CB1
receptors and TRPV1 channels, respectively. This tripartite set-point system might be exploited for the pharmacotherapy of panic attacks
and anxiety-related disorders.
Neuropsychopharmacology advance online publication, 21 September 2011; doi:10.1038/npp.2011.207
Keywords: panic; anxiety; periaqueductal gray; cannabinoid; vanilloid; anandamide





















































INTRODUCTION
Panic disorder is a subtype of anxiety spectrum disorders
characterized by recurrent episodes of panic attacks, which
comprise intense feelings of fear and distress, accompanied
by tachycardia, hyperventilation and increased blood
pressure (Katon, 2006; Roy-Byrne et al, 2006). Although
its precise neural basis has remained uncertain, evidence
indicates that it might result from a malfunction in brain
systems related to defense reactions (McNaughton and
Gray, 2000). Accordingly, panic attacks exhibit isomorph-
ism with flight responses regarding their autonomic,
behavioral and psychological aspects (Bandler et al, 2000;
McNaughton and Gray, 2000).
Among the brain regions that may participate in the
elaboration of both panic and innate defense reactions is the
midbrain dorsal periaqueductal gray (dPAG), comprising
dorsomedial and dorsolateral columns (Del-Ben and Graeff,
2009; Schenberg et al, 2001). In humans, electrical stimula-
tion of this structure induces an intensive feeling of
aversion, fear and imminent death along with autonomic
changes (Nashold et al, 1969). Moreover, neuroimaging
studies detected increased activity in this region in patients
suffering from panic (Del-Ben and Graeff, 2009) and in
healthy volunteers exposed to a proximal threatening
stimulus (Mobbs et al, 2007). In laboratory rats, local
electrical or chemical dPAG stimulation induces autonomic
changes along with escape responses (Beckett and Marsden,
1995; Krieger and Graeff, 1985; Schenberg et al, 2001). In
addition, systemic or intradPAG injections of panicolytic
drugs increase the threshold required to induce escape
responses (Hogg et al, 2006; Jenck et al, 1995; SchenbergReceived 5 July 2011; revised 5 August 2011; accepted 10 August 2011
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et al, 2001; Schütz et al, 1985). Due to its robust face,
construct and predictive validity, the escape reaction
resulting from electrical stimulation of the rat dPAG has
been proposed as a model of panic attacks (Beckett and
Marsden, 1995; Del-Ben and Graeff, 2009; Jenck et al, 1995;
Schenberg et al, 2001).
Diverse types of receptors are expressed in the PAG,
including the G-protein coupled cannabinoid type 1
receptor (CB1) and the transient receptor potential type-1
(TRPV1) channel (Cavanaugh et al, 2011; Cristino et al,
2006; Herkenham et al, 1990, 1991; Mezey et al, 2000; Tóth
et al, 2005; Tsou et al, 1998). These receptors may bind
common endogenous ligands, which are thus termed
endocannabinoids/endovanilloids, such as arachidonoyl
ethanolamide (anandamide) (for reviews, see Di Marzo,
2008; Di Marzo et al, 2001 and Starowicz et al, 2007a).
Despite this similarity, electrophysiological and neurochem-
ical pieces of evidence indicate that they may have opposite
functions. In the PAG, local CB1 activation inhibits calcium
channels and excitatory neuronal activity (Vaughan et al,
2000), whereas TRPV1 promotes calcium influx and
glutamate release (Starowicz et al, 2007b; Xing and Li,
2007). At the behavioral level, CB1 knockout mice show
deficits in extinction and habituation of conditioned fear
(Kamprath et al, 2006; Marsicano et al, 2002) and
exacerbated anxiety-like behavior (Haller et al, 2002, 2004;
Jacob et al, 2009; Martin et al, 2002). On the contrary,
TRPV1 knockout mice show reduced fear- and anxiety-like
responses (Marsch et al, 2007). Finally, either local
activation of CB1 or blockade of TRPV1 at level of the
dorsolateral columns of the PAG-induced anxiolytic-like
effects (Lisboa et al, 2008; Moreira et al, 2007, 2009; Terzian
et al, 2009). The same is observed with either systemic or
intraprefrontal cortex injections (Aguiar et al, 2009; Micale
et al, 2009; Rubino et al, 2008).
So far, most studies have investigated the roles of CB1 and
TRPV1 separately. However, there is evidence that they may
act in concert to modulate behavioral responses (Maione
et al 2006; Micale et al, 2009; Rubino et al, 2008). They are
co-expressed in several regions related to aversion, such as
prefrontal cortex, amygdaloid complex and hippocampus,
where they may modulate anxiety-related responses (Cris-
tino et al, 2006; Micale et al, 2009), as well as in the
ventrolateral PAG (vlPAG), where they control nociceptive
reactions (Cristino et al, 2006; Maione et al, 2006).
Considering this background, the present study tested the
hypothesis that CB1 and TRPV1 exert opposite effects on
panic-like responses at level of the dPAG and looked for
interdependences of the two signaling systems.
MATERIALS AND METHODS
Animals
Male Wistar rats were obtained from the animal facilities at
the University of São Paulo, Ribeirão Preto. The animals,
weighing 300–330 g, were housed in groups of 4–6 per cage
under a 12-h dark/12-h light cycle (lights on at 0700 h) at
22±1 1C, and given free access to food and water. All
experiments were carried in accordance with the Brazilian
Society of Neuroscience and Behavior for the care and
use of laboratory animals and were approved by the
Experimental Animal Ethical Committee of University of
São Paulo (protocol number: 114/2007). All efforts were
made to minimize animal suffering.
Surgery
Rats were anesthetized with 2,2,2 tribromoethanol (250 mg/
kg i.p.) combined with local anesthesia (2% lidocaine with a
vasoconstrictor; Harvey, Brazil), and fixed in a stereotaxic
frame (David Kopf) for implantation of a chemitrode in the
dPAG (incisor bar 3.3 mm below the interaural line, 1.7 mm
lateral to lambda at an angle of 221 with the sagittal plane,
5.0 mm below the surface of the skull; according to Paxinos
and Watson, 1997). The chemitrode consisted of a stainless
steel guide cannula (outer diameter: 0.6 mm, length: 13 mm)
glued to a brain electrode made of stainless steel wire
(diameter: 250 mm) that was insulated by enamel except for
the cross-section of the tip. The electrode reached 1 mm
below the end of the cannula. It was connected to a male pin
parallel to the outer end of the cannula that could be
plugged into an amphenol socket at the end of a flexible
electrical cable. The chemitrode was fixed to the skull by
means of acrylic resin and two stainless steel screws. A stylet
was inserted into the guide cannula in order to prevent
obstruction. At the end of the surgery, animals were treated
with an antibiotic (Pentabiótico, Fort Dodge, Brazil; 1.0 ml/
kg, i.m.) and fluxinin meglumine (Schering-Plough, Brazil;
2.5 mg/kg, s.c.), which has analgesic, antipyretic and anti-
inflammatory properties. The animals were left undisturbed
for 5–7 days after the surgery.
Drugs and Treatment
The CB1 agonist, arachidonyl-2-chloro-ethylamide (ACEA;
Tocris) was dissolved in Tocrisolve (vehicle). The CB1
antagonist, N-(piperidin-1yl)-5-(4-iodophenyl)-1-(2,4-dichloro-
phenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251; Tocris)
and the TRPV1 antagonists, capsazepine (Tocris) and 40-
Chloro-3-methoxycinnamanilide (SB366791; Tocris), were dis-
solved in DMSO.
For local drug treatment, an injection needle (outer
diameter: 0.3 mm) was inserted through the guide into the
dPAG to a final depth of 6.0 mm below the surface of the
skull. A volume of 0.2 ml was injected for 60 s using a 10-ml
microsyringe (Hamilton) attached to a microinfusion pump
(KD Scientific). The needle was left in place for another 60 s
before removal.
Escape Threshold Determination
Escape behavior induced by dPAG electrical stimulation
was performed in accordance with previous work (Casar-
otto et al, 2010). The animals were evaluated in a circular
arena (40 cm in diameter) with 40 cm high walls made of
transparent Plexiglas. Brain stimuli were generated by a
sine-wave stimulator. The stimulation current (peak-to-
peak) was monitored on the screen of an oscilloscope
(Minipa, Brazil). The brain electrode was connected to the
stimulator by means of an electromechanical swivel and a
flexible cable, allowing ample movement of the animal in-
side the experimental cage. The escape threshold was deter-
mined in response to an electrical stimulus (AC, 60 Hz, 10 s)
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presented through the chemitrode. The interstimulus
interval was 10 s. The current intensity started at 20mA and
was increased by steps of 4mA until the rat started running
around the circular arena (escape behavior). In most cases,
this vigorous reaction was accompanied by vertical jumps.
When these behaviors were observed, electrical stimulation
to the dPAG was interrupted by the experimenter that was
blind to the treatment groups. The basal escape threshold
was defined as the lowest current intensity that evoked
escape in three successive trials of electrical stimulation.
Animals with basal thresholds 4150mA were excluded from
the study. Following basal escape threshold determination,
independent groups of animals were injected with the drugs
or vehicle into the dPAG, and the escape threshold was re-
analyzed 10 min later. The variation in escape threshold (D)
was then calculated for each animal and refers to the
difference between escape threshold values obtained post-
and pre-treatment.
Experiments
Independent batches of animals were used in each
experiment. In experiment 1, the rats were treated with
ACEA (0.01, 0.05 and 0.5 pmol) or vehicle (n¼ 6–7). In
experiment 2, new groups of animals received AM251
(75 pmol) or its vehicle followed by ACEA (0.05 pmol) or its
respective vehicle 5 min later (n¼ 5–6). In experiment 3,
they were injected with capsazepine (0.1, 1 and 10 nmol) or
vehicle (n¼ 6–9). In experiment 4, capsazepine (0.1 nmol)
or vehicle injections were followed by ACEA (0.5 pmol)
5 min later (n¼ 5 per group). In experiment 5, the rats were
treated with AM251 (75 pmol) or vehicle followed by
capsazepine (10 nmol) or vehicle 5 min later (n¼ 5–7).
Finally, in experiment 6, they were treated with AM251
(75 pmol) or vehicle followed by SB366791 (10 nmol) or
vehicle 5 min later (n¼ 5–7). The doses of ACEA, AM 251
and capsazepine were selected based on previous works
performing injections into the dPAG (Moreira et al, 2007;
Terzian et al, 2009). The dose of SB366791 was selected
based on the affinity of this substance for TRPV1 as
compared with other antagonists (Gawa et al, 2005;
Gunthorpe et al, 2004).
Histology
After the experiments, animals were deeply anesthetized
with chloral hydrate. The brain was perfused through the
heart with saline solution followed by 10% formalin
solution, before being removed and fixed in 10% formalin.
Frozen sections of 55 mm were cut using a microtome to
localize the positions of the electrode tips according to the
atlas by Paxinos and Watson (1997). Only data from rats
having chemitrode tips inside the dPAG were included in
the statistical analysis.
Immunofluorescence
Male Wistar rats were anaesthetized with urethane and
transcardially perfused with saline followed by 4% paraf-
ormaldehyde (PFA) in 0.1 M phosphate buffer (PBS, pH
7.4). The brain was removed and post-fixed over 2 h in PFA
4% and stored for at least 30 h in 30% sucrose for
cryoprotection. Coronal sections (25 mm) were obtained in
a cryostat and were washed in PBS 0.01 M. After this, the
sections were incubated in glycine 0.1 M, washed again and
incubated for 1 h in 5% bovine serum (BSA, sigma) in PBS
0.01 M, pH 7.4 containing 0.3% Triton X-100. Thereafter,
the sections were incubated for 2 days at 4 1C in a mixture of
anti-CB1 receptor N-terminus (1 : 250; Abcam raised in
rabbit) to anti-TRPV1 receptor N-terminus (1 : 100; Santa
Cruz raised in goat) diluted in PBS 0.01 M containing BSA
5% and 0.3% Triton X-100. After incubation in the primary
antiserum, the tissue sections were washed in PBS and
sequentially incubated in a mixture of Alexa 594 donkey
anti-rabbit IgGs (1 : 1000; Molecular Probes, Eugene, OR)
and Alexa 488 donkey anti-goat IgGs (1 : 1000; Molecular
Probes) for 1 h. Slides were rinsed in PBS and coverslipped
with Fluormount-G (Electron Microscopy Sciences, Hat-
field, PA). Images were first obtained using an Olympus
BX50 microscope through computerized image system
(Image Pro-Plus 4.0, Media Cybernetics). For a more
appropriate analysis of double-stained cells, the slides were
re-examined using a modified Olympus BX61WI confocal
microscope in an upright configuration, using an Argonium
laser at 488 nm. Immunostained slides (Alexa Fluor 488-
coupled anti-CB1 receptors; Alexa Fluor 546-coupled anti-
TRPV1 receptors) were exposed for 2.71 s and green and
red channels were merged digitally by Fluoview software.
Images were further exported in TIFF format. The
specificity of the primary antibodies has been demonstrated
before by means of CB1 and TRPV1 knockout mice (Maione
et al, 2006). Nevertheless, we additionally performed
negative controls for non-specific labeling. The protocol
was the same as described above, except for the fact that the
primary antibodies for CB1 and TRPV1 were switched, so
that each protocol would include a primary antibody for
one receptor and a secondary for the other.
Statistical Analysis
The effects of intradPAG drug injections were analyzed by
Student’s t-test or by one-way analysis of variance
(ANOVA) followed by Newman-Keuls post hoc test, when
appropriate. Data were expressed as mean±SEM. Statistical
significance was accepted if po0.05.
RESULTS
The sites of electrical stimulation and drug injection can be
seen in Figure 1. Electrical stimulation of the dPAG (black
dots), but not of surrounding regions (gray dots), caused an
explosive panic response, which was characterized by
running and jumping. Activation of CB1 receptors by local
administration of ACEA modified the effects of electrical
stimulation in a bell-shaped manner. It increased the
threshold for inducing escape behavior at 0.05 pmol, though
not at 0.01 or 0.5 pmol (F(3,23)¼ 4.06; po0.05; Figure 2).
The panicolytic-like effect of 0.05 nmol ACEA was mediated
by CB1 receptors, since it could be blocked by pre-treatment
with the selective antagonist AM251 (75 pmol) (F(3,17)¼ 13.86;
po0.01; Figure 3). Local blockade of TRPV1 channels by
capsazepine also raised the escape threshold at 1 and 10 nmol
(F(3,25)¼ 16.58; po0.05; Figure 4).
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These results suggest that TRPV1 has diametrically
opposite functions as compared with CB1. Considering that
certain cannabinoids may also bind TRPV1 at higher
concentrations (Huang et al, 2002; Price et al, 2004; Silveira
et al, 2010; Smart et al, 2000; Zygmunt et al, 1999),
simultaneous CB1 and TRPV1 activation could explain the
bell-shaped effects observed with ACEA in the first
experiment (Figure 2). High-dose ACEA could activate both
CB1 and TRPV1, occluding the CB1-mediated effects.
Indeed, an ineffective dose of capsazepine (0.1 nmol)
unmasked the panicolytic-like effect of ACEA (0.5 pmol)
(t(8)¼ 3.48; po0.01; Figure 5).
Finally, we tested the hypothesis that the panicolytic-like
effect of TRPV1 blockade would occur because it would
shift the action of a common endogenous agonist toward
CB1 activation. Supporting this hypothesis, the panicolytic-
like effect of capsazepine at higher doses (10 nmol) could be
Figure 1 Schematic representation of coronal sections from interaural
line of the rat brain (Paxions and Watson, 1997) showing the injection/
electrical stimulation sites inside (dark circles) of the dPAG. Sites where
electrical stimulation failed to induce escape responses are also presented
(gray circles). Due to overlaps, the number of points represented is fewer
than the number of rats actually employed in the experiments.
Figure 2 Local injection of the selective CB1-receptor agonist, ACEA,
into the dPAG increases the threshold of electric current necessary for
inducing panic-like response (n¼ 7, 6, 7, 7). Following basal escape
threshold determination, independent groups of animals were injected with
vehicle or ACEA (0.01–0.5 pmol), and the escape threshold was re-
analyzed 10 min later. The variation in escape threshold (D) was then
calculated for each animal and refers to the difference between escape
threshold values obtained post- and pre-treatment. *po0.05 Compared
with all other groups (one-way ANOVA followed by Newman-Keuls post
hoc test).
Figure 3 Local pre-treatment (5 min) with the CB1 antagonist, AM251
(75 pmol), prevents ACEA (0.05 pmol)-induced panicolytic-like effect
(n¼ 5, 6, 5, 5). *po0.05 Compared with all other groups (one-way
ANOVA followed by Newman-Keuls post hoc test). For further details, see
legend to Figure 2.
Figure 4 Local injection of the TRPV1 antagonist, capsazepine (CPZ;
0.1–10 nmol), into the dPAG increases the threshold of electric current
required for inducing panic-like response (n¼ 9, 7, 6, 7, 7). *po0.05
Compared with vehicle-treated rats (one-way ANOVA followed by
Newman-Keuls post hoc test). For further details, see legend to Figure 2.
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prevented by pre-treatment with AM251 (75 pmol), demon-
strating its dependency on CB1 signaling (F(3,20)¼ 5.74;
po0.01; Figure 6). Remarkably, this data could be
reproduced with a more selective TRPV1 antagonist,
SB366791 (10 nmol), which increased the threshold for
panic-like responses to the same extent as capsazepine,
again in a CB1-dependent manner (75 nmol), as presented in
Figure 7 (F(3,20)¼ 16.3; po0.01; Figure 7).
At the cellular level, both CB1 and TRPV1 are expressed in
neurons within the dPAG (Figure 8). Immunofluorescent
labeling revealed neurons that were exclusively CB1 or
TRPV1 positive. However, many neurons co-expressed both
receptors in their cell bodies. This could be certified
through confocal microscopy examination, which allowed
us to distinguish double-stained neurons from pairs of
mono-stained neurons located in adjacent plans. There was
a medium degree of colocalization throughout the dorso-
lateral and dorsomedial aspects of the PAG. This pattern of
co-expression supports the notion that they could be
simultaneously activated at a given synapse. Importantly,
no staining was observed in protocols in which the
antibodies were switched, so that the primary for one
receptor was combined with the secondary for the other
(Figure 9). This re-assures the specificity of the antibodies
used in the present protocols.
DISCUSSION
The present work provides evidence for opposite functions
of CB1 and TRPV1 in an animal model of panic attacks, the
electrical stimulation of the dPAG. In this model, local
application of antipanic drugs increases the current thresh-
old necessary for the induction of explosive escape
behaviors. We demonstrated that the selective CB1 agonist,
ACEA, increased the threshold for inducing panic-like
reaction in a bell-shaped manner. This panicolytic-like
effect was completely prevented by the CB1 receptor
antagonist, AM251. Although this effect was lost in a higher
dose, it could be unmasked by previous treatment with an
inactive dose of capsazepine, a TRPV1 antagonist. In
addition, pharmacological blockade of TRPV1 per se also
exerted panicolytic-like effects, suggesting the existence of
Figure 5 Local pre-treatment (5 min) with the TRPV1 antagonist,
capsazepine (CPZ; 0.1 nmol), unmasks the panicolytic-like effect of high-
dose ACEA (0.5 pmol) (n¼ 5 per group). *po0.05 Compared with all
other groups (one-way ANOVA followed by Newman-Keuls post hoc test).
For further details, see legend to Figure 2.
Figure 6 Local pre-treatment (5 min) with the CB1 antagonist, AM251
(75 pmol), prevents the panicolytic-like effect of capsazepine (CPZ;
10 nmol)-induced (n¼ 5, 7, 5, 7). *po0.05 Compared with all other
groups (one-way ANOVA followed by Newman-Keuls post hoc test). For
further details, see legend to Figure 2.
Figure 7 Local pre-treatment (5 min) with the CB1 antagonist, AM251
(75 pmol), prevents the panicolytic-like effect of SB366791 (10 nmol)
(n¼ 6, 6, 5, 7). *po0.05 Compared with all other groups (one-way
ANOVA followed by Newman-Keuls post hoc test). For further details, see
legend to Figure 2.
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tonic modulation by TRPV1, whose function opposed that
of CB1. Remarkably, capsazepine effect could be prevented
by AM251, revealing that the effect of TRPV1 blockade was
completely dependent on CB1 signaling. Noteworthy,
capsazepine effect could be mimicked by another TRPV1
antagonist, SB366791, whose action was also prevented by
AM251. Together with the co-expression of CB1 and TRPV1
observed at level of the dPAG, these data suggest the
existence of a set-point system, whereby activation
of TRPV1 vs CB1 balances the induction of panic-like
responses.
The dPAG model of panic has some limitations in terms
of a broader interpretation in relationship to human
psychopathology. It mimics only the panic attacks, which
actually occur with several other symptoms of panic
disorder, such as behavioral and physiological signs of
intense anxiety, fear and distress (Katon, 2006; Roy-Byrne
et al, 2006). Moreover, it is based on the measure of an
all-or-none response to electrical stimulation of a specific
brain structure, which is only part of a more complex neural
circuitry generating fear, anxiety and panic responses
(Del-Ben and Graeff, 2009). Despite of these drawbacks,
this model presents face, construct and predictive validities
(Jenck et al, 1995; Beckett and Marsden, 1995; Del-Ben and
Graeff, 2009; Schenberg et al, 2001). The face validity is
supported by the fact that the behavioral and autonomic
responses observed in this model resemble those seen in
panic attacks (Schenberg et al, 2001). As for the theoretical
construct, the PAG is a midbrain structure activated during
escape responses induced by natural aversive stimulus
either in laboratory animals or in healthy volunteers
(Dielenberg et al, 2001; Mobbs et al, 2007). Neurosurgery
patients, in whom this structure has been electrically
stimulated, reported feelings of fear and despair similar to
those described in panic patients (Nashold et al, 1969).
Finally, and more relevant for the present study, the
pharmacological predictability of the model is supported
by the observations that drugs used to treat panic disorder
increase the threshold of escape responses induced by
electrical stimulation of the dPAG (Jenck et al, 1995;
Schenberg et al, 2001; Schütz et al, 1985).
In this model, ACEA induced a panicolytic-like effect in
an intermediary dose, which could be prevented by AM251,
in line with previous experiments in anxiety-related
reactions (Moreira et al, 2007). These results support the
concept of general anti-aversive effects of CB1 signaling at
level of the PAG. Accordingly, local injections of other
cannabinoids inhibit the escape responses induced by local
injection of an excitatory amino acid (Finn et al, 2003) and
Figure 8 CB1 receptors and TRPV1channels are co-expressed in neurons in the dPAG. The photomicrographs (25 mm thick section) show image of
double-label immunofluorescence of CB1 (red, Alexa Fluor 594; a, d) and TRPV1 receptors (green, Alexa Fluor 488; b, e), as revealed by fluorescence (a–c)
and confocal (d–f) microscopy. Panel (c) (the composite images of (a, b)) shows neurons expressing both receptors. One representative double-stained
neuron is shown in higher magnification in f (arrow). Scale bars: 100 mm (a–c) and 50mm (d–f).
Figure 9 Negative controls for the double-labeled immunofluorescence.
The photomicrographs (25 mm thick section) show images of the dPAG
from protocols combining TRPV1 secondary (Alexa Fluor 488) with CB1
primary antibodies (a) or CB1 secondary (Alexa Fluor 594) with TRPV1
primary antibodies (b). Images resulting from protocol in which the primary
antibodies were omitted as seen in the microscopy though filters for Alexa
Fluor 488 (c) and Alexa Fluor 594 (d) are also shown.
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promote anxiolytic-like effects in several animal models (for
a review, see Moreira et al, 2009).
Contrary to CB1, TRPV1 seems to mediate pro-aversive
effects, since we detected a clear panicolytic-like effect after
its blockade with capsazepine or SB366791. Moreover, an
ineffective dose of capsazepine was able to unmask the
panicolytic-like effects of higher dose of ACEA. Therefore,
the bell-shaped dose–response curve of ACEA seems to
result from an activation of CB1 at lower concentrations
(panicolytic), whereas higher concentration of ACEA also
activates the less affine TRPV1 channels (panicogenic),
counteracting CB1-mediated actions, resulting in a net null
effect. This is in line with ACEA affinities profile, binding
CB1 in lower dose (Gawa et al, 2005) and both CB1 and
TRPV1 in higher dose (Huang et al, 2002; Price et al, 2004;
Silveira et al, 2010; Smart et al, 2000; Zygmunt et al, 1999).
The panicolytic consequences of TRPV1 antagonists
speak for a tonic activation of TRPV1 under basal
conditions. This is in accordance with previous studies,
which reported decreased anxiety upon pharmacological or
genetic interruption of TRPV1 signaling. For instance,
systemic injection of capsazepine reduced anxiety-like
behavior in rats (Kasckow et al, 2004). Moreover, a detailed
investigation on the behavior of TRPV1 knockout mice
unveiled a phenotype of reduced anxiety-like behavior in
the elevated plus maze and in the light-dark box, as well as
reduced fear conditioning (Marsch et al, 2007). In addition,
the effect of systemically administered capsazepine is
mimicked by local injection into specific structures, namely
the ventral hippocampus (Santos et al, 2008), the dorso-
lateral PAG (Terzian et al, 2009) and the prefrontal cortex
(Aguiar et al, 2009; Rubino et al, 2008). This is consonant
with neurochemical and electrophysiological data showing
that this ion channel stimulates calcium influx and
glutamate release in the PAG, increasing local neuronal
activity (Starowicz et al, 2007b; Xing and Li, 2007). In
addition, it has been demonstrated in other brain regions
related to anxiety and emotional processing, such as the
hippocampus and the nucleus accumbens, that anandamide
acts upon TRPV1 modulates long-termed depression of
synaptic activity (Chavez et al, 2010; Grueter et al, 2010).
Although it remains unclear how these electrophysiological
events would reflect behavioral responses, these studies
suggest that anandamide could be the endogenous sub-
stance activating this ion channel (Di Marzo, 2010; Chavez
et al, 2010; Grueter et al, 2010). Other lipids, including
N-arachidonoyl dopamine, N-oleoyldopamine and some
lypooxigenase products have also been among the main
candidates proposed as endovanilloids (Di Marzo et al,
2001; Starowicz et al, 2007a).
Remarkably, the effects of TRPV1 blockade could be fully
prevented by pre-treatment with the selective CB1 antago-
nist, AM251. Thus, we have shown that the effect of TRPV1
antagonists is ultimately mediated by CB1 receptor, possibly
because the actions of an endogenous agonist would be
entirely shifted to CB1, after TRPV1 blockade. This finding
adds to previous observations about opposite roles for CB1
and TRPV1 in various behavioral responses (Maione et al,
2006; Micale et al, 2009; Rubino et al, 2008). We suggest that
CB1 and TRPV1 might be simultaneously activated at a
given synapse, since we observed co-expression of CB1 and
TRPV1 at level of the dPAG. Similar observations were
obtained before in the prefrontal cortex, amygdala complex,
hippocampus and vlPAG (Cristino et al, 2006; Maione et al,
2006; Micale et al, 2009). In accordance with previous
studies, we also detected dPAG neurons that were either
exclusively CB1 positive (Herkenham et al, 1990, 1991; Tsou
et al, 1998) or TRPV1 positive (McGaraughty et al, 2003;
Mezey et al, 2000; Tóth et al, 2005).
Our pharmacological and histological experiments sup-
port a scenario in which TRPV1 and CB1 would counteract
each other to balance the threshold for panic-like responses
in multiple ways. For instance, the opposite effects of CB1
and TRPV1 could be mediated by different neurons that
converge on the same output system. Alternatively, they
could result from divergent influences on intracellular
signaling, neural firing rates and neurotransmitter release
within the same neurons (Kawahara et al, 2010; Starowicz
et al, 2007b; Vaughan et al, 2000; Xing and Li, 2007).
Regarding the physiological modulation of these mechan-
isms, there might be an endogenous agonist, with affinity
for both, which would be part of a tripartite system to
establish set points for behavioral responses. One candidate
would be anandamide, which has been proposed as an
endocannabinoid/endovanilloid (Zygmunt et al, 2000), with
higher affinity for CB1 as compare with TRPV1 (Di Marzo
et al, 2001; Starowicz et al, 2007a).
Despite of the facts that anandamide has lower affinity for
TRPV1 and has its actions limited by the enzyme fatty acid
amide hydrolase (FAAH; Piomelli, 2003), the local levels of
this substance are significantly increased by electrical
stimulation of the dPAG (Walker et al, 1999). Therefore, it
is conceivable that, in the present model, anandamide levels
would increase and act upon both receptors, whereby
TRPV1-mediated actions may prevail over CB1 (Tognetto
et al, 2001), thus facilitating panic-like behavior. Blockade
of this ion channel would increase the threshold by shifting
anandamide action entirely to CB1 receptors, whose
selective activation is panicolytic. This hypothesis is
reinforced by recent electrophysiological and behavioral
experiments. In PAG slices, anandamide could either
facilitate or inhibit excitatory transmission through TRPV1
and CB1, respectively, in the presence of the hydrolysis
inhibitor URB597 (Kawahara et al, 2010). Accordingly,
FAAH knockout mice have a phenotype of lower anxiety-
like behavior due to higher CB1 activation by anandamide.
However, CB1-antagonist treatment induced anxiogenic-like
effects in these animals, but not in wild-type controls,
possibly by shifting anandamide activity toward TRPV1
(Cassano et al, 2010).
In conclusion, we have shown opposite functions for
TRPV1 and CB1 receptors in the modulation of panic-like
responses at the level of the dPAG. Anandamide actions via
CB1 vs TRPV1 may constitute a set-point system that
represents a promising target for the pharmacotherapy of
panic and other anxiety spectrum disorders.
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Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R
et al (2000). Distribution of mRNA for vanilloid receptor
subtype 1 (VR1), and VR1-like immunoreactivity, in the central
nervous system of the rat and human. Proc Natl Acad Sci USA
97: 3655–3660.
Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago
F et al (2009). Anxiolytic effects in mice of a dual blocker of fatty
acid amide hydrolase and transient receptor potential vanilloid
type-1 channels. Neuropsychopharmacology 34: 593–606.
Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N,
Seymour B et al (2007). When fear is near: threat imminence
elicits prefrontal-periaqueductal gray shifts in humans. Science
317: 1079–1083.
Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL,
Resstel LB et al (2009). Antiaversive effects of cannabinoids: is
the periaqueductal gray involved? Neural Plast 2009: 625469.
Moreira FA, Aguiar DC, Guimarães FS (2007). Anxiolytic-like
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Abstract—The transient receptor potential vanilloid type 1
channel (TRPV1; originally vanilloid receptor VR1) is acti-
vated in peripheral terminals of nociceptive fibers by noxious
heat, low pH, and natural products such as capsaicin, the
pungent ingredient of red-hot chilli peppers. Evidence has
been accumulating that TRPV1 is expressed also in the brain,
where it seems to be involved in antinociception, locomotor
control, and regulation of affective behaviors. This ion chan-
nel might be activated by arachidonoyl ethanolamide (anan-
damide), the endogenous agonist of the cannabinoid type 1
(CB1) receptor. However, while CB1 activation leads to a de-
crease in intracellular calcium and attenuation of synaptic
transmission, anandamide binding to TRPV1 results in ele-
vated calcium levels and potentiated synaptic transmission.
This suggests a tripartite regulatory system with antagonistic
effects of CB1 and TRPV1, which are tied together by the
same endogenous ligand. Such a system may have important
implication for the modulation of behavioral responses. The
present commentary elaborates on this interplay between
CB1 receptors and TRPV1 channels in the context of fear- and
nxiety-related behaviors. © 2011 IBRO. Published by
lsevier Ltd. All rights reserved.
ey words: anandamide, cannabinoid, vanilloid, anxiety, fear,
tress.
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TRANSIENT RECEPTOR POTENTIAL
VANILLOID TYPE 1 (TRPV1) CHANNELS AND
CANNABINOID TYPE 1 (CB1) RECEPTORS:
BIOCHEMISTRY, BINDING PARTNERS, AND
INTRACEREBRAL EXPRESSION
Both TRPV1 channels and CB1 receptors were initially
identified as molecular targets of natural products (capsa-
icin and tetrahydrocannabinol (THC), respectively) (Ca-
terina et al., 1997; Devane et al., 1988). They were cloned
as “orphan receptors,” meaning that no endogenous li-
gands were known by that time (Caterina et al., 1997;
Matsuda et al., 1990). Today, a number of endogenous
binding partners could be identified. Most prominent ligands
of CB1 are fatty acid derivates, such as anandamide and
2-arachidonoyl glycerol (2-AG), termed endocannabinoids
(Devane et al., 1992; Mechoulam et al., 1995). Remarkably,
anandamide also binds to TRPV1 (Zygmunt et al., 1999; Di
Marzo et al., 2001; van der Stelt et al., 2005; Vriens et al.,
2009). Although it is difficult to compare affinities of a sub-
stance for such different molecular targets, it has been sug-
gested that anandamide would bind TRPV1 with lower affinity
and intrinsic efficacy as compared to what is observed for this
compound at CB1 (Pertwee et al., 2010; Ross, 2003). Other
ndogenous binding partners of TRPV1 include N-arachi-
onoyldopamine (NADA), N-oleoylethanolamine (OLEA) and
ydroperoxyeicosatetraenoic acids (HPETE; for review see
an der Stelt and Di Marzo, 2004).
The CB1 receptor is a seven-transmembrane receptor
Matsuda et al., 1990) coupled to Gi/o proteins. Extracel-
ular binding of endocannabinoids inhibits adenylate cy-
lase, leads to a decrease in intracellular calcium, and
ctivates inwardly rectifying K channels (Howlett et al.,
2002). In concert, these actions result in a decrease in
transmitter release at both GABAergic (e.g. Katona et al.,
1999) and glutamatergic synapses (e.g. Domenici et al.,
2006; Melis et al., 2004; Monory et al., 2006; Shen et al.,
1996; Takahashi and Castillo, 2006; Vaughan et al., 2000).
Unlike CB1 receptors, TRPV1 channels belong to the tran-
sient receptor potential superfamily, with six-transmem-
brane domains and a nonselective cation-permeable
pore (Clapham et al., 2003, 2005; Owsianik et al., 2006;
Wu et al., 2010). These channels are activated at intra-
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F. A. Moreira et al. / Neuroscience xx (2011) xxx2cellular binding sites, leading to an increase in intracel-
lular calcium and a potentiation of glutamatergic trans-
mission (e.g. McGaraughty et al., 2003; Starowicz et al.,
007a,b; Xing and Li, 2007; Kawahara et al., 2011).
oth, CB1 receptor and TRPV1 channel properties might
e modified by a variety of factors, including desensiti-
ation/internalization, heterodimerization, and phos-
horylation (Hudson et al., 2010; Premkumar and Ahern,
000). In fact, the observation that TRPV1 channel be-
ame activated only at temperatures 43 °C seemed to
reclude a significant involvement in signaling processes
ithin the brain. However, phosphorylation of TRPV1 by
rotein kinase C (PKC) shifts the activation threshold to the
hysiological range (Premkumar and Ahern, 2000) and
ould, thus, enable TRPV1 signaling or facilitate its activa-
ion at body temperature.
Receptor autoradiography and expression analyses
evealed that CB1 belongs to the most abundantly ex-
ressed G-protein coupled receptors in the brain (Herken-
am et al., 1990; 1991; Tsou et al., 1998). It is present in
variety of neuronal subpopulations with most prominent
xpression in cholecystokinin-positive interneurons, but
onsiderable expression also in serotonergic and glutama-
ergic neurons (Häring et al., 2007; Marsicano and Lutz,
999). CB1 receptors can be detected throughout the
brain, including cortex, hippocampus, amygdala, dorsal
raphe nucleus, periaqueductal gray (PAG), and cerebel-
lum. At ultrastructural level, CB1 is primarily localized at
resynaptic terminals (Egertová et al., 1998). The fact that
B1 receptors were found presynaptically, whereas its
endogenous ligands were primarily synthesized at post-
synaptic sites led to the assumption that endocannabi-
noids may act as retrograde messengers from the post-
synaptic to presynaptic terminals. This possibility has been
further supported by electrophysiological means: depolar-
ization of postsynaptic neurons leads to mobilization of
endocannabinoids and, after binding to presynaptic CB1
receptors, to a decrease in GABA (depolarization-induced
suppression of inhibition, DSI) and glutamate (depolariza-
tion-induced suppression of excitation, DSE) release
(Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001).
Unlike CB1, it is still a matter of debate to what extent
RPV1 channels are expressed in the brain. In particular,
recent study with mutant mice expressing TRPV1 gene
eporters speaks against a broad expression of TRPV1
ithin the brain. This study reported a highly restricted
xpression in the posterior caudal hypothalamus, the ros-
ral midbrain, the PAG and, in a very limited manner, the
ippocampus (Cavanaugh et al., 2011). These observa-
ions stand in contrast to the results of other studies, which
eported much stronger expression patterns by immuno-
istochemistry, in situ hybridization, RT-PCR, and receptor
utoradiography (Cristino et al., 2006, 2008; McGaraughty
t al., 2003; Mezey et al., 2000; Tóth et al., 2005), with
rominent expression in the cortex, hippocampus, and the
AG. Those studies revealed that TRPV1 and CB1 were
ccasionally co-expressed either within the same neurons
r within the same synapses (Cristino et al., 2006; Maione
t al., 2006; Micale et al., 2009). In most cases, TRPV1 c
Please cite this article in press as: Moreira FA, et al., Cannabinoid type
channels in fear and anxiety—two sides of one coin?, Neuroscience (2nockout mice were used for control experiments to con-
rm the specificity of the methodological approaches. We
urrently do not know the reasons for the discrepancies of
he anatomical studies but assume that dynamic changes
n TRPV1 expression due to differences in rearing and
ousing conditions might play a role.
Strong support for an intracerebral expression of
RPV1 comes from electrophysiological studies, which
evealed an involvement of TRPV1, among others, in fa-
ilitation of glutamatergic transmission (McGaraughty et
l., 2003; Starowicz et al., 2007a; Xing and Li, 2007;
awahara et al., 2011), long-term potentiation in the hip-
ocampus (Marsch et al., 2007; Li et al., 2004), and long-
erm depression in this structure (Chávez et al., 2010;
ibson et al., 2008) as well as in the nucleus accumbens
Grueter et al., 2010) and in the developing superior col-
iculus (Maione et al., 2009). This diversity in TRPV1 ac-
ions may depend on its expression in postsynaptic vs.
resynaptic nerve terminals. Remarkably, pharmacologi-
al blockade and genetic deletion of TRPV1 or CB1 often
revealed opposite changes in synaptic plasticity (Heifets
and Castillo, 2009).
The results of the anatomical, biochemical, and elec-
trophysiological studies can be integrated in the follow-
ing hypothetical scenario (see also Di Marzo, 2008):
CB1 receptors, TRPV1 channels, and their endogenous
agonist anandamide form a tripartite regulatory system.
The action of anandamide can occur upon presynaptic
neurons co-expressing TRPV1 and CB1. Alternatively,
anandamide may bind TRPV1 at postsynaptic neuron
and interfere with 2-AG synthesis (Maccarrone et al.,
2008), which would restrain neurotransmitter release
upon binding to presynaptic CB1 receptors. The follow-
ng section will elucidate to what extent these antago-
istic effects of CB1 vs. TRPV1 apply to the behavioral
regulation of fear and anxiety.
OPPOSING ROLES FOR CB1 AND TRPV1 IN
MODULATION OF FEAR AND ANXIETY-
RELATED RESPONSES
Several brain regions expressing CB1 receptor are part of
the fear and anxiety matrix of the brain. This comprises,
among others, the prefrontal cortex (PFC), the hippo-
campus, the amygdala, the hypothalamus, and the PAG
(McNaughton and Gray, 2000; Corr and McNaughton, 2004;
Canteras et al., 2010). The existence of CB1 receptor in all
hese structures may explain the extensively described
ehavioral and emotional changes induced by Cannabis
nd cannabinoids in humans and experimental animals
D’Souza et al., 2009; Moreira and Wotjak, 2010; Moreira
t al., 2009; Viveros et al., 2005). Most studies have dis-
ected these mechanisms in laboratory rodents by gene
eletion or pharmacological treatment, followed by behav-
oral analyses of innate anxiety or learned fear responses.
nnate anxiety was typically assessed in approach/avoidance
onflict tasks, such as the elevated plus maze (EPM) and the
ight–dark box (LDB). Conditioned fear was measured in
lassical conditioning tasks, where the animals associated an
1 receptors and transient receptor potential vanilloid type 1
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F. A. Moreira et al. / Neuroscience xx (2011) xxx 3explicit stimulus (e.g. tone, light) or a complex set of different
stimuli (i.e. context) with an electric foot shock.
In low doses, cannabinoids tend to induce anxiolytic-
ike effects (for a review, see Moreira and Wotjak, 2010).
n turn, pharmacological blockade of CB1 (e.g. by rimon-
bant or AM251) or gene deletion result in exacerbated
nxiety-like behavior (Haller et al., 2002, 2004; Jacob et
l., 2009; Martin et al., 2002). Another prominent effect
f attenuated/abolished CB1 signaling refers to deficits
in acute fear adaptation and fear extinction (Marsicano
et al., 2002; Kamprath et al., 2006; Chhatwal et al.,
2005; Pamplona et al., 2006; Niyuhire et al., 2007; Lis-
boa et al, 2010; Plendl and Wotjak, 2010; for review see;
Resstel et al., 2009; Pamplona et al. in this Special
issue). Noteworthy, the involvement of CB1 in memory
extinction seems to be restricted to aversive memories, since
it cannot be observed under appetitive conditions (Hölter et
al., 2005; Niyuhire et al., 2007). Considering the neuromodu-
latory aspects of the endocannabinoid system, a possible
mechanism through which CB1 activation would attenuate
versive responses could be the modulation of glutamatergic
ctivity (Jacob et al., 2009; Kamprath et al., 2009). Because
lutamate is widely distributed in the brain and has a well-
stablished role in facilitating aversive responses (Millan,
003), cannabinoids could ultimately act by inhibiting gluta-
atergic synapses in the anxiety and fear circuitry (for review
ee Moreira and Wotjak, 2010).
TRPV1 is also present in glutamatergic synapses, but
ts role in fear and anxiety is by far less well explored than
hat of CB1. Based on the accumulating histological, elec-
trophysiological, biochemical, and pharmacological evi-
dence, it was tempting to assume that this ion channel
facilitates anxiety and fear, contrary to the effects of CB1
receptors. One of the first reports about such an involve-
ment of TRPV1 goes back to Kasckow and co-workers
(2004), who demonstrated that systemic injection of the
TRPV1 antagonist capsazepine reduced anxiety-like be-
havior in rats in the EPM. Behavioral analyses of TRPV1
knockout mice strengthened the notion that TRPV1 affects
anxiety diametrically opposite to CB1, since TRPV1 knock-
out mice showed decreased anxiety in the EPM and LDB
and displayed impaired fear expression in response to a
tone or a context previously paired with electric foot shocks
(Marsch et al., 2007).
A number of pharmacological studies confirmed and
extended the notion of anxiolytic effects of CB1 receptor
s. anxiogenic effects of TRPV1 channel activation. In-
eed, compounds with affinity for both receptors, such
s anandamide analogs, (i) exert anxiolytic effects in low
oses, but (ii) promote anxiety at higher doses, (iii) likely
ia activating TRPV1 channels. (iv) Pharmacological
lockade of TRPV1 not only abolished the effects of high
oses of CB1 agonists but also resulted in an anxiolytic
phenotype without concomitant CB1 agonist treatment.
or instance, local administration of anandamide or the
B1 receptor agonist WIN 55,212–2 into the dorsolateral
PAG induced anxiolytic-like effects in rats in the EPM
(Moreira et al., 2007; Campos and Guimarães, 2009).
These effects were mimicked by local injection of arachi- T
Please cite this article in press as: Moreira FA, et al., Cannabinoid type
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prevented by AM251, pointing to a role for CB1 receptor.
Interestingly, arachidonoyl chloroethylamide and WIN
55,212-2 showed bell-shaped dose–response curves
(Moreira et al., 2007; Campos and Guimarães, 2009),
which led us to conclude that the anxiolytic-like effects
mediated via CB1 receptors are lost at higher doses
upon activation of TRPV1 channels (Moreira et al.,
2009). Indeed, blockade of TRPV1 within the dorsolat-
eral PAG with capsazepine consistently induced anx-
iolytic-like effects (Terzian et al., 2009) and prevented
the anxiogenic-like effects of higher doses of WIN
55,212-2 (Campos and Guimarães, 2009). These ef-
fects could be confirmed in the Vogel conflict test (Lis-
boa et al., 2008; Terzian et al., 2009), a model that
involves a different type of conflict-based anxiety (Sousa
et al., 2006). However, because of the complex nature of
CB1 and TRPV1 pharmacology, we cannot rule out that
some of the effects of CB1 receptor agonists were me-
iated via direct desensitization of TRPV1 (at least in
ase of WIN 55,212-2; Patwardhan et al., 2006).
Studies with local drug treatment in other parts of the
ear/anxiety matrix revealed essentially the same findings
s obtained in the dorsolateral PAG (Fig. 1): injection of
oth THC and the anandamide analogue methanand-
mide, into the medial PFC of rats, reduced anxiety-like
ehavior in the EPM (Rubino et al., 2008a,b), with biphasic
ffects of methanandamide (Rubino et al., 2008b). The
nxiolytic effects of lower doses and the anxiogenic effects
f higher doses were mediated by CB1 and TRPV1, re-
spectively (Rubino et al., 2008b). Local blockade of TRPV1
within the medial PFC had an anxiolytic profile in rats both
in the EPM and the Vogel conflict test (Aguiar et al., 2009).
Finally, within the ventral hippocampus, both activation of
CB1 by THC (Rubino et al., 2008a) and blockade of TRPV1
by capsazepine (Santos et al., 2008) decreased anxiety-
ike responses in the EPM.
CONCLUSIONS
This commentary compiles a number of biochemical,
anatomical, electrophysiological, and behavioral stud-
ies, which suggest opposite roles of CB1 receptors and
Fig. 1. Bidirectional modulation of anxiety-like behavior via CB1 and
TRPV1. Studies combining intracerebral drug treatment with behav-
ioral analyses revealed that activation of CB1 receptors reduces,
hereas activation of TRPV1 channels promotes anxiety-like behavior
t level of the prefrontal cortex (PFC), ventral hippocampus (vHPC),
nd periaqueductal gray (PAG). For details see text.RPV1 channels in synaptic transmission, fear, and
1 receptors and transient receptor potential vanilloid type 1
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F. A. Moreira et al. / Neuroscience xx (2011) xxx4anxiety: whereas activation of CB1 receptors promotes
acute fear adaptation and decreases anxiety, TRPV1
channels exert anxiogenic actions. The co-existence of anxi-
olytic and anxiogenic transmitter systems is reinforced by the
several pieces of evidence indicating a close interaction
between CB1 receptors and TRPV1 channels (i.e. endo-
annabinoid and endovanilloid actions), such as shared
inding partners (i.e. anandamide) and co-expression
ithin the same neurons and/or synapses. Even though
he mechanisms of how anandamide acts at CB1 receptors
nd TRPV1 channels are far from being clear, there might
e, at least, indirect effects via changes in the synthesis/
obilization of other endocannabinoids (e.g. 2-AG). Any-
ow, the promiscuous binding capabilities of some canna-
inoids could explain the well-known bell-shaped dose–
esponse curves and biphasic effects of some of these
ompounds by activation of CB1 receptors at lower and of
TRPV1 channels at higher doses (Fig. 2; see also Di
arzo et al., 2008; Di Marzo, 2008). These effects ask for
careful investigation of the receptor types involved in a
articular behavioral study. The same applies to com-
ounds that supposedly interfere with endocannabinoid
Fig. 2. Hypothetical scenario for the bidirectional modulation of an
receptors leads to a decrease in transmitter release (e.g. glutamat
postsynaptic TRPV1 channels promotes depolarization and anxiety
e.g. anandamide). Noteworthy, this hypothetical scenario is furt
nvolvement of different transmitter systems. (B) Agonists of CB1 of
nxiolytic and higher doses anxiogenic effects. Co-administration of
f CB1 receptors at lower and TRPV1 channels at higher concentra
thus resulting in a decrease in anxiety. (D) At higher concentrations
of the TRPV1 loop prevails (direct activation of the postsynaptic si
anxiety.ptake and degradation, but may directly affect TRPV1
Please cite this article in press as: Moreira FA, et al., Cannabinoid type
channels in fear and anxiety—two sides of one coin?, Neuroscience (2channels, such as AM404 (Mallet et al., 2010; Zygmunt et
al., 2000a).
There is an urgent need for detailed studies on the role
f anandamide as a potential endocannabinoid/endovanil-
oid, given the steadily increased application of FAAH in-
ibitors in animal models of psychopathology (Moreira and
otjak, 2010). The same applies to our poor knowledge
bout dynamic regulation of TRPV1 channels within the
rain, including phosphorylation and desensitization, in
articular, in light of the contradictory studies about TRPV1
xpression.
On the basis of our current knowledge, antagonists of
RPV1 channels represent promising compounds for the
reatment of anxiety disorders. Moreover, the opposing
ctions of CB1 and TRPV1 may guide the development of
novel therapeutic drugs. For instance, increasing brain
levels of anandamide (through FAAH-inhibition) induces
CB1-mediated anxiolytic-like effects (Moreira et al., 2008;
Kathuria et al., 2003; Patel and Hillard, 2006), although this
effect can be subtle in certain models (Naidu et al., 2007)
and depends on the aversiveness of the test situation
(Haller et al., 2007). Nonetheless, the effects of FAAH-
behavior via CB1 and TRPV1. (A) Activation of presynaptic CB1
n consequence, to a reduction in anxiety. In contrast, activation of
1 and TRPV1 might be activated by the same endogenous ligands
plicated by presynaptic expression of TRPV1 channels and the
bimodal effects on anxiety-like behavior, with lower doses causing
antagonists revealed that this bimodality results from an activation
) At lower concentrations, the CB1 agonists primarily bind to CB1,
nist binds to TRPV1 in addition to CB1. In consequence, activation
sing trans-synaptic regulatory loops) and results in an increase inxiety-like
e) and, i
. Both CB
her com
ten exert
selective
tions. (C
, the agoinhibition can be potentiated by simultaneous antagonism
1 receptors and transient receptor potential vanilloid type 1
011), doi: 10.1016/j.neuroscience.2011.08.046
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with arachidonoyl serotonin (Micale et al., 2009). Thus,
dual FAAH/TRPV1 blockers represent a particularly prom-
ising novel class of anxiolytic drugs.
Taken together, CB1 and TRPV1 seem to embody the
two sides of the same coin (Zygmunt et al., 2000b) also in
he context of fear and anxiety. Despite the significant
rogress in the field, further experiments are required for a
etter understanding of the relevance of the proposed
ripartite CB1–anandamide–TRPV1 system in physiology
and pathology. These studies might lead to the develop-
ment of novel drugs for the treatment of psychiatric disor-
ders that will allow us to influence what side of the coin is
laying face-up: CB1 or TRPV1.
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2012  FENS-CSHL School – Cellular Biology of Addiction. Barcelona, Spain  
 The Young Investigator Training Programme (YITP) – FENS-Internship program – 
Lab of Prof. Andrés Ozaita. PRBB. Barcelona, Spain 
 FENS School – Drugs and the Brain: an Update in Psycho-pharmacology from 
Experimental to Clinic. Braga, Portugal 
                 Workshop in Electrophysiology. Max-Planck Institute of Psychiatry. Munich, Germany 
 
2011 ECNP Workshop in Psychopharmacology. Nice, France 
 Workshop on Coping with the challenges of a PhD study, (16h), Ludwig-Maximilian 
Universität. Munich, Germany. 
Workshop on Learning How to Teach (16h), Ludwig-Maximilian Universität. Munich, 
Germany. 
 
2010 Workshop on Brain Oscillation, GSN-LMU (16h), Ludwig-Maximilian Universität. 
Munich, Germany.  
 
2008 1a Escola de Altos Estudos CAPES, IINN-ELS/UFRN. (171h). Instituto Internacional 
de Neurociências de Natal (IINN-ELS). Natal, RN, Brasil.  
 
2007 III IBRO School in Brazil (ISBRA), University of São Paulo. Ribeirão Preto, SP, Brazil.  
 
2005 Symposia of Child Neurodevelopment (4h), School of Medicine of Ribeirão Preto, 
FMRP-USP. Ribeirão Preto, SP, Brazil.  
Nervous System Comunication (4h), Reunião da Federação das Sociedades de Biologia 
Experimental (FESBE). Águas de Lindóia, SP,  Brazil.  
Chronic Liphoproliferative Illness (3h), International Congress of Pharmaceutical 
Science (CIFARP). Ribeirão Preto, SP, Brazil.  
Neural Network (3h), IV Semana da Física Médica. Ribeirão Preto, SP, Brasil. 
Ana Luisa B. Terzian +49 (0)17670437239                            anaterzian@gmail.com             
KEY SKILLS 
 
 Strong communicative skills: lab meetings and conferences 
 Initiative, adaptability, creativity and problem solving 
 Strong interactive skills: successfully training and coaching people 
 Independent and cooperative 
 International mobilit
 
ADDITIONAL COMPETENCES  
 
Operating systems & Softwares Windows; Microsoft Office: Word, Excel, PowerPoint 
Statistical programs  SPSS, StatWin, Statistica, Prism 
Graphical and image processing programs  SigmaPlot, PhotoShop  
Tracking Software  ANY-Maze, Ethovision 
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